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Abstract 
The development of hormone therapies, such as tamoxifen, have substantially 
improved breast cancer outcomes for hormone receptor positive breast cancers. A 
subtype of breast cancers known as the triple negative breast cancers (TNBC) 
however, cannot benefit from these therapies due to their lack of receptors or 
overexpression of HER2 (ER-/PR-/HER2-). The triple negative subtype is associated 
with poorer prognosis and earlier relapse; novel therapies are urgently required for 
this cancer of unmet clinical need.  
The liver X receptor (LXR) is a ligand induced transcription factor with essential roles 
in cholesterol metabolism. LXRα and its binding partner RXRβ were found to be 
expressed at significantly higher levels in triple negative breast cancers relative to 
ER-positive breast cancers. I hypothesised that LXRα activity was altered between 
breast cancer subtypes and may influence chemotherapy efficacy. 
Enhanced LXRα response to ligand was identified in the TNBC subtype relative to the 
Luminal A subtype. Furthermore, LXRα was identified as a mediator of 
chemotherapy resistance through the control of the p-glycoprotein/ABCB1 in TNBC. 
I further hypothesised that the p-glycoprotein/ABCB1 may be targetable through 
phytosterol treatments which were shown to antagonise oxysterol-induced LXRα 
activity and expression of its targets which, we have been shown to include p-
gp/ABCB1. 
In summary, I have identified a novel LXRα target gene (p-gp/ABCB1) in TNBC which 
confers chemotherapy resistance through enhanced export of the chemotherapy 
drug epirubicin. I have also established a mechanism to impair the oxysterol:LXRα 
axis through phytosterol treatment. The data presented here may have important 
implications to aid better treatment plans for patients undergoing chemotherapy 
treatment. It may also help identify individuals at risk of therapy failure. 
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Chapter 1 
Introduction 
1.1  Breast Cancer 
Breast Cancer (BCa) is the most frequent malignancy worldwide in females and the 
second most common cause of cancer related death [1, 2]. Worse disease-free 
survival is observed with patients who are overweight or obese [3, 4], and those who 
have associated co-morbidities such as elevated levels of low-density lipoprotein 
cholesterol (LDL-C) [5], or high saturated fat intake [6] when compared to their 
leaner counterparts. Improvements in the treatment and early detection of breast 
cancers through mammography screening programs are contributing to the 
reduction of BCa mortality [7] however in Europe and the US combined, over 
120,000 annual BCa deaths are still expected [7, 8]. Drug development time and the 
costs associated with development and testing of new drugs are high, as such, focus 
on preventing the development of metastatic breast cancer may be a more efficient 
use of time and resources, especially when primary breast cancer is rarely the cause 
of breast cancer mortality. 
1.1.1  Classification 
Classification of breast cancers is essential for informed treatment decisions. 
Molecular receptor expression in breast cancer subtypes can dictate how a patient 
responds to certain therapies and if treatment plans are not personalised this can 
result in poor treatment efficacy. Other factors, such as stage and grade of the 
tumour are also important for classification of breast tumours to provide the best 
treatment plan for that tumour subtype at that specific grade/stage. 
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1.1.1.1  Grade/Stage 
The stage and grade of a cancer are contributing factors that will influence the 
treatment decision. The stage of a cancer assesses the size and spread of the cancer 
into surrounding tissues. The grade of a tumour assesses the proliferation and 
phenotype of the cancer cells compared to healthy cells. Around 60 % of women 
who present at clinic with stage I or stage II breast cancers undergo breast-
conserving surgery (BCS), which may be either a partial mastectomy or a 
lumpectomy [9]. Over 35 % of women who present with stage I or stage II breast 
cancers will undergo mastectomy [9].  Furthermore, women who present at clinic 
with stage III are more likely to undergo mastectomy (72 %) compared to BCS (21 %) 
or radiotherapy and or chemotherapy (7 %) [9]. And over half of the women who 
present with stage IV BCa receive radiation therapy alone or in combination with 
chemotherapy (76 %). Notably, 79 % of women with hormone receptor-positive BCa 
receive hormone therapies regardless of stage [10] suggesting hormone-receptor 
status is also important in the treatment of breast cancers. 
1.1.1.2  Molecular Receptors 
BCa can be sub-classified based on receptor status to inform treatment decisions as 
well as prognosis. This characterises tumours based on the cancer cell expression of 
molecular receptors such as, the estrogen receptor (ER) and progesterone receptor 
(PR) and the overexpression of human epidermal growth factor receptor 2 (HER2) 
receptors combined with proliferative index through the Ki-67 status [11]. The 
estrogen receptor and the progesterone receptor are receptors which bind the 
respective hormones, estrogen and progesterone. Cancer cells that express these 
hormone receptors (ER/PR) require the binding of the specific hormones to grow and 
- 21 - 
metastasize. BCas are categorised into four main subtypes, Luminal A, Luminal B, 
HER2-positive (HER2+) and triple negative breast cancer (TNBC). Luminal A BCas are 
hormone receptor-positive for the ER and or the PR and HER2-negative with low ki-
67 levels, Luminal B BCas are hormone receptor-positive for the ER and or the PR 
and either HER2-positive or HER2-negative with high ki-67 levels. HER2+ BCas are 
hormone receptor-negative and HER2-positive, whereas the TNBC subtype is 
negative for all three receptor types. As studies and research evolve, further sub-
classification of breast tumours into new molecular entities is expected. This was the 
case for a TNBC subtype known as Claudin-low, which was identified and 
characterized in human and mouse tumours, and in a panel of BCa cell lines (BT549, 
MDA-MB-231, MDA-MB-435 and Hs578T) [12, 13]. TNBC subtypes all have poor 
prognosis and a higher risk of relapse which demonstrates the requirement for novel 
therapeutics targeting new molecular targets particularly in this subtype. 
1.1.2  Breast Cancer survival rates 
Luminal breast cancers are the most common breast cancer subtypes accounting for 
30-70 % of all BCas. Luminal breast cancers have the highest 10-year recurrence 
regional free survival (RRFS) rate, (Luminal A, 96 %., and Luminal B, 88 %) when 
compared to other subtypes [14, 15]. The TNBC subtype accounts for 20 % of all BCas 
[16] but are less likely to respond to treatment. TNBCs are also more likely to become 
metastatic and the patients therefore have a poorer prognosis [17]. Patients with 
TNBC have approximately 10 % higher risk of relapse within the first 5 years post-
surgical resection, which then declines to below that of other BCa subtypes after that 
[18-20].  
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Over the last few decades marked improvements in the successful treatment of 
breast cancers have been observed coinciding with the development of targeted 
therapies such as tamoxifen and herceptin. Overall, the 5-year survival rate for non-
subtype specific breast cancer is 89 % and the 10-year survival rate is 83% [9]. A large 
proportion of these statistics however, will be representative of luminal breast 
cancers which have hormone therapies available, or BCas that are HER2-positive and 
can be treated with monoclonal antibodies such as herceptin.  
1.1.3  Treatments 
Molecular differences in BCa subtypes dictate which course of systemic treatment 
the patient receives. Cancer cells within tumours that express the ER and/or the PR 
require the binding of estrogen/progesterone to grow and metastasize. Tamoxifen 
is a hormone therapy that inhibits the estrogen receptors which inhibits the growth 
and spread of the BCa. The endocrine axis is successfully targeted through inhibiting; 
hormone synthesis with aromatase inhibitors and hormone receptors with 
antagonists like tamoxifen. HER2 signalling is successfully interrupted with 
monoclonal antibody therapies such as herceptin [21]. Targeting of the endocrine 
axis has benefited patients with hormone receptor positive cancers however, 
treatment of the TNBC subtype remains challenging with no targeted therapies 
developed to date [21]. 
1.1.3.1  Tamoxifen, herceptin and aromatase inhibitors 
Hormone therapies are systemic and therefore affect cells all over the body. They 
are often given as adjuvant therapy (post-surgery) to reduce the risk of recurrence 
or occasionally as a neoadjuvant therapy (pre-surgery).  Hormone therapies, such as 
tamoxifen are usually taken for 5-10 years after the primary diagnosis but can also 
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be used to treat local secondary ER-positive tumours or ER-positive metastatic 
tumours. Tamoxifen is an example of a cancer chemoprevention agent which inhibits 
the ER. Unfortunately many of these agents have side effects, such as tamoxifen, 
which is an extremely successful agent used to prevent tertiary BCa development 
[22] however the use of tamoxifen increases the risk of other reproductive system 
cancers [23]. 
Some tumour cells have increased expression of a growth promoting protein 
HER2/neu (HER2) which usually display enhanced tumour growth and metastatic 
progression. Herceptin is a commonly used drug to treat tumours that are HER2 
enriched which is a monoclonal antibody that specifically targets the HER2 receptors. 
Aromatase inhibitors (AI) are drugs that stop the production of estrogen by 
interfering with aromatase which converts androstenedione into estrone then 
estradiol, and/or testosterone into estradiol (as shown in Figure 1.1). Aromatase 
inhibitors are often used in post-menopausal women as small amounts of estrogen 
are made in fat tissue by the enzyme aromatase even after menopause. Letrozole 
and anastrozole are examples of aromatase inhibitors which are given daily. AIs are 
commonly given after surgery either alone or after tamoxifen to stop tumour 
recurrence. Pre-menopausal women whose tumour is ER-positive are likely to be 
treated with tamoxifen post-surgery with the addition of AIs later if necessary, given 
with luteinizing hormone-releasing hormone (LHRH) which is an ovary suppression 
drug [24]. 
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Figure 1. 1 Aromatase inhibitor mode of action.  
Cholesterol is converted to pregnenolone and then progesterone, both of which can be converted to 
androstenedione. Androstenedione is then either converted directly to esterone by aromatase, or to 




1.1.3.2  Systemic Chemotherapy 
Chemotherapy is the delivery of toxic agents into the patient’s cancer cells to 
damage the cell and force the process of apoptosis. Chemotherapy can be given as 
neoadjuvant chemotherapy to reduce the tumour size and invasiveness before 
surgery, or as adjuvant chemotherapy to eradicate any remaining cancerous cells left 
after surgery. Chemotherapy may also be used to treat metastatic tumours that have 
colonised in other tissues. Chemotherapy is also used to reduce the risk of BCa 
recurrence, however high doses of anthracyclines (which are the most commonly 
used chemotherapy drugs) for long periods of time can result in cardiotoxicity [25].  
1.1.3.3  Radiotherapy and Surgery 
Surgery is commonly used to remove breast cancer tumours. Patients who present 
at clinic with low stage and grade tumours often receive surgery in combination with 
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other treatments such as tamoxifen to stop the growth of the tumour and reduce 
the risk of recurrence. A report completed by the National Cancer Intelligence 
Network (NCIN) showed out of all patients diagnosed with breast cancer in England 
between 2004-2006, 90 % of patients in the age groups 40-49, 50-59 and 60-69 
received surgery for a major resection through the NHS [26].   
Radiotherapy is often used to treat stage I-IV cancers usually in combination with 
other treatments such as breast conserving surgery. Radiation can be used to 
destroy any remaining cancer cells after surgical resection of large tumours or to 
target metastatic cancers where large sections cannot be removed such as in bone 
or the brain. Typically, two types of radiotherapy are used to treat breast cancer, 
external beam radiation or internal radiation.  
1.1.4  Risk Factors 
Cancer is a heterogenous and complex problem. Cancers from the same subtype 
with similar molecular markers can respond to the same treatments very differently, 
and this is believed to be due to individual characteristics. Understanding these 
characteristics that make patients more at risk for poor response to treatment may 
help identify targets to improve patient outcomes.  
1.1.4.1  Prognostic factors 
There are multiple prognostic factors associated with an increase in breast cancer 
occurrence and recurrence, some of which are modifiable and some that are not.  
The non-modifiable prognostic factors for breast cancer include; grade, stage, 
receptor status, heterogeneity of the tumour microenvironment, genetics [27, 28], 
mammographic density and pathological response to neoadjuvant chemotherapy 
(NACT). The modifiable risk factors for breast cancer include; waist-to-hip ratio [29], 
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body mass index (BMI) [30], obesity [31-34] saturated fat intake [6], physical 
inactivity [35], first pregnancy at later stages of life [36], and lifestyle [37]. 
 
1.1.4.2  Non-modifiable prognostic factors 
One of the most widely accepted biomarkers for BCa risk is mammographic density 
[38], which has been associated with a 4-6-fold increase of BCa risk in women with 
highly dense mammographic density [38]. Mammographic density is thought to be a 
non-modifiable risk factor associated with an increased risk of BCa, although there 
are some studies that have shown changes in mammographic density caused by 
hormone therapies [39, 40] which have been shown to alter the risk associated with 
BCa [41]. As previously mentioned, stage, grade and the receptor status of the 
tumour all impact the level of risk associated with the particular breast cancer. 
 
1.1.4.3  Modifiable prognostic factors 
Most modifiable prognostic factors are dietary related, but there are some that are 
not. For example, BCa risk in women is known to double every decade before the 
menopause, after which risk increase slows substantially. With this in mind, it is 
interesting to note that BCa is more frequently diagnosed in women after 
menopause which suggests other factors like diets high in fat are of great importance 
to the development of BCa [37]. This is further supported by multiple studies 
showing generation of women who have migrated from low risk countries (such as 
Japan) to high risk countries (such as America) and have displayed the increased  risk 
of cancer associated with the new region [42-45]. The World Cancer Research Fund 
Continuous Update Project (WCRF CUP) and many other studies continue to assess 
the many factors that contribute to the development of BCa.  
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One of the most modifiable risk factors for breast cancer is physical inactivity [35]. 
Physically active women displayed a 20-30 % reduction in breast cancer risk 
compared to women who were physically inactive [35], and the same study observed 
a 30-40 % reduction in colon cancer risk in both men and women who were physically 
active [35]. Furthermore, physically active lifestyles or long-term pharmacological 
therapies (such as statins) that reduce LDL-C [46, 47] and diets rich in phytosterols 
(plant-based diets) [48] are associated with reduced risk of primary breast cancer, 
improved patient survival and a reduction in recurrent breast cancer.  
Postmenopausal women whose BMI is greater than 25 are also known to have an 
increased risk of developing invasive BCa compared to women with  a healthier BMI 
[30], and an overall increased risk of 61 % (95 % CI 1.43-1.80) [49]. Furthermore, 
obesity is associated with hypercholesterolemia, and has been linked to a 2-fold 
increase in BCa risk [37, 44]. Diet has been labelled as the second most preventable 
cause for cancer [50] after cigarette smoking, and as such demonstrates key roles 
with the support of other evidence, that cholesterol is linked to BCa through obesity 
and high circulating LDL-C levels. Additionally, many studies ultimately highlight 
obesity as a BCa risk factor [31-34] and in women has been linked with an increase 
in cancer death [51]. 
 
1.1.4.4  Secondary prevention 
The treatment of primary breast cancers is often successful particularly for those 
with hormone receptor positive breast cancers. The majority of breast cancer deaths 
occur due to failure of treatment and the formation of secondary tumours, 
highlighting a key area for improvement. As mentioned physically active lifestyles 
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that lower LDL-C [46, 47] and plant-based diets [48] are associated with a reduction 
in recurrent breast cancer, and high LDL-C is largely associated with an increase in 
BCa recurrence [51].  
Secondary tumours can either be local, regional or distal/metastatic. Metastatic 
tumours are those that have invaded the lymphatic system or vascular systems 
allowing distribution via the lymph nodes or venous/arterial system. Once the 
cancerous cells have exploited the lymph nodes and vascular system, the tumour 
cells can form secondary tumours in other niche organs often resulting in the need 
for chemotherapy or radiotherapy. Metastatic relapse is a major cause of BCa 
treatment failure, however it remains unclear why some patients with similar 
disease succumb to relapse, but others do not [28, 52]. It is clear however, that some 
subtypes (particularly the TNBC) are more likely to relapse within the first 5 years 
post treatment. For example, the study analysed a dataset of 269 TNBC patients and 
showed the 5-year overall survival (OS) rate to be 74.5 % for this subtype [53], with 
metastasis recurrence rates for TNBC to be 2 % local and 31.5 % distal. Furthermore, 
out of those TNBC patients who relapsed 77.6 % of these patients did not survive, 
equating to 70 patient deaths out of the 90 patients who relapsed [53]. 
For patients who have ER-positive BCa, tamoxifen is often used to inhibit the growth 
of the cancer through blocking estrogen interactions with the estrogen receptor. The 
development of metastatic tumours are lethal and often result in death. Therefore, 
finding novel therapeutic targets linked to risk factors associated with LDL-C and 
cholesterol pathways is essential to understand the mechanisms underpinning why 
cholesterol and diet are associated with BCa recurrence. 
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1.1.5  Chemotherapy resistance 
BCa is the most common malignancy in women and although treatment of primary 
cancer is successful, chemoresistance is still a major issue for the treatment of 
secondary tumours. Chemoresistance occurs when treatment of cancer is 
unsuccessful or fails, this could be due to a variety of mechanisms such as; the 
detoxification of anti-cancer therapies either by metabolising the drug into an 
inactive molecule [54] or by efflux of drug from the cell [55], interruption of the 
apoptotic signalling pathway [56]. The TNBC relapse is linked to failure of 
chemotherapy drug delivery and retention within the cell, linking further to drug 
exportation.  
The definition of chemoresistance or chemotherapy resistance (CR) is the lack of or 
partial response by a tumour to systemic chemotherapy. Metastatic cancer or 
metastasis is defined as the migration of cancer cells from the primary tumour and 
the formation of secondary tumours in other tissues either through the lymph 
system or bloodstream. Proximal metastasis is cancer that has migrated to an area 
near the primary site and distal metastasis is cancer that has spread to other regions, 
usually a different organ.  
BCa recurrence is particularly common in TNBC, with 35 % of TNBC patients relapsing 
within the first 6 years post treatment [57]. In a study of 123,780 BCa patients with 
stages I, II and III, the authors found the 5-year free survival (FS) rate for TNBC (75-
80 %) was considerably lower than the FS rate for other BCa subtypes (90.75 %) [58], 
which reflects the lack of targeted treatment available for this subtype. Lower 
survival rates and high relapse rates in the TNBC subtype demonstrates the 
aggressiveness of this BC subtype. Furthermore, another study with 2394 patients 
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found survival rates for the TNBC patients to be 62 % which was notably lower than 
the rate for the Non-TNBC subtypes at 72 % [59]. Although both studies show TNBC 
survival rates to be lower than the non-TNBC subtypes, the rates across both studies 
are varied suggesting other factors other than subtype effect the survival and relapse 
risk in BCa patients. 
Although targeted endocrine therapies have a large success in the treatment of 
primary tumours in the first instance, countless patients relapse with endocrine 
therapy resistant disease [21] and chemotherapy resistance [60]. Chemoresistance 
(innate or acquired), can apply to individual chemotherapy agents or a class with 
analogous mechanistic of actions [61]. Additionally, interruption of the apoptotic 
signalling pathway is often a major cause for the failure of anticancer therapies [56]. 
Innate chemoresistance occurs immediately after the first exposure to 
chemotherapy treatments, whereas acquired chemotherapy resistance usually 
arises when a patient has been exposed to one class of treatment for an extended 
period. Interestingly, the bidirectional interplay between the extracellular matrix 
(ECM) and tumours has recently been shown to promote resistance to endocrine 
and other targeted therapies [62, 63]. 
Active efflux of chemotherapy agents from within cancer cells is one of the key 
mechanisms of chemoresistance, others include; mutations or changes in mitotic 
checkpoint signals, modification of drug targets, detoxification of cytotoxic 
chemotherapy agents, drug appropriation, and improved deoxyribonucleic acid 
(DNA) repair mechanisms [61]. The increased expression of liver x receptor (LXR) 
canonical target genes belonging to the ATP-biding cassette transporters (ABC-
transporters) can be associated with unsuccessful drug effect and cancer cell survival 
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during chemotherapy. ABCA1 is a recognised target gene of LXR with roles in 
cholesterol efflux, however other ABC-transporters are also thought to be regulated 
by LXR. ABCB1, ABCC1 and ABCG2 are ABC-transporters with roles in chemotherapy 
drug efflux [64]. Increased expression of ABCA1 and ABCG1 has been shown to 
enhance cellular cholesterol efflux in THP-1 monocytes when treated with Riccardin 
C via LXR activation [65]. Furthermore, ABCA1, ABCG1 and ABCG8 were shown to 
be increased in the liver and small intestine via LXR activation by the synthetic LXR 
agonist  T0901317 [66]. Cholesterol and its metabolites (including the oxysterols) are 
LXR ligands and as such drive LXR activity, targeting genes involved in cholesterol 
efflux, exportation and maybe chemotherapy resistance linking the cholesterol-LXR 
axis with regulation of ABC-transporters and the development of chemoresistance. 
1.2  The Liver X Receptor 
Metabolic processes and gene expression cascades are regulated by nuclear 
receptors (NRs), which are a major family of signal-stimulated transcription factors. 
Transcriptional interactions at target gene promoters involve ligand/signal-
dependent communications of NRs with many co-regulatory proteins [67]. These 
NRs respond by controlling transcriptomes involved in important processes such as 
proliferation [68]. Type 1 NRs such as ER, androgen receptor (AR) or PR bind to ligand 
in the cytosol, form homodimers or heterodimers and translocate from the 
cytoplasm into the nucleus to bind to DNA hormone response elements (HREs). Type 
2 NRs remain in the nucleus even in the absence of ligand binding as heterodimers 
to DNA. In the absence of ligand, the type 2 NRs such as LXR or retinoid x receptor 
(RXR) will associate with co-repressor proteins and when ligand binding occurs the 
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co-repressors dissociate, and the NRs recruit co-activator proteins along with 
ribonucleic acid (RNA) polymerase to facilitate transcription. 
The liver x receptor (LXR) is a member of the nuclear receptor superfamily and is a 
ligand activated transcription factor [69]. Two forms of LXR are known to exist LXRα 
(NR1H3) and LXRβ (NR1H2), both of which were identified in cDNA libraries [70-72] 
and originally believed to be orphan nuclear receptors. The human LXRα gene is 
located on chromosome 11p11.2, has 11 exons and is predominantly expressed 
expressed in metabolically active tissues and cells such as the liver, macrophages and 
small intestine [70, 73]. The human LXR gene is located on chromosome 19q13.3, 
has 8 exons [74] and is ubiquitously expressed [75]. Both LXR isoforms form 
heterodimers with the retinoid X receptor (RXR) and initiate transcription through 
binding to response elements in target gene promoters [73]. Nuclear receptors such 
as LXRα, can have multiple isoforms [76] and often have alterations in their domain 
structures as shown in Figure 1.2.  
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Figure 1. 2 LXR protein and domain structure. 
The protein structures of LXRα [77] and LXRβ [78] are shown (A) with a synthetic ligand bound to each 
from the front view (left) and from the back view (right). The helices are numbered 1-12. The protein 
structure of LXRα also shows the coactivator (SRC-1) bound (red spiral). B) Shows a schematic 
representation of the known three LXRα isoforms (originally published by Chen et al, 2005 [76] and 
LXRβ genomic structure. All three LXRα variants (LXRα1, LXRα2, and LXRα3) and LXRβ have; a ligand-
independent transcriptional activation function (AF-1) domain which is located at the N-terminus 
[red], a DNA binding domain (DBD) [yellow], a hinge region which is involved in conformational 
changes between active and inactive states [green], and a ligand binding domain (LBD) [blue] ending 
with a carboxyl terminus. The LXRα variants LXRα2 and LXRα3 each have alterations in their structure. 
LXRα2 has a shorter AF-1 region than LXRα1 and LXRα3. LXRα3 has a region within the LBD that is 
missing amino acids (aa) [purple box, red annotation]. 
 
1.2.1  LXR form and function 
NRs are categorized based on affinity, and steroid receptors such as the ER or the AR 
or seco-steroid receptors such as  the vitamin d receptor (VDR) and retinoic acid 
receptor (RARs) belong to the NR group with high affinity for ligand which respond 
to dietary factors in the low nanomolar range. Low binding affinity NRs such as LXRs, 
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farnesoid x receptors (FXRs) and peroxisome proliferator activated receptor (PPARs) 
respond to a much wider range of lipophilic molecules at the micromolar range. The 
remaining group of NRs are the orphan NRs, which have no known endogenous 
ligands or ligand binding domains identified yet, such as NR4A1 or NuR77 and utilize 
cofactors instead of ligands to regulate through changes in protein bioavailability.  
High and low affinity NRs are stimulated by ligand interaction with the binding 
domain, and these ligands are typically dietary derived compounds often involved in 
processes like glycolysis and oxidative phosphorylation [79]. LXR and LXR are 
important NRs that interact with dietary ligands regulating the expression of genes 
involved in cholesterol storage, efflux and eradication.  
The two LXR and LXR isotypes share 75 % sequence homology in their ligand-
binding and DNA-binding domains and function.  The LXR-RXR heterodimer binds to 
the DNA within gene regulatory regions favorably identifying LXR response elements 
(LXRE). Both LXR and LXR and can be activated either by an LXR agonist (such as 
T0901317/GW3965) or an RXR agonist (9-cis retinoic acid) [80]. LXR is 
phosphorylated at Ser198 and ligand-induced LXR phosphorylation at this site 
changes its activity in a gene-specific fashion [67, 81]. Interestingly, T0901317 has 
been shown to promote LXR phosphorylation at serine 198, however the RXR ligand 
9-cis retinoic acid (9-cis) inhibits LXR phosphorylation [67, 81]. Furthermore, LXR 
serine 198 (S198) phosphorylation has been shown to regulate the chemokine 
receptor type 7 (CCR7), which is not expressed in all cell types however in those cells 
that do, an open chromatin configuration is observed [81].  
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1.2.2  Cofactors 
Nuclear receptors are controlled through interactions with ligands, and in the 
absence of ligand the nuclear receptor LXR recruits co-repressors to constitutively 
associate with and bind to the promoter of the LXR target genes. The first 
corepressors, nuclear receptor interacting protein 1 (NCOR1) [82] and nuclear 
receptor interacting protein 2 (NCOR2/SMRT) [83] were discovered in 1995, and the 
ligand recruited corepressor (LCOR) [84] in 2003. Corepressors such as NCOR1 and 
NCOR2/SMRT are large proteins which possess independent repression domains and 
bind to nuclear receptors in the absence of ligand [85]. Their nuclear receptor 
binding and repression functions are facilitated through the carboxyl and amino 
terminal halves of the molecules and upon binding, changes the positioning of the 
helix 12 (H12) in the ligand binding domain of the NR. The H12 positioning has been 
shown to be critical for the binding of coactivators [86] and interestingly, loss of H12 
enhances repression and corepressor binding of nuclear receptors such as RXR [87, 
88] and PPAR [89]. A corepressors role is to downregulate the expression of genes 
under the control of transcription factors by binding to specific transcription factor 
binding sites.  
Coactivators such as nuclear receptor coactivator 1 (NCOA1) and nuclear receptor 
coactivator 3 (NCOA3) are recruited to the transcription factor binding site by 
nuclear receptors in the presence of ligand to increase the rate of transcription for 
genes under the control of the nuclear receptor (see Figure 1.3). However, 
corepressors and coactivators both bind to the same binding sites, but cannot be 
bound simultaneously, they must compete for binding. 
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Figure 1. 3 Type I and type II nuclear receptors. 
Nuclear receptors (NRs) are categorized based on affinity. High affinity NRs are shown in the top 
diagram: a hormone (yellow oval) enters the cytoplasm of a cell. The NR dissociates the heat shock 
protein (HSP) and the hormone binds creating a NR/hormone complex. The NR either remains as a 
monomer or forms a homodimer or heterodimer and translocates into the nucleus (grey oval) binding 
to a hormone response element (HRE) in the DNA. The NR dimer recruits coregulators such as a 
corepressor or coactivator and RNA polymerase (light blue oval). The mRNA is translated to protein 
and cell function is changed. Low affinity NRs are shown in the bottom diagram: a ligand (yellow oval) 
enters the nucleus (grey oval) of a cell. The NR heterodimer remains in the nucleus bound to the 
response element (RE) in the DNA. In basal conditions corepressors (red shape) are associated with 
the NR complexes. In the presence of ligand the NR heterodimer recruits a coactivator (green shape) 
and RNA polymerase (light blue oval) causing the corepressor to dissociate and initiating 
transcription. The mRNA is translated to protein and cell function is changed.  
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 1.2.3  Nuclear receptor de-regulation in cancer 
The three main co-activators associated with expression and regulation in BCa are 
NCOA1, nuclear receptor coactivator 2 (NCOA2) and NCOA3, and interestingly 
NCOA3 expression has been shown to be more highly expressed than NCOA1 and 
NCOA2 in MCF-7 (ER-positive BCa) cells compared to SK-BR-3 (HER2+) cells [90]. 
However, NCOA1 is known for its role in supporting BCa metastasis through 
activation of the matrix metalloproteinase and Twist1 genes [91, 92]. Furthermore, 
NCOA1 was more responsive to changes in nutrient status in aggressive metastatic 
cancers such as MDA-MB-231 (ER-negative BCa) and PC-3 (prostate cancer) than the 
less aggressive cells such as MCF-7 (ER-positive BCa) and lymph node carcinoma of 
the prostate (LNCaP) [93].  
The three main co-repressors of LXR are NCOR1, NCOR2 and nuclear receptor 
interacting protein 1 (NRIP1) and enhanced expression of these co-repressors has 
been observed in cancer [94, 95]. LXRα conformation and serine 198 
phosphorylation have been linked to the influenced recruitment of cofactors, such 
as NCOR [67, 81]. NCOR1 and NCOR2 skew the transcriptome selectively through 
restriction of NR signalling, which has been linked to further facilitating the Warburg 
effect [79]. Additionally, basal mRNA levels in tumour cells are also frequently 
enhanced in cancer relative to non-cancerous cells, and decreased LXR-ligand 
sensitivity is often observed [79]. Additionally, loss of function in NCOR1 and NCOR2 
mutations has been found to aid BCa development [96], underlining the complexity 
of NRs, cofactors and their interactions with ligands. 
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1.3  Cholesterol, LXR and Cancer 
Cholesterol is the primary sterol component of mammalian cells and is of key 
importance for cell function and viability [97]. Large amounts of energy expenditure 
are required to regulate cholesterol levels through mechanisms such as; de novo 
synthesis, storage and elimination of cholesterol via efflux (see Figure 1.4), 
intracellular transfer and metabolic pathways [98, 99]. Cholesterol also serves as a 
structural constituent of the cellular membrane and when incorporated into a 
phospholipid bilayer it organises itself, so the hydrophobic tail is in the bilayer and 
the polar hydroxyl group (head) of the compound is close to the surface, allowing 
the polar group interactions with neighbouring phospholipids altering the 
membrane structure [100].  
Cholesterol is an important component of cell membranes and because of this, cells 
have evolved intricate mechanisms to regulate distribution of sterols and their 
abundance [101]. Cholesterol is synthesised in the endoplasmic reticulum, travels to 
the golgi, combines with sphingolipids and is then transported to the plasma 
membrane in lipid rafts [102]. Lipid rafts are made up of lipids arranged in an ordered 
phase [103], and its these rafts that are responsible for the molecular sorting of 
membrane proteins into select areas of the membrane.  
LXR is stimulated by the interaction with oxidized cholesterol or oxysterols. The 
synthetic LXR agonists T0901317 and GW3965 and the antagonist GSK2033 have 
been the focus for many studies, which have demonstrated their efficacious 
regulation of LXR. Sabol et al, established the up-regulation of the ATP-binding 
cassette G1 (ABCG1) through treatment of 1 M T0901317 in Raw264.7 cells 
transfected with an ABCG1 promoter and (LXRE), and further demonstrated the 
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same in the HepG2 liver cell line [104]. Nelson et al, established the activation of LXR 
in the development of breast tumours in the ER-positive MCF-7 cell line by the 
synthetic LXR agonist GW3965 [105], demonstrating cholesterol synthesis and LXR 
have a role in BCa development. LXR ligands have been linked to cancer in many 
studies [66, 73, 106-108] via their LXR-driven luciferase activity or increased 
expression of LXR target genes involved in cholesterol efflux. LXR has several 
endogenous ligands that have been established in a series of different cell lines and 
tumours [66, 73, 104-112]. 
 
Figure 1. 4 Oxysterols serve as signalling molecules to control cholesterol metabolism via LXR.  
LXR is regulated by oxysterols/ligands binding which controls reverse cholesterol transport in 
macrophages through inhibition of the low density lipoprotein receptor (LDLR) by LXR activation of 
the inducible degrader of the LDL receptor (IDOL). LXR activation upregulates expression of ABCA1 
and ABCG1 which efflux cholesterol out of the macrophages and into the liver. In the liver cholesterol 
either regulates genes involved in lipogenesis such as fatty acid synthase (FAS) and acetyl CoA 
carboxylase (ACC) to convert acetyl-CoA into triglycerides for storage in fat tissue or is converted to 
bile acids. In the intestine, upregulation of ABCA1, ABCG5 and ABCG8 lower triglyceride  absorption 
to maintain cholesterol levels. 
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1.3.1  Cholesterol, obesity and statins 
In high-income countries such as the UK [113] and USA [114], obesity prevalence is 
high, in comparison to low-income countries such as Brazil [115]. Furthermore, 
altered cholesterol metabolism, which is considered a co-morbidity of obesity, has 
recently emerged as an independent risk factor of BCa in post-menopausal women 
[116]. High dietary cholesterol intake in a cohort of women increased risk of BCa 
cancer by 48 % [117] demonstrating the impact of altered cholesterol signalling and 
obesity in BCa development.  
Statins are routinely used in high risk patients to lower circulating LDL-C levels. 
Statins have been shown to induce cell cycle arrest in the G1 phase in vitro reducing 
cell proliferation in BCa cell cultures [118, 119] and a variety of other cell types [120]. 
Importantly, statins reduce the relative risk (RR) of several diseases, such as vascular 
events regardless of age, baseline LDL-C, and sex RR=0.79 (95% CI 0.77-0.81, per 1.0 
mmol/L reduction) [121]. Several epidemiologic studies have been conducted 
assessing the effects of statins on BCa, whilst most studies have shown reductions in 
BCa occurrence [122] there are studies who have not observed this same effect [123, 
124].  
These differences in epidemiologic study outcomes may be explained by the use of 
different statin types. There are two main types of statins, lipophilic and lipophobic 
statins. Lipophilic statins interrupt mevalonate synthesis in peripheral and liver 
tissues due to their ability to diffuse across membranes, showing possibilities of 
cholesterol dependent and independent effects [125]. Lipophobic statins affect 
hepatocytes that express transporter molecules due to active transport being their 
only mode of uptake [125]. Kumar et al, conducted one of the largest retrospective 
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ER-negative tumour studies during which they analysed data from 2,141 female 
participants who had a BCa incident. The study assessed statin use among the 
women previous to the BCa incidence and identified women taking lipophilic statins 
for more than a year had proportionally fewer ER/PR-negative tumours OR=0.63 
(95% CI 0.43-0.92: p=0.02) relative to women who did not use statins or had been 
for less than a year [122], which supports the need for larger meta-analysis to 
analyse the effects of lipophilic and lipophobic statin use separately.  
Evidence signifying statins as a pharmacological compound to reduce BCa 
reoccurrence by inhibiting cholesterol absorption has been shown [121, 125-129].  A 
meta-analysis showed a safe decrease of the 5-year cardio-vascular incidence by 21 
% with each 1.0 mmol/L reduction of cholesterol in patients when treated with 
statins [121]. Furthermore, Garwood et al, presented a pilot study of 40 women with 
stage I BCa or had a confirmed diagnosis of ductal carcinoma in situ (DCIS) who were 
treated with fluvastatin which is a lipophilic statin [125]. Ahern et al, reviewed these 
studies and concluded that a clinical trial of BCa therapy with statins, particularly 
simvastatin would develop existing data demonstrating statins as a prevention of 
BCa recurrence [126].  
Cholesterol is modified by members of the cytochrome P450 family to produce a 
pool of signalling molecules termed oxysterols (as shown as Figure 1.5). Oxysterols 
allow local and systemic homeostatic control of cholesterol metabolism via their 
binding affinity for LXR. The different oxysterols converted from cholesterol have 
varying capacities to drive LXR-mediated transcription suggesting an element of 
selective modulation. Furthermore, there appears to be little variation between 
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oxysterol concentrations in BCa subtypes [130] suggesting LXR activity or response 
to ligand may be altered in different subtypes.  
 
 
Figure 1. 5 Chemical structure of cholesterol, side-chain oxysterols and plant sterols/stanols:  
(a) cholesterol differences from oxysterols 24(S)-OHC, 25-OHC, (25R)26-OHC and 24(S),25-EC are 
highlighted; (b) structures of phytostanol (sitostanol (STAN)) and phytosterols (β-sitosterol (SITO); 
campesterol (CAMP); brassicasterol (BRAS); stigmasterol (STIG) used in this study. Differences in 
structure with cholesterol are shown in red. Image previously published by Hutchinson et al [131]. 
 
1.3.2  Oxysterols and the cholesterol pathway 
Oxysterols were first acknowledged as the main endogenous ligands for LXRα in 1996 
and confirmed shortly after in 1997 [111, 112, 132]. A variety of oxysterols are known 
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to exist, some of which include: 7-ketocholesterol (7KETO), 22-hydroxycholesterol 
(22OHC), 24-hydroxycholesterol (24OHC), 25-hydroxycholesterol (25OHC), 25,26-
hydroxycholesterol (26OHC) and 24,25-epoxycholesterol (24,25-EC) [73]. Oxysterols 
bind to and activate LXRα inducing expression of LXRα target genes.  Janowski et al, 
were the first to show enhanced LXRα activation in CV-1 cells after treatment with 
22OHC, 24OHC, 25OHC and 26OHC (previously referred to as 27OHC) at 10 μM [111], 
followed by Forman et al, who also showed increased LXRα activation by 22OHC, 
25OHC and 26OHC in CV-1 cells at 10 μM [132]. Furthermore, activation of both LXRα 
and LXRβ in CV-1 cells was observed when treated with 22OHC and 24OHC [112], 
and in Raw264.7 cells when treated with 22OHC [133]. The canonical LXR target 
genes HMGCR, NPC1L1, SR-BI and LDLR were repressed by 25OHC in HepG2 cells 
[109], however in HEK293 cells, 24,25-EC successfully stimulated LXRα driven 
luciferase activity by 9-fold [66]. Interestingly, 25OHC and 26OHC failed to activate 
LXRα in luciferase driven CV-1 cells [112], suggesting LXRα response to oxysterols is 
cell type and oxysterol conformation dependant. 
Oxysterols are anti-proliferative when bound to LXRα, but when bound to estrogen 
they are pro-proliferative [110, 134]. Hydroxylation of the cholesterol side-chain is 
the initial stage in the bile acid synthesis pathway and results in hydroxycholesterols 
(OHCs) with reactive –OH groups. They can damage DNA and proteins but are also 
signalling molecules for regulators of cholesterol biosynthesis and lipid homeostasis 
pathway (e.g. LXR/, ROR). Of all the oxysterols, 26OHC is the most researched 
oxysterol, possibly due to its abundance rather than efficacy as a ligand. 26OHC has 
been shown to be elevated in ER-positive breast tumours [110] when compared to 
healthy tissue and is able to encourage epithelial-mesenchymal transition (EMT) in 
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ER-positive BCa [135] and TNBC [105] cells (if applied at supra-physiological 
concentrations, although without a carrier the hydrophobicity of oxysterols makes 
assessing their solubility in vitro challenging). Furthermore, circulating levels of 
25OHC have been found elevated in patients treated for metastatic relapse 
compared to patients receiving treatment in the adjuvant setting [136], linking 
elevated oxysterol concentrations with BCa progression and relapse. 
In normal cell biology, nuclear receptors such as LXRα act as sensors to control 
intracellular cholesterol levels. In high cholesterol conditions, LXR activity is 
enhanced to transcriptionally control the export and trafficking of excess 
cholesterol. LXR controls the expression of efflux pumps such as ABCA1 for export of 
excess cholesterol or APOE for transport of cholesterol. In cancer biology, these 
essential cholesterol signalling pathways are often altered and cross-talk between 
cancer epithelial cells and support cells have been linked to cancer progression [137], 
metastatic relapse [138], and cancer stem cell (CSC) self-renewal [139]. Furthermore, 
patients who have tumours that are heterogenous with enhanced support networks 
(supported by fibroblasts, macrophages, adipocytes) tend to have poor prognosis.  
 
1.3.3  Oxysterols from support cells 
Breast cancer tumours are heterogeneous supported by a tumour 
microenvironment (TME) composed of multiple non-cancer cell types [140]. The 
TME is made up of support cells, immune cells and adipose cells which store and 
secrete factors into the TME, aiding and influencing cancer epithelial cell signalling 
pathways [141]. Macrophages, adipocytes and fibroblasts regulate expression of 
cytochrome P450 (CYP) enzymes to synthesise oxysterols and secrete them into the 
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TME supporting cancer epithelial cells [142]. Patients who have tumours with 
enhanced support cell microenvironments tend to have a poor prognosis, allowing 
the cancer cells to employ TME-driven metastatic and proliferative behaviours via 
paracrine signalling [143-145]. 
 
1.3.3.1  Fibroblasts 
Fibroblasts are support cells which provide collagen and ECM to the surrounding 
cells. They have migratory capacities and often exhibit an asymmetrical forked 
cytoplasm. Fibroblasts have been shown to not only produce 24OHC, 26OHC [146] 
and 25OHC [147], but also further modify oxysterols through CYP7B1 regulation 
[147]. Additionally, fibroblasts have been shown to regulate HMG-CoA reductase 
activity through 24,25-EC production [148]. 
There is evidence suggesting patients with breast tumours supported by fibroblasts 
tend to have poorer prognosis [144, 149] and tumour-stroma may have prognostic 
value [150]. Fibroblasts in the TME are often referred to as cancer associated 
fibroblasts (CAFs). One miRNA in particular has been linked to the progression of 
fibroblasts into CAFs, mir-21, which has been shown to inhibit smad7 translation (an 
inhibitor of TGF-β) which resulted in the transformation of resident fibroblasts (or 
non-cancerous fibroblasts) into CAFs [151], and has been shown to support cancer 
progression [152]. CAFs have also been shown to promote breast cancer tumour 
growth and metastasis in 4T1 orthotopically injected Balb/c mice [153]. 
Furthermore, fibroblasts derived from malignant breast tissue of women with 
invasive breast cancer were found to have different gene expression profiles when 
compared to fibroblasts from women with non-cancerous breast tissue [154]. 
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Additionally, another study by Bauer et al, compared the gene expression profiles in 
matched breast CAFs and non-cancerous fibroblasts from six primary human breast 
carcinoma and also found a panel of up-regulated genes in the CAFs relative to the 
non-cancerous fibroblasts but also found high variance in non-cancerous fibroblasts 
suggesting heterogeneity may originate from the non-cancerous fibroblasts. 
1.3.3.2  Macrophages 
Macrophages are immune cells which are known for their fundamental role of 
phagocytosis and secondary roles as antigen presenting cells stimulating T 
lymphocytes. Macrophages are not specifically associated with a region of the body, 
but are signalled or recruited to a site by chemokine receptors such as chemokine 
receptor 2 (CCR2) [155], or growth factors such as colony stimulating factor 1 (CSF1) 
secreted by BCa cells [156]. Monocytes are undifferentiated macrophages prior to 
recruitment and once stimulated they differentiate, mature and become 
macrophages. There are two subtypes of macrophages: M1 and M2 macrophages. 
M1 macrophages are classically activated macrophages which typically display anti-
tumorigenic properties and have roles in the pathogenic defence [156]. M2 
macrophages are alternatively activated macrophages and these are pro-
tumorigenic which express anti-inflammatory cytokines ( IL-4, IL-10 and IL-13) [156] 
and angiogenic factors (EGF and VEGF) [157, 158]. Interestingly, macrophages 
originally located in the tissue prior to tumour formation contribute little numbers 
to the TME [159]. Tumour associated macrophages (TAMs) are recruited to the 
tumour formation site as monocytes and differentiate into macrophages [160]. 
Macrophages are recruited by chemokines and the most commonly formed 
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chemokine is the chemokine ligand 2 (CCL2), which has been shown to positively 
correlate with macrophage accumulation in human breast tumours [161]. 
In normal cell biology oxysterol levels in macrophages are low [162], but outside 
their normal role as immune cells, macrophages have been shown to produce high 
levels of oxysterols to increase cholesterol elimination to inhibit foam cell formation 
[163] signifying they may have a central role in the cross-talk between lipid 
metabolism and immune regulation in disease. CYP27A1 is highly expressed in both 
macrophage subtypes [163], resulting in 26OHC production and delivery to cancer 
cells. In monocytes (early stage unstimulated macrophage cells) however, 26OHC 
production is low and only increases after maturation [162]. Interestingly, CH25H 
(the enzyme responsible for the conversion of cholesterol to 25OHC) is abundantly 
expressed in M1 macrophages, whereas CH25H expression in the M2 macrophage 
remains relatively low similar to the expression levels in monocytes [164]. 
Production of 24,25-EC has also been shown to enhance expression of ABCA1 and 
ABCG1 in macrophages promoting cholesterol efflux and inhibiting foam cell 
formation [165] linking these immune cells and their oxysterol production with 
enhanced LXR signalling in tumours supported by the TME. 
 
1.3.3.3  Adipocytes 
Adipocytes are non-cancerous cells which vary in size, storing fat in the forms of 
cholesterol or triglycerides. Their roles typically include energy expenditure and the 
secretion of adipokines which are signalling proteins. Adipocytes, like macrophages 
express high levels of CYP27A1 however adipocytes express low levels of the enzyme 
CYP7A1 which suggests adipocytes produce 26OHC without further modification of 
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the molecule [166]. CYP11A1 is also upregulated in mature adipocytes relative to 
adipocytes prior to maturation, demonstrating their ability to synthesise 22OHC 
[166]. Furthermore, synthesis of 25OHC was demonstrated in adipocytes prior to 
differentiation (pre-adipocytes) through enhanced expression of CH25H [167], and 
regulation of CYP46A1 by calorie consumption in adipocytes [168].  
 
1.3.4  Cholesterol in Cancer 
Cholesterol is a crucial compound with vital roles in the membrane structure and the 
synthesis of bile acids, vitamin D and steroid hormones [169]. Cholesterol in cancer 
is also a key requirement for the fast rate of uncontrollable cancer cell proliferation 
as shown by Shimizu et al, demonstrating increased plasma cholesterol enhanced 
tumour formation and increased tumour burden [170]. Cholesterol is tightly 
regulated within healthy individuals preventing over accumulation within the body, 
where this fails the development of atherosclerosis can happen due to the build-up 
of cholesterol plaques in the arteries [109]. Cholesterol homeostasis is regulated by 
several pathways with vital roles in the generation of endogenous cholesterol, the 
absorption of dietary sterols and its eradication and the production of bile acids. 
Prevention of cholesterol accumulation is controlled by the LXRs regulation of target 
genes involved in cholesterol catabolism, storage, efflux and elimination [169]. 
Cholesterol homeostasis is important for the body to generate and reutilize 
metabolites for energy production. 
Cholesterol absorption is regulated by the NRs LXRα and LXRβ which are known to 
respond to elevated cholesterol levels via transactivation of LXR target genes 
(ABCA1, ABCG1, ABCG5 and ABCG8) involved in sterol transport [169]. LXR has been 
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shown to control lipogenesis, including fatty acid synthesis (FAS) and export of very 
low-density lipoprotein (VLDL) showing links to hyperglyceridaemia induced by high 
carbohydrate/low-fat diets, atherosclerosis and hyperglycaemia [171]. Furthermore, 
treatments of plant sterols disrupted cholesterol homeostasis through decreased 
cholesterol synthesis inhibited SREBP-2 processing  in mice and via LXRα-mediated 
luciferase activity in CHO-7 cells [172]. These alterations in cholesterol homeostasis 
and cancer metabolism indicate a role for cholesterol in cancer progression. 
Enhanced circulating LDL-cholesterol (hypercholesterolemia) and surplus glucose 
from diet are therefore linked as contributing factors in cancer development as such, 
targeting members of the nuclear receptor family, LXRα in particular [105, 106, 110, 
134] has become of particular interest in BCa research.  
 
1.3.5  Oxysterol regulation of LXR 
Cholesterol and its role in cancer progression was suggested as early as 1913, when 
Robertson and Burnett, demonstrated tumour growth was accelerated following 
injections of cholesterol into xenographs [173]. Multiple studies have compared 
cholesterol levels in cancer tumours and healthy tissue, many of which have shown 
increased cholesterol levels in a range of different tumours, for example oral [174], 
gastrointestinal [175], thyroid [176], colon [177], prostate [178] and breast [110, 
136].  Interestingly, low serum cholesterol levels have been observed in patients with 
cancer [179, 180] which suggests cholesterol may accumulate within tumours. Many 
have looked at mechanisms that increase intracellular cholesterol in cancer cells, 
including the rate limiting HMG-CoA activity in the cholesterol synthesis pathway 
[181] and its loss of feedback inhibition by cholesterol [182]. The LDLR was also 
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shown to increase uptake of extracellular cholesterol [183, 184] and reduce the 
expression of the canonical LXR target gene ABCA1 a well-known cholesterol efflux 
pump [184, 185]. Thus, demonstrating the complexity of the interconnected 
mechanisms of cholesterol acquisition by cancer cells and tumours. 
1.3.5.1  In Prostate Cancer 
Evidence of oxysterol roles in prostate cancer have also been explored given that 
hypercholesterolemia leads to the increased risk of prostate cancer [186]. Prostate 
cancer development is dependent on the hormone androgen, mediated by the AR. 
Proliferation of prostate cancer cells is triggered by the AR and is associated with 
poor disease free survival in patients [187]. The LXR synthetic ligand T0901317, was 
shown to inhibit cell proliferation and tumour formation in tumour xenografts of 
LNCaPs prostate cells in athymic nude mice, showing a significant reduction in the 
growth of the tumours. Furthermore, LXRα signalling was determined by mRNA 
analysis showing a 3.5-fold increase of ABCA1 induction [188]. LXRα appears to have 
a protective role in the repression of prostate cancer [189] which is also supported 
by Chuu et al, who also showed a reduction in tumour growth and progression of 
LNCaP prostate xenografts in athymic nude mice when treated with T0901317 [190], 
and further showed LXR agonists stimulate cell cycle arrest via the up-regulation of 
p27 [191]. Therefore, demonstrating LXR regulation by its ligands has a beneficial 
effect on prostate cancer. 
 
1.3.5.2  In Breast Cancer 
In the last 5 years new roles for oxysterol signalling in BCa have been identified, with 
most studies focusing on 26OHC, largely due to abundance. 26OHC is however, a 
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weak ER and LXR ligand in BCa [105]. Nevertheless, elevated levels of 26OHC were 
found in breast tumour relative to normal breast tissue [110]. And treatment of 
26OHC was shown to drive ER-positive BCa growth via the ER and LXRα-dependent 
EMT [105]. Furthermore, Nelson et al, established that knockdown of the CY27A1 
enzyme accountable for the conversion of cholesterol into 26OHC resulted in the 
reduction of hypercholesterolemia-promoted tumour growth in mice [105]. 
Additionally, in MCF-7 cells, ABCG1 relative mRNA expression was significantly 
increased by 20 M T0901317 as well as 22OHC [106], whereas Wu et al 
demonstrated treatment of 26OHC promoted ER-positive BC growth via diminished 
CYP7B1 expression [110]. More recently, 26OHC was also shown to drive metastasis 
of breast tumours via γδT cells [21]. In addition to this, larger tumours derived from 
ER-negative MDA-MB-231 cells were observed in mice with high circulating LDL-C 
concentrations compared to mice with low LDL-C [51]. Finally, studies have reported 
that high total cholesterol is associated with an increase in BCa recurrence [192] and 
reduced disease free survival with high serum LDL-C [5]. Thus, showing that oxysterol 
signaling via LXRα has clear roles in the progression of BCa. 
 
1.3.6  Dietary ligands 
Phytosterols are similar in structure to several well-known LXR ligands, notably the 
oxysterols (Figure 1.5). The most abundant phytosterol in the human diet is β-
sitosterol, and phytosterol mixtures commonly include other sterols such as 
campesterol, stigmasterol and dihydrobrassicasterol [193]. Phytosterols and 
phytostanols are consumed either as whole foods as part of the human diet or as 
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components added to margarines or yoghurt drinks to reduce LDL-C. Another way 
to lower LDL-C is through pharmacological intake of statins. 
1.3.6.1  Plant sterol biology 
Phytosterols are natural plant constituents and by the early 1970s, over 40 different 
sterols had been identified from 7 different plant classes [194]. By the 2000s more 
than 100 sterols had been identified [195], and over 250 sterols are now known to 
exist [196]. Phytosterols and phytostanols (PSSs) are essential components of plant 
cell membranes [197] which lower the intestinal absorption of dietary cholesterol 
[198-200]. Lowering LDL-C significantly reduces the risk of cardiovascular disease, 
which can be achieved through the means of pharmacological statins [121] or by as 
high as 15 % through the consumption of a phytosterol rich diet (approx. 2-3 g/d) 
[201-203]. A reduction in cholesterol absorption by phytosterol intake has been 
linked to phytosterol/cholesterol competition for micelle incorporation, due to the 
displacement of cholesterol by phytosterols which have a higher affinity for 
intestinal micelles [202]. Phytosterols have been shown to be in the low micromolar 
range in the serum of the general population [204], however phytosterols are not 
easily absorbed, as such a moderate daily intake (approx. 2-3 g/d) is recommended 
for phytosterol consumption.  
Plant sterols or phytosterols are essential components of plant cell membranes [197] 
and have equivalent cellular functions in plants to those of cholesterol in mammals. 
Phytostanols are saturated sterols (shown in Figure 1.5) lacking a double bond in the 
ring structure and are hydrolysed in the upper small gut [205]. Phytosterols have 
similar structures to that of the oxysterols which allows them to be considered as 
selective modulators of LXRα and act as inhibitors of other nuclear receptors such as 
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FXR as shown by Carter et al [206]. Selective modulator is a term used to describe 
compounds that act in a tissue specific manner, for example, Tamoxifen is an 
antagonist of the estrogen receptor in breast tissue but is an agonist in other regions 
such as bone [207]. A full agonist is a compound that activates a receptor in all tissue 
types. It is unclear why there are so many variants of plant sterols but the range of 
structural forms, some of which mimic mammalian cholesterol modifications [208], 
provide exploitable biophysical properties (such as side chain branching and 
saturation) [209] for use in prevention and/or treatment of human cholesterol-
related diseases. 
1.3.6.2  Phytosterol/phytostanol regulation of LXR 
Given the structural similarities of PSSs and oxysterols it is not surprising there is a 
range of molecular evidence to suggest that PSSs are LXR ligands. If PSSs are 
accumulated in adequate amounts they integrate into the plasma membrane 
altering membrane fluidity, signalling cascades and lateral pressure on protein 
complexes [209]. Systemically, PSSs can alter cholesterol metabolism through; 
impairing cholesterol uptake from the diet [210], inhibiting enzymatic conversion of 
cholesterol to oxysterols [211] and inhibiting enzymes involved in cholesterol 
metabolism [172].  
In vitro PSSs have been shown to be LXRα ligands in HEK293 LXRα luciferase 
reporters, which were responsive to treatments of sitosterol, brassicasterol, 
campesterol and stigmasterol at 10 µM [66]. Down regulation of the canonical LXR 
target genes NPC1L1, HMGCR, SR-BI and LDLR was observed in HepG2 cell cultures 
treated with sitosterol and stigmasterol, and interestingly to a similar suppression 
level as that of 25OHC [109]. Other canonical LXR genes have also been shown to be 
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regulated by phytosterols as demonstrated by Plat, Nichols and Mensink who 
showed ABCA1 up-regulation by sitosterol, sitostanol and campesterol in Caco2 cell 
cultures [212]. Evidence of phytosterol regulation of LXR has also been 
demonstrated in hamsters when fed phytosterol diets. Plasma levels of LDL-C, 
cholesterol absorption and triglycerides were reduced in the hamster group which 
were fed phytosterols, but not in those which were fed phytosterol oxidised 
products (POP) [213]. Furthermore, the expression of the ABC-transporter ABCG5, 
microsomal triglyceride protein (MTP) and the esterification enzyme  acetyl CoA 
acetyltransferase (ACAT) were also reduced [213].  
Interestingly Alemany et al, saw a decrease in the expression of ABCG5 in Caco2 cells 
when incubated with 7-ketostigmasterol at 60 µM, as well as a decrease in ABCG8 
expression. NPC1L1 however, was not altered by POP treatments but there was an 
increase in HMG CoA in the Caco2 cell cultures resulting in an increase in cholesterol 
synthesis [214]. In a co-activator peptide recruitment assay phytosterols from the 4-
desmethylsterol family were shown to be effective LXRα agonists, with campesterol 
and sitosterol inducing ABCA1 expression in Caco2 [212]. ABCA1 and ABCG1 
expression was also increased in mouse peritoneal macrophages (MPMs) when 
treated with stigmasterol (10 µM), 25OHC (10 µM) or T0901317 (1 µM), however 
25OHC significantly decreased expression of HMGCR and LDLR [215]. PSSs can bind 
and may activate LXR in a cell type dependent manner and has been suggested by 
O’Callaghan, that phytosterols control cholesterol absorption by reducing 
esterification within the enterocyte which reduces the packaging of cholesterol into 
chylomicrons via MTP [216]. Additionally, Brauner et al, demonstrated an increase 
in ABCA1 expression by cholesterol treatment in Caco2 cell cultures, however co-
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treatment of cholesterol with either campesterol or sitosterol attenuated 
transcriptional output of the LXR target gene [211], suggesting phytosterols are 
selective modulators of LXR and actively compete for binding. 
1.3.6.3  Breast cancer risk and cholesterol status 
Other than how PSSs can lower LDL-C, very little is known about their functions at 
the molecular level in healthy tissue or in cancer biology. There is however 
circumstantial evidence (where dietary intake of plants and therefore PSS are 
assessed for BCa risk) which suggest anti-cancer properties of phytosterols.  
There have been numerous studies exploring the consumption of phytosterols and 
their effects on lower circulating cholesterol. For example, a study by Miettinen et 
al, showed patients who were fed sitosterol-containing margarine had a reduction 
in serum cholesterol levels (1 year mean reduction 10.2 %) when compared to a 
control group which had a mean increase of 0.1 % [199]. Furthermore, a meta-
analysis of 217 epidemiologic studies found a strong association between fruit and 
vegetable consumption and the incidence of cancer [217]. Additionally, other 
analyses have shown a reduction in the risk of developing common cancers by 50 % 
when at least 5 servings per day of fruit and vegetables are consumed (when 
compared to those who ate less than 2 servings per day) [218]. Reduced cancer risk 
was also shown in observational studies where healthy dietary patterns linked to 
high PSS intake [219] and the consumption of plant-rich diets [220] have shown 
improved survival and reduced cancer incidence. Furthermore, clinical intervention 
trials demonstrated reduced rates of BCa and/or an increase in survival when 
saturated fat intake was lowered [48, 221]. 
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Pharmacological intake of statins is used to help reduce circulating LDL-C in high risk 
patients. Stains have been shown to reduce LDL-C in multiple studies, one of which 
also reduced the risk of major vascular events RR=0.79 (95 % CI 0.77-0.81, per 1.0 
mmol/L) irrespective of previous vascular events, age, sex and baseline LDL-C [222]. 
There are many studies that have looked at the effects of statin use, and some of 
these have specifically looked at the effects on BCa risk. One of the largest published 
cohorts who were looking specifically at the impact of statin use on overall risk (OR) 
in ER-negative BCa tumours, demonstrated a reduction in ER-negative BCa OR=0.63 
(95 % CI 0.43-0.92: p=0.02) in women taking lipophilic statins for more than a year 
[122]. In human BCa cell line models, research has shown interesting anti-cancer 
effects of statins when used in combination with the chemotherapy drug 
doxorubicin or cisplatin [119]. Statins have also been shown to reduce cell 
proliferation in vitro by inducing cell cycle arrest in the G1 phase [119] and induce 
apoptosis [129] in multiple BCa cell lines. Furthermore, fluvastatin (a lipophilic statin) 
was shown to reduce proliferation and increase apoptosis in women with high grade 
BCa [125]. However, not all studies have shown favourable effects for all statin types. 
Pocobelli et al, reported they found no change in BCa risk in patients who used 
hydrophilic statins, but they did observe a reduction in BCa risk in women who had 
taken fluvastatin OR=0.5 (95 % CI 0.3-0.8) for less than 5 years [124].  
 
1.3.7  Chemoresistance and LXR through the p-glycoprotein 
The ABC-transporters are a superfamily of essential efflux pumps responsible for the 
ATP powered translocation of substrates such as cholesterol or chemotherapy drugs 
across cell membranes. The canonical LXR target gene ABCA1 for instance, is an ABC-
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transporter that controls intracellular cholesterol efflux. Others such as ABCG1, 
ABCG5 and ABCG8 are known sterol efflux pumps also under the control of LXR, but 
LXRs control of other ABC-transporters such as ABCB1 (p-glycoprotein) in breast 
tissue remains unidentified. P-gp/ABCB1 is an important protein, with its roles in 
chemotherapy drug efflux established in cancer [223]. Chemotherapy efflux pumps 
can reduce the efficacy of chemotherapy treatment by exporting toxic drugs out of 
the cancer cells which stops the drug intercalating with DNA and minimalizes the 
drug effects. This is a common cause of chemotherapy resistance and is associated 
with the over expression of chemotherapy drug pumps, such as the p-gp/ABCB1 
[224], multidrug resistance protein (MDRP) [225] and the breast cancer resistance 
protein (BCRP) [226]. LXRα is not commonly associated with regulated expression of 
the p-glycoprotein/ABCB1 (p-gp/ABCB1). One study however, showed 24OHC, 
26OHC and T0901317 increased the expression of p-gp/ABCB1 in the blood brain 
barrier (BBB) which resulted in the efflux of oxysterols across the membrane and 
restriction of ameloid-β peptide Aβ peptide efflux [227]. This suggests a therapeutic 
role for LXRα regulation of p-gp/ABCB1 in the brain, but also in regions were LXRα 
activity is enhanced. 
Overall links between breast risk and cholesterol status have been discussed, 
whether it be through plant-based diets improving survival and lowering cancer 
incidence [219, 220], reduced risk of major vascular events by statin-associated LDL-
C reduction [222] or reduced rates of BCa incidence by decreasing saturated fat 
intake [48, 221]. Furthermore, cholesterol metabolites have been shown to promote 
BCa growth [105, 110] and metastasis [21], induce EMT [105] and has been found 
elevated in patient serum at relapse [136]. Finally, the LXR ligands 24OHC and 26OHC 
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were shown to regulate the chemotherapy efflux pump p-gp/ABCB1 [228] which is 
often linked to the development of chemotherapy resistance [223]. Therefore, 
suggesting roles for; altered oxysterol signalling in breast cancer with cross-talk from 
support cells, oxysterols-LXR dependent chemotherapy resistance through the p-
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Chapter 2 
Hypothesis:  
Regulation of the oxysterol-LXR-axis leads to the development of chemoresistance 




a) Establish whether LXR activity and function is enhanced in TNBC relative to 
Luminal A/ER-positive disease. 
b) Determine if enhanced LXR activity leads to chemoresistance in TNBCs. 
c) Establish if fibroblasts can activate LXRα in TNBC and Luminal A breast cancer 
epithelial cells. 
d) Determine if phytosterols antagonise LXR activation in TNBC. 
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Chapter 3 
Materials and Methods 
3.1 Cell culture  
The BCa cell lines MDA-MB-468, MDA-MB-231 and MCF-7 and the breast fibroblasts 
NF2 and LaCAF were provided by Dr Thomas Hughes (St. James University Hospital, 
Leeds). BCa cells were cultured in Dulbecco’s modified eagle medium (DMEM, 
Thermo Fisher, Cat: 31966047) supplemented with 10 % foetal calf serum (FCS) 
(Thermo Fisher, Uk, Cat: 11560636) and maintained at 37 oC with 5 % CO2 in a 
humidified incubator (Panasonic, MCO-170A1CUV-PE, UK). Cells were seeded to 1 x 
106 cells in a T75 tissue culture treated flask (Nunc, Thermo Fisher, UK, Cat: 
10364131) for routine passaging every 3-4 days to ensure confluency remained 
between 20-80 % which was determined using an inverted microscope (Ceti, 
Medline, UK, X20 lens). Routine passaging of cells was completed as follows. Cells 
were washed with 5 mL phosphate buffered saline (PBS; Thermo Fisher, UK, Cat: 
10209252) and detached with 3 mL 1X trypsin (Thermo Fisher, UK, Cat: 10779413). 
Trypsin was deactivated after 3-5 minutes with 7 mL DMEM containing FCS. Cells 
were resuspended using a sterile stripette and pipette to ensure a single cell 
suspension, before 10 L was used to count cells using a haemocytometer with 
trypan blue (Thermo Fisher, UK, Cat: 15250061) to distinguish between live and dead 
cells.  
3.1.2 Drugs and reagents  
Drugs stocks were stored at -20 oC and diluted or dissolved as stated in the table 
below. Oxysterols were prepared in a sterile unit and diluted in nitrogen flushed 
ethanol (NFE) to prevent auto-oxidation. The following phytosterols were provided 
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by E. Trautwein (Unilever, Vlaardingen, Holland) or later purchased from Avanti and 
stored in NFE at 5 mM or 20 mM stocks at -20 oC. Epirubicin was protected from light 
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Table 1 Nuclear receptor ligands. 
The ligand name is included in the first column followed by its acronym in the second column. The third column provides details of the company the ligand was purchased from 
and the fourth column for the catalogue or identifier code. The diluent is shown in the fifth column and the stock concentration in the sixth. The seventh column provides the 
ligand EC50 or IC50 followed by the model details in the eighth column. The ninth column provides details of known target receptors the ligand interacts with. 




EC50/IC50 Model Target Receptors 
T0901317 T090 Cayman 71810 DMSO 10 mM 50 nM HEK293 LXRα, LXRβ, FXR. 
GW3965 GW ToCris 2474 ETOH 10 mM 190 nM Cell based LXRα, LXRβ, PXR 
GSK2033 GSK ToCris 5694 ETOH 10 mM 17 nm HEK293 LXRα, LXRβ, ERα, ERβ, PR, GR, RXR, VDR, PXR, 
FXR, CAR, RORα 
 22-hydroxycholesterol 22OHC Avanti 700058 NFE 10 mM 5 µM CV-1 LXRα, LXRβ 
24-hydroxycholesterol 24OHC Avanti 700071 NFE 10 mM 4 µM CV-1 LXRα, LXRβ 
25-hydroxycholesterol 25OHC Avanti 700019 NFE 10 mM 7 µM CV-1 LXRα, LXRβ, ERα 
25,26-hydroxycholesterol 26OHC Avanti 700021 NFE 10 mM 85 nM HEK293 LXRα, LXRβ, ERα, ERβ 
24,25-epoxycholesterol 24,25 Avanti 700037 NFE 10 mM 10 µM CV-1 LXRα, LXRβ 
7-ketocholesterol 7-KETO Avanti 700015 NFE 10 mM N/A N/A LXRα, LXRβ 
β-sitosterol SITO Avanti 700095 NFE 5 mM 42 nM CoA Peptide LXRα, LXRβ 
β-sitostanol STAN Avanti 700121 NFE 5 mM 136 nM CoA Peptide LXRα, LXRβ 
Campesterol CAMP Avanti 700126 NFE 5 mM 43 nM CoA Peptide LXRα, LXRβ 
Brassicasterol BRAS Avanti 700122 NFE 5 mM N/A N/A LXRα, LXRβ 
Stigmasterol STIG Avanti 700062 NFE 2.5 mM N/A N/A LXRα, LXRβ 
ETOH; ethanol, NFE; nitrogen flushed ethanol, DMSO; dimethyl sulfoxide, CoA Peptide; coactivator peptide assay.
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Table 2 List of drugs. 
The chemical or drug name is included in the first column followed by its acronym in the second 
column. The third column provides details of the company the item was purchased from and the 
fourth column for the catalogue or identifier code. The diluent is shown in the fifth column and the 
stock concentration in the sixth. 
Chemical Acronym Company Identifier Diluted in Stock conc. 
Puromycin 
Hydrochloride 
Puro Santa Cruz sc-108071 NFW 25 mg/mL 
MK-571 MK Cambridge 
Bioscience 
10029 DMSO 10 mM 
KO143 KO Sigma K2144 DMSO 10 mM 
Verapamil V20 Insight 
Biotechnology 
sc-3590 NFW 10 mM 
Epirubicin EPI Cambridge 
Bioscience 





MTT Sigma M2128 PBS 5 mg/mL 
Crystal Violet CV Sigma V5265 H2O, ETOH, 
MeOH 
1 % CV 
solution 
ETOH; ethanol, NFW; nuclease free water, DMSO; dimethyl sulfoxide, PBS; phosphate buffer solution, 
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3.2 Generation of LXR-reporter cell lines 
Cignal lentiviral particles (LXRα) were purchased from Qiagen (Cat: CLS-7041L, LXRα 
TRE sequence: TGAATGACCAGCAGTAACCTCAGC) and transduced into the cells. Each 
vector contain at least 5 TRE repeats. Schematic diagrams of A) the LXRα Cignal 
lentiviral particles, B) the negative control lentiviral particles and C) the constitutively 
active positive control lentiviral particles used to generate the reporter cell lines are 
shown below in Figure 3.1. Following the schematic is a table of the vector key 
features.  
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Figure 3. 1 Schematic diagrams of LXRα reporter constructs. 
The Cignal lentiviral particles used to generate A) LXRα responsive B) negative control and C) 
constitutively active positive control reporter cell lines are shown here. Key differences include; the 
addition of the LXRα transcription response element (TRE) in the LXRα responsive reporter, the lack 
of TRE in the negative control reporter and the addition of a CMV constitutively active promotor 
in the positive control. Key features are shown in Table 3. 
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Table 3 The Lentiviral reporter features and functions. 
The plasmid features from the LXRα reporter construct schematic diagrams are shown in the first 
column with the function described in the second column. 
 
 
3.2.1 Puromycin titration curve 
Cell were seeded at 3x104 cells per well in a 96-well plate, incubated overnight and 
a puromycin titration applied to the plate ranging from 8 µg/mL to 0 µg/mL. Cells 
were in DMEM containing puromycin for 5 days with media replaced fresh on day 3. 
After 5 days the wells were inspected under a microscope and the lowest 
concentration of puromycin that resulted in complete cell death was chosen for 
reporter cell isolation.  
3.2.2 Transduction with lentiviral particles 
Cells were seeded at 30,000 cells per well in a 24-well plate and incubated overnight. 
Cignal lentiviral particles (LXRα) were purchased from Qiagen (Cat: Cat: CLS-7041L) 
Feature Function 
RSV-5’ LTR; Hybrid Rous sarcoma 
Virus (RSV) enhancer/promoter-U5 
long terminal repeat  
Permits reverse transcription of viral mRNA and 
viral packaging 
Psi; Packaging signal Allow viral packaging 
RRE; Rev response element Involved in the packaging of viral transcript  
cppt; Central polypurine tract  Involved in the nuclear translocation and 
integration of transduced viral genome 
Reporter gene (firefly luciferase) Allow quantification of transcription 
hPGK; human phosphoglycerate 
kinase eukaryotic promoter  
Permits high-level expression of the 
mammalian selection marker (puromycin) 
PuroR; puromycin resistance gene  Can be used for mammalian selection  
SIN/3’LTR; 3’ self-inactivating long 
terminal repeat 
Modified 3’LTR that allows viral packaging but 
self-inactivates the 5’LTR for biosafety purpose. 
The element also contains a polyadenylation 
signal for efficient transcription termination  
f1 ori; f1 origin of replication Origin of DNA replication for bacteriophage f1 
AmpR; ampicillin resistance gene  Allows selection of the plasmid in E.coli 
LXRα TRE; LXRα Transcription 
response element 
Permits regulation of reporter gene expression 
by a specific transcription factor - LXRα 
TATA box Act as an minimal promoter  
CMV;  Cytomegalovirus Constitutively active promotor 
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and transduced into the cells using 10,000 particles/µL (total amount used varied 
dependant on cell line MOI) and 8 µg/mL SureEntry transduction reagent. MDA-MB-
468 cells had 150,000 transduction units/well, MDA-MB-231 cells had 30,000 
transduction units/well and MCF-7 cells had 60,000 transduction units/well. After 18 
h the particles were removed and fresh DMEM supplemented with 0.1 mM non-
essential amino acids (Thermo Fisher, Cat: 12084947) and 100 U/mL penicillin and 
100 g/mL streptomycin (Thermo Fisher, Cat: 10378016) were added to the cells. 
Cells were passaged to a 6-well plate after 24 h to avoid over confluency and 
incubated for a further 24 h. DMEM was then replaced with DMEM containing 
puromycin (1 µg/mL as determined in section 3.2.1) to isolate successfully 
transduced cells.   
3.2.3 Luciferase assay 
The method for cell culture was followed, once the luciferase reporter cells were re-
suspended to 1x106 cells/mL dilute 1/10 to achieve 10,000 cells/100 L. 100 L of 
cell suspension was plated in a 96 well white walled tissue culture (TC) plate (Greiner 
Bio-one, Cat: 655098) and incubated for 8 h. Cells were treated with oxysterols 
(Avanti: 1 pM-50 µM), phytosterols (Avanti: 1 pM-50 µM) and synthetic ligands 
(GSK2933, T0901317 and GW3965: 1 pM-50 µM) as positive controls /vehicle control 
(NFE, DMSO) as required and incubated overnight for 16 h. Cells were washed with 
PBS and lysed with 30 L/well passive lysis buffer 1X and placed on a rocker for 15 
min. Injectors were used on the Tecan Spark 10M (TECAN, Spark 10M, UK) to inject 
50 L (optimised) LAR II (Promega, Uk, Cat: E1501) into the sample well and 
luminescence was then measured. This was completed well by well. LXRα activation 
was normalised to a vehicle control, error bars represent standard deviation. 
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3.2.4 Clone selection, storage and copy number analysis 
3.2.4.1 Clone selection 
Following reporter generation, cells were harvested using trypsin and cells counted. 
Cell suspensions were diluted to achieve 100 cells/200 µL, and, using a p200 
multichannel pipette, 200 µL per well was plated into the first column of a 96 well 
plate. The rest of the plate was filled with 100 µL of fresh media and a 2-fold serial 
dilution was performed moving 100 µL of cell suspension from the first column to 
the second, mixed, from the second to the third and so on. The dilution series aimed 
to plate single cells roughly between columns 6-9. Cells were incubated for 16-24 h. 
Using a microscope, wells containing single cells were identified and marked on the 
plate. Plates were returned to the incubator and allowed to proliferate until 80-90 % 
confluency was achieved. Cells were then passaged into a 6 well plate and returned 
to the incubator. Cells were expanded until adequate cell numbers had been reached 
to freeze cells down, plating into a luciferase assay, DNA extraction for copy number 
analysis and further expansion.  
3.2.4.2 Storage/freezing down cells 
Cells were washed with PBS, detached using trypsin and counted. Cells were pelleted 
by centrifugation and gently resuspended to 1x106 cells/mL in freezing media (90 % 
FBS, 10 % DMSO). 1 mL cell suspension was then added to labelled cryotubes and 
placed in a freezing container in the -80 ⁰C freezer overnight to allow a controlled 
rate of freezing (1 ⁰C per min). Cryotubes were then moved to the liquid nitrogen 
storage within 24 h. 
3.2.4.3 Copy number analysis 
Cells were harvested (1x106 cells/mL) and washed twice with PBS. Cells were then 
resuspended in 1 mL DNA buffer (1 M Tris-HCL, pH 8.0, 0.5 M EDTA in dH20) and 
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transferred to 1.5 mL sterile Eppendorfs. Cells were centrifuged for 10 min at 10 ⁰C 
(225 rcf), supernatant removed and the cell pellets resuspended in 300 µL DNA 
buffer. Proteinase K (2.5 µL: 20 mg/mL) and 20 % SDS (20 µL) was added to the 
Eppendorfs and were shaken vigorously. Eppendorfs were then incubated overnight 
at 45 ⁰C. The next morning 350 µL of phenol was added to the Eppendorf’s and 
shaken vigorously for 10 min at room temperature. Eppendorfs were then 
centrifuged for 10 min at 10 ⁰C (956 rcf). The supernatants were transferred to a new 
sterile Eppendorf and the volume measured. One part phenol and one part 
chloroform/isoamyl alcohol (24:1) were added to equal the volume of the 
supernatants. Eppendorfs were shaken vigorously for 10 min at room temperature 
then centrifuged for 10 min at 10 ⁰C (956 rcf). The supernatants were transferred to 
a new sterile Eppendorf and the volume measured. Phenol and chloroform/isoamyl 
alcohol (24:1) were added to equal the volume of the supernatants. Eppendorfs 
were shaken vigorously for 10 min at room temperature then centrifuged for 10 min 
at 10 ⁰C (956 rcf). The supernatants were transferred to a new sterile Eppendorf and 
the volume measured. 3 M sodium acetate (pH 5.2) was added to equal 1/10th of the 
volume of the supernatants. 1 mL of 100 % isopropanol was added and the 
Eppendorfs were rotated end to end for30 min at 4 ⁰C until the DNA precipitated. 
The DNA was pelleted by centrifugation (10 min at 10 ⁰C, 956 rcf) and resuspended 
in 1.5 mL 70 % ETOH. This was repeated twice to wash the pellet, then centrifuged 
for 20 min at 10 ⁰C, 20817 rcf). The supernatant was removed and the pellet left to 
air dry for >20 min. The dried DNA pellet was then resuspended in 20 µL of NFW and 
placed in a thermomixer overnight at 37 ⁰C. DNA was quantified using the Tecan 
Spark 10M using NanoQuant plateTM with 1 L DNA. Blanking was completed before 
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and between sample reads. Quantification was performed by assessing absorbance 
at A260 nm and quality assessed with A260/280 and A260/A230. Remaining DNA 
was stored at 4 ⁰C.  
DNA was then used to assess copy number by qPCR using primers targeted to an 
endogenous gene with known copy number and targeted to the luciferase ORF 
(unknown copy number). GoTaq qPCR Master Mix kit was used for qPCR (Promega, 
UK, Cat: A6002) and product guidelines were followed (TM318). CXR (reference dye) 
was added 1 in 100 as required by the QuantStudio Flex 7 (Applied Biosystems Life 
Tech, Thermo Scientific, UK). Primer stocks were stored at -20 oC in NFW at 100 µM. 
For DNA copy number analysis, the sequences used are shown in the table below. 
All primers were designed to span exon boundaries, have GC Clamp, and melting 
temperature 58-62 oC. Primers were validated before use and all amplified with 
efficiencies of between 96 % and 100 %.  
Table 4 Gene sequences. 
The gene name for each primer are shown in the first column, with the direction of prime in the 
second column. The third column shows the primer sequences in the 5’-3’ direction. Primers were 
purchased from Sigma Aldrich, UK. 
Gene Forward or 
reverse prime 
Sequence 
β-actin  Forward 5’ CAACTCCATCATGAAGTGTGAC 3’ 
Reverse 5’ CCACACGGAGTACTTGCGCTC 3’ 
LXRE-2 Forward 5’ GAAGGCGGAGGAGGAAAGC 3' 
Reverse 5’ TCTTGAAACCTGAGCTGGGG 3’ 
Luciferase 
ORF 
Forward 5’ GAGATACGCCCTGGTTCCTG 3’ 
Reverse 5’ GCATACGACGATTCTGTGATTTG 3’ 
 
3.3 Time course assays 
Cells were maintained as described above (see section 2.1) then 250,000 cells/well 
plated in 6 well plates. Cells were incubated overnight before treatments of VC 
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(ETOH), GW3965 (1 µM), GSK2033 (1 µM) and epirubicin (25 nM) were treated at 
various time points (0 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 16 h and 24 h). 
3.4 RNA extraction and quantification 
Promega Reliaprep RNA Cell Miniprep System was used for the RNA extraction 
(Promega, UK, Cat: #Z6012), and product guidelines were followed (TM370). 
Approximately 5x105 cells were harvested and cell pellets re-suspended in 250 L 
BL+TG buffer (Guanidine Thiocyanate + 1-Thioglycerol) and 85 L 100 % isopropanol 
to lysate cells. On column DNA digestion was performed with DNase 1 in Yellow Core 
Buffer, 0.09 M MnCl2 at room temperature for 15 minutes. 30 L NFW was used to 
elute the RNA and was stored at -80 oC. 
RNA quantification was measured using the Tecan Spark 10M using NanoQuant 
plateTM with 1 L RNA. Blanking was completed before and between sample reads. 
Quantification was performed by assessing absorbance at A260 nm and quality 
assessed with A260/280 and A260/A230.  
3.5 Reverse transcription 
GoScriptTM Reverse Transcription kit (Promega, UK, Cat: A5003) was used for the 
cDNA synthesis, and product guidelines followed (TM316). 500 ng/reaction of RNA 
was used as template with 1 L random primers. Primers were annealed in a pre-
heated block for 5 min at 70 oC, then immediately placed on ice for 5 min. Mastermix 
was prepared (NFW, GoScriptTM 5X reaction buffer, MgCl2 (5 mM), PCR Nucleotide 
mix (0.5 mM), and GoScriptTM Reverse Transcriptase (160u/L) and 15 L was added 
to each sample tube. RT cycle followed in line with product manual. cDNA produced 
was then diluted 1 in 5 in NFW and stored at -20 oC.  
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3.6 Gene expression analysis 
3.6.1 Taqman 
Taqman Fast Advanced Mastermix (Thermo Fisher, Paisley, UK, Cat: 4444557) was 
used with Taqman assays (Thermo Fisher, Paisley, UK, Cat: 4331182) on a 
QuantStudio Flex 7 (Applied Biosystems Life Tech, Thermo Scientific, UK) for gene 
expression experiments. Taqman assays and Mastermix were stored at -20 oC. Gene 
expression was analysed using the cT method and normalised the housekeeping 
gene HPRT1. 
Table 5 Taqman Assays. 
The gene name for each primer are shown in the first and fourth column, with the company 
identification number in the second and fifth column. The third column is left blank for separation 
purposes.  
 
Gene Name Taqman ID 
 
































3.7 Colony forming assay 
The method for cell culture was followed as described above (see section 2.1), and 
once cells were suspended to 1x106 cells/mL, 250 L/well of cell suspension was 
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plated into a wells of a 6-well plate and topped up to 2 mL with DMEM-10 %. Cells 
were incubated overnight and then treated with T0901317 (2.5 M), GW3965 (1 
µM), GSK2033 (1 µM), oxysterols (10 µM) or vehicle control (VC) (ETOH/DMSO/NFE) 
and incubated for 24 h. Then epirubicin (25 nM) or VC (nuclease free water) was 
added for a further 24 h. Cells were then counted and 500 cells per treatment were 
plated in triplicate in 6 well plates (Nunc, Thermo Fisher, UK, Cat: 10119831). These 
were incubated for 12 days, until colonies were around 50 cells per colony. Colonies 
were washed with PBS and stained with a 0.1 % crystal violet staining solution was 
this in 50 % methanol, 30 % ethanol and 20 % ddH20 (Sigma, UK, Cat: V5265-250 ML). 
Colonies were left to air dry overnight then manually counted. The raw data were 
normalised to the vehicle control samples and presented as mean ± SD. 
3.8 Chemotherapy efflux assay 
This assay was designed to utilise the natural fluorescence of the chemotherapy drug 
epirubicin to measure the effect of LXR ligands on the chemotherapy drug export. 
Cells were plated (50,000 cells/well) in clear bottom black walled tissue culture 96 
well plates (Greiner Bio-One, UK, Cat: 655986) using a p200 multichannel pipette and 
incubated for 8 h. Cells were pre-treated with either VC (ETOH) or LXR ligands 
(GSK2033, GW3965 at 1 µM, 24OHC, 26OHC, SITO, STAN at 10 µM) for 16 h before a 
high dose of chemotherapy agent (50 µM epirubicin) for 1 h. Cells were gently 
washed with PBS taking care not to disrupt/detach cells and fresh PBS (100 µL) was 
placed in the wells and fluorescence was measured using a basic plate reader at 485 
nm excitation and 590 nm emissions. Cells were then placed in the incubator with 
fresh growth media in the wells and wash steps and fluorescence reads routinely 
measured over the course of 1.5-2 h. Fluorescence reads for treated cells were 
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normalised to VC cells. For pump inhibitor treatment, drugs were administered to 
the cells 30 min before epirubicin loading (verapamil - 20 µM, MK571 – 50 µM, and 
KO143 – 15 µM). 
3.9 siRNA knockdowns 
Cells were plated in 6 well plates (250,000 cells/well) and incubated overnight. 
Lipofectamine RNAiMAX (Thermo Fisher, Cat: 13778030), siRNA (origene; catalogue 
numbers in Table 6) and the universal negative control siRNA (origene; Cat: SR30004) 
were diluted in OptiMeM (Thermo Fisher, Cat: 31985062) and added to the cells at 
the final concentration of 30 nM. The cells were incubated for 22 h and the media 
was changed for fresh DMEM. After 36 h of exposure to the siRNAs, RNA was 
extracted in BL+TG buffer as described above. RNA was quantified by assessing 
absorbance at A260 nm and quality assessed with A260/280 and A260/A230, 
followed by reverse transcription ad qPCR analysis. 
Table 6 siRNA catalogue numbers. 
The gene name for the targeting siRNAs are shown in the first column, with the company 
identification number in the second column. Each siRNA is provided as three 3 unique siRNA duplexes. 
Each duplex is individually and collectively validated for silencing efficiency in each cell line. 







3.10 TCGA Dataset analysis 
Genes of interest were analysed in the cBioportal database [229]. The TCGA Nature 
2012 study [230] was selected from the section labelled breast, under the 
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subcategory Invasive Breast Carcinoma. Once selected, mRNA expression z-scores 
was highlighted and mutations and copy number deselected. Breast cancer subtype 
was chosen using the PAM50 classification (Basal, Claudin Low, Luminal A, Luminal 
B, Her2 enriched or Luminal A/B). Finally, the genes of interest were entered into the 
query box and submitted. Gene expression in the selected patient dataset was then 
downloaded in a tab delimited format and collected in excel. Data was then imported 
into graphpad prism and gene expression analysed between BCa subtypes. Statistical 
analysis was assessed using 2-tailed unpaired t-tests where significance is shown to 
be *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
3.11 Volcano plots 
3.11.1 LXRα target gene plot 
Top 100 scoring genes in LXRα-ChIP-Seq datasets sourced from Cistrome.org [231] 
were downloaded from 7 available datasets in various cell types (macrophages, 
adipocytes and colorectal cancer cells). Genes that were common in two or more 
datasets were selected for further analysis (148 genes). The selected genes were 
then assessed for expression in cBioportal [229] as described in the TGCA method. 
Not all genes were expressed in the patient dataset (26 genes) and 11 genes were 
species specific genes with no human equivalent available. An additional 24 genes 
that are established LXR targets that did not necessarily reach the cut-off scores were 
added. The final list of 135 genes (Appendix 1 – A.1) were assessed for expression in 
the TGCA dataset [230] of human breast cancers in the PAM50 subtypes. Gene RNA-
Seq mRNA expression (log transformed relative to array median) was then correlated 
with NR1H3/LXR and NR1H2/LXR expression. R values (X axis) and P values were 
plotted in an XY scatter graph to generate the volcano plots. A False Discovery Rate 
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(FDR) of 1 % was applied followed by a Fisher’s exact test used to establish if the 
number of genes correlating with NR1H3 was significantly different between the two 
subtypes. Summary of the target gene selection process is shown in Figure 3.2. 
 
Figure 3. 2 LXRα target gene selection. 
Flow diagram describing the gene selection process for the LXRα target gene plot. Exclusion criteria 
are included and statistical analysis outline. 
 
3.11.2 Systematic literature search for chemotherapy resistance genes 
Chemoresistance gene plot 
A list of genes implicated in chemotherapy resistance was generated using a 
literature search. Terms searched were “chemotherapy” and “resistance” and 
combined into one table of associated chemotherapy genes (see Appendix A - A.2). 
If gene duplicates occurred from different sources multiple references were included 
in the table, likewise if multiple types of resistance were identified these were 
incorporated into the table. The literature search was completed in March 2019, the 
selection process is summarised in Figure 3.3. 
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Figure 3. 3 Chemotherapy resistance gene selection. 
Flow diagram describing the gene selection process for the chemotherapy resistance gene plot. 
Exclusion criteria are included and statistical analysis outline. 
 
3.11.3 Evaluation of LXRα binding  
Genes identified for the literature search were then assessed in Cistrome.org [231] 
for LXR occupancy in their promoter regions, and genes associated with a binding 
score were assessed for expression in patient tumours in the TGCA dataset [230], 
however, not all genes were expressed in the patient dataset. The remaining genes 
were assessed for expression in human breast cancers of the PAM50 subtypes.  
Gene expression was then tested for correlation (Pearson’s correlation) against 
NR1H3/LXR and NR1H2/ LXR expression. R values (X axis) and P values were 
plotted in an XY scatter graph to generate the volcano plots. A False Discovery Rate 
(FDR) of 1 % was applied followed by a Fisher’s exact test used to establish if the 
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number of genes correlating with LXRα was significantly different to the other 
isoform LXRβ.  
3.12 Primary breast tumour analysis 
69 BCa tumours (41 TNBC, 11 Luminal A, 1 Luminal B, 16 HER2 enriched) were 
obtained from the Leeds Breast Tissue Bank (LBTB) through two separate ethics 
applications 09H1326/108 (pilot study with 11 Luminal A and 11 TNBC tumours) and 
15/HY/0025 (validation study with 30 TNBC, 16 HER2-positive 1 Luminal B tumours). 
The total, esterified and free oxysterol concentrations were measured by Dr Hanne 
Roberg-Larsen (Oslo, Department of Chemistry) using LCMS/MS. Patient tumour 
characteristics are shown in Table 7 (09H1326/108) and 8 (15/HY/0025). 
3.12.1 Tumour characteristics 
Table 7 Patient tumour characteristics. 
Tumour tissue was obtained from the Leeds Breast Research Tissue Bank at Leeds Teaching Hospital 




Characteristic Categories No. of patients (%) n=22 
Subtype Classification TNBC 9 (40.9)  
Luminal A 11 (50)  
Luminal B 1 (4.55)  
HER2 enriched 1 (4.55) 
ER Status Negative  11 (50)  
Positive 11 (50) 
PR Status Negative  13 (59.1)  
Positive 9 (40.9) 
HER2 Status Negative  20 (90.9)  
Positive 2 (9.1) 
Invasive Tumour Grade 1 2 (9.1)  
2 8 (36.4)  
3 12 (54.5) 
Invasive Tumour Size* </= 35mm 14 (63.6)  
>35mm 7 (31.8) 
Survival Status Alive  19 (86.4)  
Deceased 3 (13.6) 
Recurrence/Metastasis None 13 (59.1)  
Local and/or Distal 9 (40.9) 
 
- 79 - 
Table 8 Patient tumour characteristics. 
Tumour tissue was obtained from the Leeds Breast Research Tissue Bank at Leeds Teaching Hospital 
Trust. *denotes tumour size not available for one patient. 69 tumours in total. 
 
3.12.2 LCMS 
The method for LCMS has been previously published [130]. 
3.12.2.1 Derivatisation with Girard T reagent 
Methods for derivatisation with Girard T reagent has previously been described 
[232] with alterations as described [233]. Analytes were charge tagged following the 
process outlined and cholesterol oxidase (0.03 mg/mL) from Streptomyces sp. 
(Sigma-Aldrich) was aliquoted in 200 µL volumes in 50 mM PBS (pH 7.0) and added. 
The solutions were heated at 37 ⁰C for 1 h. Girard T reagent (15 mg – Sigma Aldrich), 
15 µL glacial acetic acid (VWR) and 500 µL MeOH were added to each 
sample/standard solution. Samples were kept at room temperature in a dark room 
overnight. All solutions were kept at 4 ⁰C after derivatisation. 
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3.12.2.2 Breast cancer tumour samples 
Breast cancer samples were obtained as mentioned in section 3.12. Each tumour had 
three consecutive 5 mg slices taken, homogenised in 500 µL 1.5 nM internal standard 
mixture solution and 30 µL autoxidation monitoring solution (6 µL cholesterol-
25,26,27-13C, Sigma Aldrich) using an IKA T10 Ultra-Turrax homogeniser. To analyse 
the free oxysterols within tumour samples, 100 µL of the sample solution was mixed 
with 100 µL isopropanol and placed in an Oasis PRiME HLB 1 cc (30 mg)  SPE cartridge 
(Waters), and the oxysterols were eluted with 200 µL MeOH. Using an Eppendorf 
concentrator plus (Hamburg, Germany), solvents were evaporated and the residues 
reconstituted in 20 µL of isopropanol. This was followed by derivatisation as detailed 
above. To measure the total (free and esterified) oxysterol content in tumour 
samples, alkaline hydrolysis was performed by adding 100 µL sample solution to 35 
µL 2M KOH (Sigma Aldrich) in MeOH. The sample solution was then heated for 120 
min at 60 ⁰C then followed by liquid-liquid extraction with n-hexane. 150 µL of type 
1 water was added to the sample followed by n-hexane (150 µL - VWR) to achieve 
phase separation. Tumour samples were mixed by vortex for 1 min before 
centrifugation for 2.5 min at 3000 rpm. The hexane layer was removed and the 
liquid-liquid extraction repeated twice with 150 µL n-hexane (combining all the 
hexane phases at the end). Using an Eppendorf concentrator plus solvents were 
evaporated and the residues reconstituted in 200 µL of isopropanol. Sample solution 
was placed in an Oasis PRiME HLB 1 cc (30 mg)  SPE cartridge (Waters), and eluted 
with 200 µL MeOH. Using an Eppendorf concentrator plus solvents were evaporated 
and the residues reconstituted in 20 µL of isopropanol and followed by derivatisation 
as detailed above.  
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3.12.2.3 Chromatographic system 
A Dionex UltiMate 3000 UHPLC system was connected to a TSQ Vantage triple 
quadrupole mass spectrometer (Thermo Fisher Scientific, Waltman, MS, USA) 
operated in selected reaction mode (SRM). Injection volume was 0.7 μL for column 
evaluation which was increased to 60 μL when the AFFLSPE-LC system was used. All 
connections were Thermo Scientific Vipers™ stainless steel fingertight fittings with 
180 μm inner diameter (ID). Columns investigated were; ACE SuperC18 core-shell 
(2.1  mm ID × 150mm dp 2.5 μm, core-shell), ACE SuperPhenyl Hexyl (2.1 mm ID × 
150 mm, dp 2.5μm, core-shell) ( both from Advanced chromatography technologies 
LTD, Aberdeen, UK), Thermo Scientific HyperSil GOLD C18 (1mm ID×50mm, dp 
1.9μm), Waters Torus 2-PIC (2-picolylamine, 2.1 mm ID×100mm, dp 1.7 μm) and 
Waters Torus 1-AA (1-aminoantracene, 2.1 mm ID×100mm, dp 1.7 μm). Also 
investigated were the in-house packed 0.1 mm ID × 100 mm columns, using the ACE 
SuperPhenyl Hexyl particles. 
3.12.2.4 Automatic filtration and filter back flush solid phase extraction 
A 10 port valve (Waters CapLC selector valve) with a 1 μm in-line filter and a non-line 
HotSEP C18 SPE column (Teknolab, Ski, Norway) was linked up. Loading mobile phase 
was 0.1% FA in type 1 water which was delivered by a HitachiL-7110 pump (Merck) 
with a standard flow  rate of 500 μL/min. In position 1, solutions and samples were 
injected and filtered. Derivatized oxysterols were retained on the SPE column, while 
surplus derivatization reagent was washed to waste. In position 2, the derivatized 
analytes were eluted off the SPE column and subsequently separated on an ACE 
SuperPhenyl Hexyl column (2.1 mm ID × 100 mm, core-shell) by a Dionex Ultimate 
3000 UHPLC pump with a standard flow rate of 650 μL/ min. Mobile phase A was 
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0.1% FA in type 1 water, B was 0.1 % FA in MeOH and C was 0.1 % FA in ACN. Isocratic 
elution conditions were 57/ 10/33 (v/v/v,A/B/C) for 4.3 min, followed by a 2 min 
washing step (50/50, v/v, B/C).Including on-line sample clean-up and conditioning of 
the column, total method run time was 8 min. 
3.12.3 Tissue RNA extraction 
Three 5 mg slices per tumour were taken from different areas of the breast tissue 
added to sterile Eppendorf tubes. RNA was extracted following the guidelines issued 
with the Promega ReliaPrep RNA Tissue Miniprep System. In short, tumour tissue 
was homogenised in LBA + TG buffer (1-Thioglycerol) to inactivate the ribonucleases 
present in tissue and pipetted up and down 10 times to shear the DNA. Isopropanol 
was added and the sample vortexed before transfer to labelled minicolumns. RNA 
was then bound to the minicolumns by centrifugation at 12,000 x g for 1 min at 21 
⁰C. RNA was washed with RNA wash solution and centrifuged again at 12,000 x g for 
30 seconds at 21 ⁰C. RNase-free DNase I enzyme was applied directly to the 
membrane in a mastermix containing 0.9 M MnCl2 and yellow core buffer for 15 min 
at room temperature to digest contaminating genomic DNA. Post-incubation the 
minicolumns is washed with column wash solution and centrifuged at 12,000 x g for 
15 seconds at 21 ⁰C. The bound total RNA is further purified from contaminating 
salts, cellular components and proteins by washing with RNA wash solution and 
centrifuged at 12,000 x g for 30 seconds at 21 ⁰C, then again at 12,000 x g for 2 min 
at 21 ⁰C. To finish, the total RNA is eluted from the membrane by adding nuclease-
free water (NFW) and centrifuging one last time at 7000 x g for 1 min at 21 ⁰C. RNA 
was then stored at 80 ⁰C. 
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3.12.4 Reverse transcription and qPCR 
Tumour cDNA libraries (250 ng each) were generated using the same reagents and 
procedure used in section 3.5. Gene expression of HPRT1, LXRα, LXRβ, ABCA1, 
ABCB1, LCAT, NCOR1, NCOR2 and LCOR was assessed using Taqman assays as 
described in section 3.6, in a 384 well plate. Mastermix volume (2.5 µL) and cDNA 
volume (2.5 µL) per reaction totalled 5 µL per well. 
3.12.5 Correlations with LXR expression 
The average ΔΔCt value for the triplicate sections of each tumour were generated 
for each gene analysed. The average Ct score for ABCA1, ABCB1 and LCAT for each 
tumour were then correlated with the average Ct score for LXRα and LXRβ for each 
tumour.  
3.13 in vivo Mouse study 
The in vivo mouse study was designed to support the colony forming assay data. Dr 
Erik Nelson (Illinois, Chicago) agreed to collaborate on the work. Treatment plans 
were designed by the author with guidance from Dr Nelson. All experimental work 
was completed in Chicago by Dr Nelson’s group. All procedures involving animals 
were approved by the University of Illinois IACUC. Mice were housed in standard IVC 
cages at up to 5/cage, with standard enrichment. They were provided acidified water 
and irradiated chow, ad libitum. Mice were 11 weeks old at the start of the study 
with 10 mice per treatment group. Mice were humanely euthanized by CO2 followed 
by a secondary method of either bilateral thoracotomy or decapitation. These 
methods are consistent with the Panel on Euthanasia of the American Veterinary 
Medical Association. 
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3.13.1 Treatment Plan 
4T1 cells (ER-negative) were grafted orthotopically into the axial mammary fat pad 
of BALB/C mice. Mice were treated with either placebo or the LXR ligand GW3965 
(daily, 30 mg/kg) 24 h post-graft. Treatments with placebo or epirubicin (every other 
day, 2.5 mg/kg) commenced 48 h post-graft. Tumour volumes were measured by 
direct calliper, and plasma, liver and tumour were harvested after 12 days. 
3.13.4 Tumour analysis 
Mouse tumours were manually homogenised and lysed in TRIzol (Thermo Fisher 
Scientific) to extract RNA. Once RNA was isolated from tumour tissue cDNA libraries 
were generated from equal total RNA mass with iScript reverse transcriptase 
supermix (Bio-Rad). cDNA libraries were then analysed by qPCR with iTaq universal 
SYBR Green supermix (Bio-Rad) on a CFX384 touch real-time PCR detection system 
(Bio-Rad). Relative expression of ABCA1, ABCB1, ABCG2, and CXCL5 was determined 
using the ΔΔCt method and normalised to the housekeeping gene TBP. Statistical 
analysis was assessed using 1 Way ANOVA with SNK test. 
3.14 MTT assay 
TNBC cells (MDA-MB-468 and MDA-MB-231) and Luminal A cells (MCF-7) were 
seeded in 96 well plates at 2.5 x 104 cells/well. Cells were incubated for 16 h before 
vehicle (ethanol) or a panel of PSSs were added for 48 h. PSS treatments were in the 
range of 1 pM to 100 µM. After 48 h of exposure, media was removed and cells were 
washed with PBS. Phenol red free DMEM with 10 % FCS was added to each well with 
MTT reagent at the final concentration of 0.5 mg/mL. Cell were incubated for 4 h at 
37 ⁰C before media was removed and replaced with 100 µL of DMSO/well. 
Absorbance was read at 540 nm using a CLARIOstar. 
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Chapter 4 
LXRα activity and function is enhanced in triple negative breast cancer 
relative to Luminal A BCa 
4.1  Introduction 
Data presented in this chapter have in part been published in a peer-reviewed article 
[234]. Journal article included in Appendix B - 1.1.  
 
Cholesterol is mostly synthesized de novo in the liver, with lesser contributions from 
diet combining to ensure circulating cholesterol levels are constant. Balanced 
cholesterol levels are important to ensure extra-hepatic tissues have enough 
cholesterol to produce a range of metabolites such as bile acids, seco-steroids and 
steroid hormones [235]. Cholesterol is hydroxylated by members of the cytochrome 
P450 family (CYPs) producing cholesterol metabolites known as oxysterols [236]. 
LXRα and LXRβ are NRs that bind and respond to oxysterols regulating the expression 
of genes involved in cholesterol storage, efflux and metabolism. Type 1 NRs such as 
the ER, AR or the glucocorticoid receptor (GR) bind to ligand in the cytosol, form 
heterodimers or homodimers and translocate from the cytoplasm into the nucleus 
to bind to DNA HREs [237-239]. Type 2 NRs such as LXR and RXR remain in the 
nucleus even in the absence of ligand, binding as heterodimers to DNA [240]. LXRα 
expression is inducible in the liver, intestine, adipocytes and macrophages, whereas 
LXRβ is expressed ubiquitously. As well as differences in the expression of LXRs, 
oxysterol concentrations are also diverse between tissues, and relative to each 
other, with some as high as 1000-fold difference between two oxysterols [204]. 
Variations in receptor expression and oxysterol concentrations within tissue can also 
depend on disease status [110]. Oxysterols also have different capabilities in LXR 
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activation and driving LXR-mediated transcription of target genes, suggesting an 
element of selective modulation in oxysterol-LXR signaling. An example of this is the 
oxysterol 26OHC which is the most abundant oxysterol in human tissue but appears 
to be a fairly weak LXR agonist [69, 241]. 
The capacity for type 2 nuclear receptors to regulate their target genes is dependent 
on nuclear localization and genome binding, co-activator and co-repressor 
expression, ligand bioavailability and expression levels of the receptors themselves. 
For instance, the expression of co-repressors such as NCOR1 and NCOR2/SMRT 
dictate how multiple cancers respond to nutritive ligands [94, 95, 242] as discussed 
in section 1.2.2. LXRβ binding affinity for the corepressors NCOR1 and NCOR2 is 100-
fold less than LXRα [243]. Furthermore, deregulation of the corepressors NCOR1 and 
NCOR2/SMRT has been shown to impair sensitivity to ligand in bladder [242] and 
prostate cancer cells [68, 94] and enhanced coactivator expression has been shown 
to facilitate growth of malignancies in the breast [244], prostate [245, 246] and 
pancreas [247]. Assessing the activation potential of oxysterols at different 
concentrations is required as simply measuring the oxysterol concentrations cannot 
determine their level of involvement in LXR signaling. 
Ligand bioavailability is important for nuclear receptor target gene regulation as type 
2 NRs like LXRα and RXRβ are poor activators of transcription in the absence of 
ligand. LXR ligands are typically formed through hydroxylation of cholesterol by 
cytochrome P450 family members. However, Cytochrome P450 family members are 
not uniformly expressed in all tissues and may be expressed in specific 
organs/tissues. CYP46A1, CH25H and CYP27A1 are the enzymes responsible for the 
conversion of cholesterol to 24OHC, 25OHC and 26OHC respectively and although 
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they have been detected in many tissues, they are highly expressed in the brain and 
liver [101]. Interestingly, CYP27A1 was found to be expressed in advanced breast 
tumour cells and tumour-associated macrophages [105], suggesting support cells in 
the TME may be enhancing ligand bioavailability in cancer. 
Even in the presence of ligands, receptors may not be able to regulate transcription. 
Other factors such as ligand esterification [101] are involved in nuclear receptor 
interactions. The expression of enzymes that result in ligand sulfation (SULT2B1) 
[248] and further modification (CYP7B1) [105] inhibit ligand activation of nuclear 
receptors and reduce the expression of canonical target genes of LXR. In cancer 
biology the expression of these enzymes can be altered or skewed to have selective 
advantages for cancer progression. Identifying altered expression of enzymes 
involved in oxysterol conversion, esterification and further modification in different 
subtypes of BCa may help with the understanding of why two alike cancers can have 
two different responses to treatment. 
The function of the oxysterol-LXR axis in cancer seems to be tissue specific as both 
tumour promoting and tumour suppressive roles have been identified. Oxysterol-
LXR signalling is anti-proliferative in lung cancer [249] as it is in almost every cancer 
cell line studied [68], and impairs angiogenesis and invasion in melanoma [250]. In 
breast cancer however, 26OHC promotes the growth of ER-positive BCa in vivo via 
the ER [105, 110] and drives the EMT in ER-negative BCa [105]. Furthermore, 26OHC 
mobilises γδ-T cells to promote colonisation of ER-negative metastatic tumours [21]. 
In addition, circulating levels of 25OHC was found to be elevated in patients who had 
relapsed relative to those with the primary disease [136], and the concentrations of 
multiple oxysterols are altered in breast cancer tissue relative to healthy tissue [110]. 
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Systematic assessment of oxysterol bioavailability and activation potential when 
coupled with NR cofactor expression analysis in BCa subtypes is a novel concept that 
has not been published to date. Given the therapeutic and prognostic value of 
stratifying breast cancers by hormone receptor status, further definition of the 
pathways that are altered between subtypes, such as oxysterol-LXR signalling, may 
provide insight into the evolving roles of cholesterol metabolism in cancer and have 
the potential to improve patient outcomes.  
4.2  Hypothesis and Aims 
Dietary and pharmacological interventions that lower cholesterol in humans show 
the prognosis and incidence of ER-negative breast tumours is improved 
preferentially in ER-negative tumour subtypes rather than ER-positive ones. Given 
that cholesterol metabolism into oxysterols produces ligands for LXR in both ER-
positive and ER-negative tumours, it is possible that the anti-tumour effect of these 
cholesterol lowering interventions may be due to differential activation of LXRα 
between the subtypes.  
The hypothesis that is tested in this chapter is that the oxysterol-LXRα signalling 
pathway is differentially activated between subtypes at the level of ligand synthesis, 
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The aims of this chapter were to: 
• Test whether the concentration of side-chain hydroxycholesterols, 
expression of LXRα, and/or that of its regulatory co-factors, is different 
between ER-negative and ER-positive breast tumours 
• Determine whether LXRα dependent transcription is different between ER-
negative and ER-positive breast cancer.  
• Establish if LXRα transcriptional activity within breast tumours is associated 
with patient relapse. 
 
4.3  Results 
4.3.1  Expression of LXRα and its regulatory factors, but not ligand 
concentration, is different between breast cancer subtypes 
To determine if there was potential for LXRα activity to be altered between ER 
dependent breast cancer subtypes distinct approaches were taken. First, publicly 
available breast cancer RNA-Seq datasets were mined for gene expression data 
related to differential expression of cholesterol biosynthesis enzymes, cofactor 
expression and receptor expression. These data were then assessed for patterns 
consistent with LXR pathway activation or repression. Secondly, primary BCa 
tumours were acquired from the Leeds Breast Research Tissue Bank and assessed 
for expression of the same gene expression panel using qPCR. Thirdly, the tissue 
bank tumours were assessed for oxysterol concentration using LCMS-MS. Fourthly, 
the LXRα expression and corepressor expression was assessed in ER-negative and 
ER-positive BCa cell lines to identify representative cell lines for further analysis. 
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4.3.1.1  LXRα expression is enhanced in triple negative breast cancer relative to 
Luminal A breast cancer 
First, to assess the expression of LXRα in TNBC disease compared to the Luminal A 
subtype, public data were downloaded from CBioportal [229], TCGA dataset [230] 
(see methods section 3.10). The RNA-Seq mRNA relative expression of the estrogen 
receptor (ESR1), progesterone receptor (PGR), LXRα, LXRβ and their binding partners 
the RXRs (RXRα, RXRβ and RXRγ) were assessed. The RXRs were included in the 
analysis as both LXRα and LXRβ regulate target genes by forming permissive 
heterodimers with RXRs [69]. As a control, the median expression of the ESR1 and 
the PGR were analysed and found to be significantly lower in the TNBC tumours 
relative to the Luminal A tumour (two-tailed Mann-Whitney U test: ESR1 p<0.001; 
PGR p<0.001 [Figure 4.1A]) as was expected. Median expression of LXRα (p<0.01) 
and its binding partner RXRβ (p<0.05) were found to be significantly higher in the 
TNBC tumours relative to the Luminal A tumours (Figure 4.1A). LXRβ was found to 
be uniformly expressed across the TNBC and Luminal A subtypes (ns) as was RXRγ 
(ns). And finally, RXRα was found to be expressed at significantly lower levels in the 
TNBCs tumours relative to the Luminal A tumours (ns).  
To assess if the BCa cell lines (MCF-7, MDA-MB-468 and MDA-MB-231) recapitulated 
primary TNBC and Luminal A BCa features observed in Figure 4.1A, LXRα and LXRβ 
expression was measured in the BCa cell lines (Figure 4.1B). In the TNBC cell line 
MDA-MB-468, LXRα was expressed at significantly higher levels relative to the 
Luminal A cell line MCF-7 (1-tailed unpaired t tests; p<0.001) and LXRβ was uniformly 
expressed across all three BCa cell lines (ns). In summary these data show, TNBCs 
display enhanced LXRα expression and similar LXRβ expression levels in primary 
breast tumours and cells. 
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Figure 4. 1 Expression of the nuclear receptor LXRα is higher in TNBC compared to Luminal A BCa. 
mRNA-Seq data (log transformed relative to array median with 10-90th centiles) for 89 TNBC and 235 
Luminal A tumours were obtained [230] for receptor expression analysis from CBioportal (TCGA) [229] 
(A). Receptor expression is presented as box and whisker plots with median, inter-quartile and 10-90 
percentiles shown. Statistical analysis was established using Mann-Whitney U tests. RNA was 
harvested from TNBC (MDA-MB-468 and MDA-MB-231) and Luminal A/ER-positive (MCF-7) cells and 
expression of the nuclear receptors LXRα and LXRβ was assessed by qPCR (TNBC ΔcT normalised to 
MCF-7) (B). Data shown are mean of six independent replicates with SD, statistical analysis was 
established using two-tailed student t-tests (B). 
 
4.3.1.2  The expression of cholesterol biosynthesis enzymes and genes that 
metabolise and catabolise LXR ligands are altered in triple negative breast cancers 
and Luminal A breast cancers. 
Next, the expression of genes involved in; the conversion of cholesterol into 
oxysterols, the esterification of oxysterols and the further modification of oxysterols 
were assessed in the same dataset used in Figure 4.1 [230] from cBioportal [229]. 
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were assessed in the primary tumour datasets (Figure 4.2A). CYP27A1, CH25H, 
CYP46A1 and CYP11A1 are the enzymes responsible for the conversion of cholesterol 
to 26OHC, 25OHC, 24OHC and 22OHC respectively and in the TNBC and Luminal A 
tumours, similar expression levels of CYP46A1 (two-tailed Mann-Whitney U test, ns) 
and CYP11A1 (ns) was observed.  CH25H expression however, was lower in the TNBC 
relative to the Luminal A BCa (p=0.0002), and expression of CYP27A1 was enhanced 
in the TNBC relative to the Luminal A BCa (p<0.0001).  
LCAT and SOAT1 are enzymes involved in the esterification of oxysterols and their 
expression in primary tumours were assessed (Figure 4.2B and Figure 4.2C). In TNBC 
primary tumours, expression of LCAT and SOAT1 were found to be elevated 
compared to Luminal A expression (p<0.0001, both genes), whilst expression of the 
sulphonation enzyme SULT2B1 which modifies the head of the oxysterol structure 
rendering the ligand incompetent as an LXR ligand, was significantly lower in the 
TNBC tumours relative to the Luminal A tumours (p<0.0001). Additionally, the 
expression of CYP7B1 was enhanced in the TNBC tumours relative to the Luminal A 
tumours (p<0.0001). These data suggest Luminal A tumours preferentially further 
modify ligands by sulphonation which could result in fewer ligand-LXR interactions 
and therefore lower LXR activity. 
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Figure 4. 2 The enzymes involved in cholesterol conversion to oxysterols, oxysterol esterification 
and oxysterol further modification are differentially expressed in TNBC and Luminal A BCa.  
mRNA-Seq data (log transformed relative to array median with 10-90th centiles) for 89 TNBC and 235 
Luminal A tumours were obtained [14] from CBioportal (TCGA) [13] for expression analysis of the 
enzymes responsible for cholesterol synthesis, esterification and further modification. Expression is 
presented as box and whisker plots with median, inter-quartile and 10-90 percentiles shown. 




4.3.1.3  Oxysterol concentration is similar in triple negative breast cancers and 
Luminal A tumours. 
 
To assess if ligand abundance was different between BCa subtypes we obtained 69 
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Breast Tissue Bank (LBTB) through two separate ethics applications 09H1326/108 
(pilot study with 11 Luminal A and 11 TNBC tumours) and 15/HY/0025 (validation 
study with 30 TNBC, 16 HER2-positive and 1 Luminal B tumours). The total, esterified 
and free oxysterol concentrations were measured by Dr Hanne Roberg-Larsen (Oslo, 
Department of Chemistry) using LCMS/MS. Patient tumour characteristics are shown 
in Table 7 (09H1326/108) and 8 (15/HY/0025). Total, esterified and free 
concentrations of 22OHC, 24OHC, 25OHC and 26OHC were measured by LCMS/MS 
in 22 BCa tumour samples (in triplicate sections) (Figure 4.3).  
First, 22OHC was undetected in all 3 sections of the 22 BCa tumour samples. Out of 
the remaining 3 oxysterols measured, 26OHC was the most abundant oxysterol in 
the TNBC breast tumours (range: 74-3732 ng/mg, mean 908.5 ng/mg) and Luminal 
A breast tumours (range: 57-2696 ng/mg, mean 438.9 ng/mg). 25OHC was found to 
be the lowest abundant oxysterol measurable above the Limit of Detection (LOD) 
and Quantification (LOQ) in both the TNBC tumours (range: 18-262 ng/mg, mean 
76.9 ng/mg) and Luminal A tumours (range: 10-780 ng/mg, mean 88.9 ng/mg). 
24OHC was found at slightly higher concentrations in the TNBC tumours (range: 34-
709 ng/mg, mean 229.7 ng/mg) and Luminal A tumours (range: 26-845 ng/mg, mean 
165.1 ng/mg). Analysis of three sections (5 mg each) per tumour showed large intra-
tumour variability in oxysterol concentrations (RSD >20). No significant differences 
were observed in the total, esterified or free oxysterol concentrations between the 
TNBC and Luminal A tumours (Mann-Whitney U test; ns) (Figure 4.3).  
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Figure 4. 3 Total, esterified and free oxysterol concentrations in TNBC and Luminal A BCa.  
The concentrations of total (A), esterified (B) and free (C) oxysterols were measured in Luminal A 
(purple boxes; n=11) and TNBC (green boxes; n=11) tumours. No statistically significant differences in 
mean concentrations between ER-subtypes was found (Mann-Whitney U Test). Patient characteristics 
shown in Table 7 – see methods section 3.12.1. 
 
4.3.1.4  The ratio of esterified to free/total oxysterol concentrations appears to 
have a relationship in triple negative breast cancers and Luminal A tumours. 
 
To assess if there is a relationship between the amount of esterified to free 
oxysterols or total to esterified oxysterols in patient breast tumours, correlation 
analyses were performed. The concentrations of esterified and free 24OHC did not 
significantly correlate in TNBC or the Non-TNBC tumours (Pearson correlation; ns) 
(Figure 4.4A). Next the correlation of esterified and free 25OHC correlated in the 
Non-TNBC tumours (p<0.01; R2=0.82) but not in the TNBC (ns) (Figure 4.4A). And 
finally, the concentration of esterified and free 26OHC correlated in the Non-TNBC 
tumours (p<0.0001; R2=0.89) and in the TNBC tumours (p<0.05; R2=0.61) (Figure 
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correlated in TNBC and the Non-TNBC tumours (TNBC p=0.0289; R2=0.34, Non-TNBC 
p=0.0086; R2=0.49) (Figure 4.4B). The correlation of total and esterified 25OHC 
correlated in the Non-TNBC tumours (p<0.0001; R2=0.96) but not in the TNBC (ns) 
(Figure 4.4B). And finally, the concentration of total and esterified 26OHC correlated 
in the Non-TNBC tumours (p<0.0001; R2=0.89) and in the TNBC tumours (p=0.0051; 
R2=0.54) (Figure 4.4B). Data from the correlation analyses suggested that the ratio 
of esterified oxysterols (either to free or total) appeared to be important in defining 
differences between the two subtypes, however large inter-tumour variations were 
observed and as such further analysis in a larger cohort was required to determine 
the relationship between esterified oxysterol ratios within tumours. 
 
Figure 4. 4 The ratio of 24OHC, 25OHC and 26OHC total to esterified oxysterol concentrations 
significantly correlate in the Luminal A breast tumours, but only 24OHC and 26OHC correlate in 
TNBC tumours.  
The oxysterol concentrations (total, esterified and free) in 22 patient tumours of two BCa subtypes 
[TNBC n=11, ER-positive n=11] were measured by LCMS/MS and compared across subtypes. Free and 
esterified oxysterol concentrations, and total and esterified oxysterol concentrations were analysed 
by Pearson correlation and assessed for statistical significance. 
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4.3.2  LXR cofactor expression is skewed towards transcriptional activation 
in TNBC and towards repression in ER-positive disease. 
To explore the potential for LXRα to be activated and therefore control transcription, 
publicly available datasets were assessed for the expression of regulatory co-factors 
which have previously been implicated in the deregulation of nuclear receptor 
activity [68, 79, 94, 95]. 
Using the TCGA dataset [230] accessed from cBioportal [229], essential regulators of 
LXRα activity were assessed in the TNBC and Luminal A subtypes. The cofactors 
selected for this analysis were chosen if they had been shown previously to physically 
interact with LXR in a published nuclear receptor/cofactor scan [251], and if they 
were also reported to interact with LXR in at least one other study. This resulted in 6 
co-activators (SRC, NCOA3, EP300, NCOA6, TRRAP and GPS2) and 3 co-repressors 
(NCOR1, NCOR2 and LCOR) to be selected for assessment. RNA-Seq mRNA 
expression were downloaded for TNBC and Luminal A primary tumour samples and 
assessed for differences in median mRNA expression across the two subtypes. Higher 
median expression of the co-activators SRC (two-tailed Mann-Whitney U test, 
p<0.001) and TRRAP (p<0.001) was observed in the TNBC relative to the Luminal A 
BCa subtype, but uniform expression of the remaining co-activators NCOA3, EP300, 
NCOA6 and GPS2 was observed (ns). (Figure 4.5A). Interestingly, decreased 
expression of all of LXR’s co-repressors (NCOR1: p<0.001; NCOR2: p<0.001; LCOR: 
p<0.001) were observed in the TNBC primary tumour samples (Figure 4.5B). The 
same patterns were observed when the expression of NCOR1, NCOR2 and LCOR was 
assessed in the breast cancer cell lines (2-tailed unpaired t-tests, p<0.001 for each 
gene) (Figure 4.5C). 
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Figure 4. 5 Co-activators and co-repressors are differentially expressed in TNBC and Luminal A BCa.  
mRNA-Seq data (log transformed relative to array median with 10-90th centiles) for 89 TNBC and 235 
Luminal A tumours were obtained [230] for receptor expression analysis from CBioportal (TCGA) [229] 
and the subtype specific expression of co-activators (A) and co-repressors (B) were assessed. 
Expression is presented as box and whisker plots with median, inter-quartile and 10-90 percentiles 
shown. Statistical analysis was established using two-tailed Mann-Whitney U test. RNA was harvested 
from TNBC (MDA-MB-468) and Luminal A (MCF-7) cells and expression of NCOR1, NCOR2 and LCOR 
(C) were assessed by TaqMan assays (∆∆cT and normalised to MCF-7). Data shown are mean of three 
independent replicates with SD, statistical analysis was established using 1-tailed unpaired t tests. 
 
4.3.3  Triple negative breast cancer is transcriptionally responsive to LXR 
ligands and Luminal A BCa is resistant. 
In section 4.3.1 the concentrations of all known and measurable endogenous LXRα 
ligands were found not to be significantly different between tumour subtypes. In 
4.3.2 however, expression of LXRα itself, and its regulatory factors such as the co-
repressors were found altered in a manner consistent with enhanced responsiveness 
to ligand. I next hypothesised that such altered expression of LXRα and its cofactors 
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increased sensitivity to ligand in ER-negative disease relative to ER-positive. This 
hypothesis was tested through several routes. First, a panel of luciferase reporter 
cell lines under the control of a multi-LXRE promoter (see methods section 3.2) were 
generated and luciferase activity measured after exposure to a panel of synthetic 
and endogenous LXR ligands. As LXR activation has been reported to be anti-
proliferative in a wide array of cancer cell lines, MTT assay was used to assess 
differences in cell number/viability after exposure to ligand. Finally, expression of 
LXR target genes was assessed by testing for correlation with LXRα (and co-
repressors) in ER-negative and ER-positive patient tumour samples, and after 
treatment with LXR ligands in cell lines representative of both ER- and ER+ disease.  
 
4.3.3.1  Triple negative breast cancer reporters are more responsive to LXR 
ligands than the Luminal A breast cancer reporter. 
In order to assess LXRα responsiveness to ligand in BCa, a panel of BCa and a control 
cell lines (HepG2 [control], MCF-7, MDA-MB-468 and MDA-MB-231) were stably 
transfected with a luciferase reporter construct driven by an LXRα responsive 
promoter. The stable luciferase reporter cell lines: HepG2 [control] (Figure 4.6A) and 
BCa MCF-7, MDA-MB-468 and MDA-MB-231 were treated with a panel of LXR 
endogenous ligands (Figure 4.6B) or synthetic ligands (Figure 4.6C) and LXRα activity 
was determined by luciferase assay. The synthetic controls (agonists: T0901317, 
GW3965, and antagonist GSK2033) regulated the expression of LXRα in all cell lines 
from as low as 100 nM to as high as 50 µM, although signal at this higher 
concentration was attenuated presumably through a cytotoxic effect. The panel of 
endogenous LXR ligands were also able to regulate LXRα expression however, a 
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range in ligand effectiveness to activate LXRα was observed. In the liver HepG2 cells, 
which were used as a control for LXRα activity (Figure 4.6A), endogenous ligands 
were able to successfully activate LXRα (24OHC, 10-35 fold activation; 25OHC, 5-10 
fold activation; 26OHC, 2-10 fold activation; 24,25-EC, 20-50 fold activation). The 
synthetic ligands T0901317 and GW39965, were able to successfully activate LXRα 
in all three of the breast cancer reporters, and the synthetic antagonist GSK2033 was 
able to suppress LXRα (Figure 4.6A). The endogenous ligands were able to activate 
LXRα in the two TNBC reporters, MDA-MB-468 (24OHC, 10-35 fold activation; 
25OHC, 5-10 fold activation; 26OHC, 5 fold activation; 24,25-EC, 15-40 fold 
activation) and MDA-MB-231 (24OHC, 10-35 fold activation; 25OHC, 5-10 fold 
activation; 26OHC, 2-5 fold activation; 24,25-EC, 15-40 fold activation) in a manner 
comparable to the HepG2 control reporter. In the MCF-7 reporter however, 
endogenous ligands were only able to minimally activate LXRα (24OHC, 3 fold 
activation; 25OHC, 2 fold activation; 26OHC, 2 fold activation; 24,25-EC, 3-5 fold 
activation) with a clear difference in the response to ligand observed between the 
two breast cancer subtypes.  The endogenous ligand 7KETO was the weakest ligand 
in the three breast cancer reporters (2-fold activation MCF-7 and MDA-MB-231, 5-
fold activation MDA-MB-468) and therefore not included in further analyses. These 
data indicate that oxysterols robustly activate LXRα in TNBC but the LXRα response 
is dampened in the Luminal A/ER-positive disease. This is consistent with the 
observations that co-repressor activity is lower in TNBC tumours and cells relative to 
Luminal A BCa. 
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Figure 4. 6 LXRα is transcriptionally responsive to agonists in TNBC but not ER-positive MCF-7 cells.  
Liver HepG2 cells, TNBC cells (MDA-MB-468 and MDA-MB-231) and a Luminal A cell line (MCF-7) were 
stably transfected with an LXRα luciferase positive reporter. HepG2 reporter cells [used as a control] 
(A) and BCa cells were treated with a panel of LXR ligands: (B) synthetic ([GW3965, GSK2033 – 1 µM, 
T0901317 – 2.5 µM] and (C) endogenous [7-KETO, 22OHC, 24OHC, 25OHC, 24,25-EC and 26OHC – 10 
µM]) for 16 h. LXRα transactivation was normalised to VC. Data shown are mean of 2-3 independent 
replicates with SD. 
 
The effects of oxysterols on viability of TNBC and Luminal A/ER-positive cells were 
next examined – data generated and analysed by Priscilia Lianto (Figure 4.7). Luminal 
A cells (MCF-7) and TNBC cells (MDA-MB-468 and MDA-MB-231) were exposed to 
oxysterols for 48 h and cell viability assessed by MTT. The Luminal A MCF-7 cells, 
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were more resistant than the TNBC cells to the treatment with 24OHC (non-linear 
regression comparison of fits: non-converged for MCF-7), 25OHC (MDA-MB-468; 
p<0.0001., MDA-MB-231; p=0.03) and 26OHC (MDA-MB-468; p<0.0001) in the 
micromolar range. The exception to this was treatment with 26OHC in MCF-7 cells 
compared to TNBC MDA-MB-231 cells (ns). The MDA-MB-231 cells appeared to be 
more resistant to oxysterol treatment than MDA-MB-468 with 24OHC (p<0.0001), 
25OHC (p<0.0001) and 26OHC (p<0.0001) but not as resistant as MCF-7 cells. 
 
Figure 4. 7 Luminal A BCa cells are insensitive to oxysterol treatment.  
The anti-proliferative effects of the oxysterols 24OHC, 25OHC and 26OHC were assessed by MTT in 
MDA-MB-468, MDA-MB-231 and MCF-7 cells over 48 h with EC50 given in µM. Data are presented as 
means of 3-4 independent replicates with SEM – data generated by Priscilia Lianto, Thorne laboratory 
member. Significance was assessed using non-linear fit, significance between MCF-7 and TNBC cells 
was unable to be assessed as non-linear regression was non-converged for the MCF-7 cells. 
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4.3.3.2  LXR dependent transcription from endogenous loci is significantly higher 
in triple negative breast cancer than in Luminal A breast cancer. 
A limitation of the luciferase reporter experiment was that the stable construct may 
not have been embedded in a comparable chromatin environments in the different 
cell lines. To confirm the results from 4.3.2.1 in a normal, or endogenous, chromatin 
context, LXR target genes were assessed. To assess this aim, transcriptional output 
of the LXR target genes ABCA1 and APOE were assessed after treatment with LXR 
ligands in cell culture, and their expression was tested for correlation with LXRα in 
the Luminal A and TNBC datasets reported in section 4.3.1.1 [229, 230].  
TNBC cells (MDA-MB-468 and MDA-MB-231) and Luminal A BCa cells (MCF-7) were 
exposed to LXR the synthetic ligand GW3965 and LXR endogenous ligands (24OHC, 
26OHC and 24,25-EC) for 4 h and 16 h before RNA was extracted and expression of 
the canonical LXR target genes ABCA1 and APOE were measured (normalised to 
HPRT). Enhanced expression of ABCA1 was observed in the MDA-MB-468 and MDA-
MB-231 TNBC cell lines relative to the Luminal A cell line MCF-7 (Figure 4.8) at both 
4 h (Figure 4.8A) and 16 h (Figure 4.8B). In both TNBC cell lines all agonists increased 
ABCA1 expression by between 8 and 110 fold (1-tailed unpaired t test; p<0.01 for 
all). In the Luminal A/ER+ cell line the induction was less and between 3 and 12-fold 
(p<0.05 for all except 25OHC, ns). Enhanced expression of APOE was also observed 
in the MDA-MB-468 and MDA-MB-231 TNBC cell lines relative to the Luminal A cell 
line MCF-7 (Figure 4.8) at both 4 h (Figure 4.8C) and 16 h (Figure 4.8D). In both TNBC 
cell lines all agonists increased APOE expression by between 1.5 and 5 fold at 16 h 
(p<0.01 for all). In the Luminal A/ER-positive cell line the LXR response to ligand 
resulted in down-regulation of APOE (p<0.05 for all). 
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Figure 4. 8 LXRs response to ligand is enhanced in TNBC cell cultures relative to Luminal A.  
TNBC (MDA-MB-468 and MDA-MB-231) and Luminal A (MCF-7) cells were treated with LXR ligands 
(synthetic 1 μM, endogenous 10 μM) for 4 h and 16 h and expression of ABCA1 (A+B) and APOE (C+D) 
was assessed by qPCR (∆∆cT using HPRT and normalised to vehicle). Data shown are mean of three 
independent replicates with SD, statistical analysis was established using 1-tailed unpaired t tests. P 
values in grey represent comparison between MDA-MB-468 and MDA-MB-231 cells. 
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4.3.3.3  LXRα correlates with ABCA1 and APOE in triple negative breast cancer 
primary tumours. 
 
To assess whether expression of LXRα and/or LXRβ correlates with their target 
genes, ABCA1 and APOE were assessed for correlation as they are widely accepted 
as LXR target genes [252-254]. The RNA-Seq mRNA data was downloaded and shown 
as log transformed relative to array median, with 10-90th centiles was for ABCA1, 
APOE, LXRα and LXRβ in 89 TNBC and 234 Luminal A/ER-positive breast tumours 
[230] accessed from cBioportal [229]. We then assessed if LXRα or LXRβ expression 
correlates with ABCA1 and/or APOE expression in the two tumour subtypes (Figure 
4.9). In the TNBC tumours, ABCA1 expression significantly correlated with LXRα 
expression (Pearson’s correlation with linear regression, p<0.0001, r=0.502) but not 
with LXRβ expression (ns). APOE expression also correlated with LXRα in the TNBC 
tumours (p<0.0001) but did not with LXRβ (ns). In the Luminal A/ER-positive 
tumours, ABCA1 expression failed to correlate with LXRα or LXRβ expression, 
however APOE expression correlated with both LXRα and LXRβ expression 
(p<0.0001). 
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Figure 4. 9 The LXR target genes ABCA1 and APOE significantly correlate with LXRα in TNBC patient 
tumours but not LXRβ.  
Expression of the LXR target genes ABCA1 and APOE were correlated with LXRα (A) and LXRβ (B) in 
81 ER-negative and 234 ER-positive breast tumours [230] accessed from the patient database 
CBioportal [229]. Statistical significance was assessed using Pearson’s correlation test with linear 
regression. 
 
4.3.3.4  LXRα is more likely to correlate with expression of its target genes in triple 
negative breast cancer tumours than Luminal A tumours 
The next aim was to establish if enhanced LXR activity in the TNBC relative to the 
Luminal A BCa subtype results in enhanced transcriptional output of most, if not all 
LXR target genes to remove any selection bias from ABCA1 being a highly researched 
and robust LXR target. To assess this aim, ChIP-Seq data was mined from the 
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Cistrome database [231] and genes assessed for LXRα binding in their promoters 
(method section 3.11.1). Target genes identified in this manner were then assessed 
for correlation with LXRα in the ER-negative and ER-positive primary BCa tumours 
datasets from sections 4.3.1.1) [229, 230]. The top most likely LXR target genes in 
breast tumour tissue identified from these steps were validated in cell cultures. 
First, ChIP-Seq data were mined from the Cistrome database [231]. The top 100 
genes (defined as having the highest LXRα binding scores) and appearing in at least 
two from 7 distinct datasets found across three publications [255-257] were selected 
for further analysis (see Appendix 1 – A.1 for list of genes and see materials and 
methods section 3.11.1 for flow diagram explaining gene selection). Binding scores 
were assessed in the vehicle control group (VC) compared with the GW3965 
treatment group - (shown in Appendix 1 – A.1). 135 genes were identified in this 
manner and their expression data in 81 TNBC and 234 Luminal A BCa were obtained 
from CBioportal [229, 230]. The expression of these genes was then tested for 
correlation with LXRα and LXRβ in both tumour subtypes. A False Discovery Rate 
(FDR) of 1 % was used to correct for multiple testing. The data are presented showing 
correlation coefficient against FDR for TNBC and Luminal A/ER-positive BCa tumours 
(Figure 4.11). In this analysis, LXRα significantly correlated with 48/135 LXR target 
genes in the TNBC tumours which was significantly more than the 8/135 genes in the 
Luminal A tumours (Fisher’s exact test: p<0.0001). Three genes, which were not 
previously validated in the literature as bona fide LXR target genes (LCP2, DOK2 and 
TNFRSF1B) were selected from the top 10 strongest correlations to test further in 
vitro and in vivo. First, we assessed recruitment of LXRα to target gene promoters 
are shown in Figure 4.10A and 4.10B. Second, we assessed the gene correlations 
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individually (as previously shown for the canonical LXR target gene ABCA1), to 
establish if LXRα or LXRβ correlate weakly with genes in the Luminal A BCa samples 
(Figure 4.10C).  We also included the gene APOE, which is another well-known LXR 
target gene to the analysis as it significantly correlated with LXRα in the TNBC 
tumours. As a control, LXRβ was tested for correlation with genes identified as having 
LXRα bound in their promoters LCP2, TNFRSF1B, DOK2 and APOE in the TNBC or 
Luminal A tumours (with the exception of APOE; Pearson’s correlation test: 
p<0.0001; R=0.2499). Interestingly, the selected target genes (LCP2; p<0.0001, 
R=0.6832, TNFRSF1B; p<0.0001, R=0.6601, DOK2; p<0.0001, R=0.6677, APOE; 
p<0.0001, R=0.6494)  had much stronger correlations in the ER-negative tumours 
compared to the ER-positive tumours genes (LCP2; p=0.021, R=0.1518, TNFRSF1B; 
p=0.0048, R=0.1846, DOK2; p=0.0003, R=0.2368) with the exception of APOE which 
was equally as strong (p<0.0001; R=0.2649).  
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Figure 4. 10 LXRα is recruited to canonical (A) and novel (B) target gene promoters after GW3965 
treatment and correlates with the expression of novel target genes in breast tumours.  
The promoter regions of the LXR canonical target genes ABCA1 and APOE (A) and the novel target 
genes TNFRSF1B, LCP2 and DOK2 (B) were assessed for LXRα recruitment in macrophages 24 h post 
exposure to vehicle control and the LXR ligand GW3965. Peak intensity between treatments are 
displayed highlighting the increased peak intensity within the 10 kb promoter region after LXR ligand 
stimulation. Expression of LXRα was correlated with three otherwise novel candidate target genes (C) 
in 89 TNBC and 234 Luminal A/ER-positive breast tumours accessed from the patient database 
cBioportal [229], dataset [230]. Statistical significance was assessed using Pearson’s correlation test 
with linear regression. 
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Figure 4. 11 LXRα expression correlates with target genes in ER-negative tumours but not ER-
positive.  
Genes with top LXRα occupancy scores from the seven LXRα ChIP-Seq datasets [255-257] available at 
Cistrome [231] were identified. with a further 24 canonical LXR targets identified from literature were 
added (see methods section 3.11.1). Genes were then correlated with LXRα in 81 ER-negative and 
234 ER-positive Luminal A tumours from cBioportal [229], datasets [230]. Data shown are correlation 
coefficient (R) against correlation significance (on a log10 scale). Fishers’ exact test was used to assess 
significance between LXRα and LXRβ correlations with genes implicated in chemoresistance 
(p<0.0001). Genes marked with a # were later validated by qPCR analysis.  
 
Next, we tested if transcription of the three candidate (LCP2, DOK2 and TNFRSF1B) 
genes was increased more in TNBC cell lines than Luminal A by treatment with LXR 
ligands. The LXR synthetic ligand GW3965 (Figure 4.12A) and the LXR endogenous 
ligands 24OHC, 26OHC and 24,25-EC (Figure 4.12B) were able to regulate expression 
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of the novel target genes. In the BCa cells MDA-MB-468, MDA-MB-231 and MCF-7 
treatment with GW3965 significantly increased expression of the three candidate 
genes. Increases in gene expression were generally significantly lower in the Luminal 
A cells than in the TNBC cell line MDA-MB-468 (1-tailed unpaired t tests: LCP2, 
p=0.0059., DOK2, p=0.0146., TNFRSF1B, p=p=0.0295) and MDA-MB-231 (LCP2, 
p=0.0131). However, GW3965 treatment increased the expression of DOK2 and 
TNFRSF1B to similar levels in the MCF-7 and MDA-MB-231 cells (ns). The LXR 
endogenous ligands (Figure 4.12B) were also able to enhance expression of the novel 
target genes in TNBC cells relative to the vehicle control. In the MDA-MB-468 cells, 
expression of LCP2 and DOK2 were not enhanced relative to the MCF-7 cells after 
treatment with oxysterols (ns). Expression of TNFRSF1B however, was enhanced 
after treatment with 26OHC (p=0.002) in MDA-MB-468 cells compared to the MCF-
7 cells. In the MDA-MB-231 cells, expression of LCP2 was not enhanced relative to 
the MCF-7 cells after treatment with oxysterols (ns). Expression of DOK2 and 
TNFRSF1B however, were enhanced after treatment with 24OHC (LCP2: p=0.028., 
TNFRSF1B: p=0.0006), 26OHC (LCP2: p=0.003., TNFRSF1B: p=0.0005) and 24,25-EC 
(LCP2: p=0.0029., TNFRSF1B: p<0.0001) in MDA-MB-231 cells compared to the MCF-
7 cells.  
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Figure 4. 12 LXR ligands drive expression of hypothesised LXR target genes in TNBC cell cultures 
relative to Luminal A cells.  
TNBC (MDA-MB-468 and MDA-MB-231) and ER-positive (MCF-7) cells were treated with the synthetic 
LXR ligand GW3965 (1 μM) or endogenous oxysterols (10 μM) for 16 h and gene expression of the 
three novel LXR target genes LCP2 (A), DOK2 (B) and TNFRSF1B (C) was assessed by qPCR (∆∆cT using 
HPRT and normalised to vehicle). Data shown are mean of three independent replicates with SD, 
statistical analysis was established using 1-tailed unpaired t tests. Statistics were used to assess if 
TNBC cells displayed enhanced transcriptional output of target genes relative to the Luminal A cells. 
Grey p values and lines represent statistical differences between MDA-MB-468 cells and MDA-MB-
231 cells. 
 
In summary, we have established that expressions of LXR target genes are more 
likely to correlate with expression of LXRα in TNBC than Luminal A BCa and have used 
false discovery rates to hypothesis and validate novel LXR target genes. LXR ligands 

















































































































































































- 113 - 
were shown to induce expression of hypothesised LXR target genes in both TNBC 
and Luminal A cell lines. Furthermore, expression of the target genes were typically 
enhanced in the TNBC cells relative to the MCF-7 cells. Finally, APOE expression 
appeared to be down-regulated by LXR ligands in the Luminal A cell line MCF-7, 
which may be due to enhanced expression of the ligand recruited co-repressor LCOR 
(as observed in Figure 4.5). 
 
4.3.4  Corepressors control LXRα transcriptional responsiveness in breast 
cancer. 
The next aim was to establish if enhanced LXRα luciferase activity and transcriptional 
output in the TNBC relative to the Luminal A BCa subtype was influenced by the 
decreased co-repressor expression observed in Figure 4.5. To assess this aim NCOR1, 
NCOR2 and LCOR were knocked down in TNBC and Luminal A BCa cell lines and LXRα 
luciferase activity and transcriptional output measured by luciferase assay and qPCR 
respectively.  
First, NCOR1, NCOR2 (alone or in combination) or LCOR were knocked down in the 
cell lines using three targeted siRNAs. RNA was harvested 36 h post transfection and 
knockdown efficacy validated by Taqman (Figure 4.13). NCOR1 expression in MDA-
MB-468 and MCF-7 siNCOR1 cells was significantly knocked down to 25 % of the 
levels in cells transfected with non-targeting control (2-way ANOVA; mean 0.25, 
p<0.001 for both cell lines) without altering the expression of NCOR2 (mean 1.1, ns 
for both cell lines) (Figure 4.13A). NCOR1 expression in MDA-MB-468 and MCF-7 
siNCOR1+2 cells was also significantly knocked down (p<0.001 for both cell lines; 
MCF7: mean 0.25, MDA-MB-468: mean 0.2). NCOR2 knockdown (Figure 4.13B) was 
similar in the double knockdown (MCF-7: mean 0.2.5., 468: mean 0.3., p<0.001 for 
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both cell lines) and in single knockdown (MCF-7: mean 0.2., 468: mean 0.25., p<0.001 
for both cell lines) without altering NCOR1 expression (mean 1.0, ns for both cell 
lines), therefore demonstrating knockdown specificity of different NCOR genes. 
Additionally, LCOR expression in MDA-MB-468 and MCF-7 siLCOR cells (Figure 4.13C) 
was also significantly knocked down (MCF-7: mean 0.5., 468: mean 0.4., p<0.001 for 
both cell lines). 
 
Figure 4. 13 NCOR1, NCOR2 and LCOR were successfully knocked down in MDA-MB-468 and MCF-7 
cells.  
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LCOR, NCOR1 (siNCOR1) and NCOR2 (siNCOR2) either alone or in combination (siNCOR1+2) were 
knocked-down in the LXRα luciferase reporter MCF-7 and MDA-MB-468 cells. Gene expression of the 
corepressors NCOR1 (A), NCOR2 (B) and LCOR (C) were assessed by qPCR 36 h post silencing. 
Statistical significance was established using 2-way ANOVA and mean of 2-3 independent replicates 
with SEM are presented. 
 
Since LXR transcriptional response to ligand and corepressor expression appear to 
be associated we assessed if knockdown of corepressors NCOR1, NCOR2 and LCOR 
equalized the response to ligand between the two BCa subtypes. So after validating 
the knockdowns, LCOR, NCOR1, NCOR2 and NCOR1+2 together were knocked down 
in MDA-MB-468 and MCF-7 luciferase reporters and treated with VC or 26OHC for a 
further 16 h. LXRα transactivation was measured by luciferase assay and mRNA 
assessed using qPCR. MDA-MB-468 cells transfected with universal negative control 
siRNA (siSCR) and treated with 26OHC showed significant increase in luciferase signal 
similar to Figure 4.7 (2-way ANOVA; MCF-7: mean 2-fold., 468: mean 3-fold., p<0.01) 
which again, was significantly more than the MCF-7 cells (Figure 4.14A). 
Interestingly, knockdown of NCOR1 enhanced response to 26OHC (mean 2.5-fold, 
p<0.001 both cell lines), NCOR2 (mean 2.5-fold, p<0.001 both cell lines) and 
NCOR1+2 (MCF-7: mean 4-fold., 468: mean 4.4-fold., p<0.001 both cell lines) and 
restored sensitivity of LXRα to ligand in the MCF-7 cell line, equalizing the expression 
of NCOR1, NCOR2 and NCOR1+2 to match that of the MDA-MB-468 cells (ns). 
Knockdown of LCOR also enhanced response to 26OHC in both cell lines (MCF-7: 
mean 5-fold., 468: 5.5-fold., p<0.0001 both cell lines), and equalised the sensitivity 
of LXRα to ligand in MCF-7 to match that of the MDA-MB-468 cells (ns), Figure 4.14B.   
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Figure 4. 14 NCOR and LCOR knockdown restores sensitivity to ligand..  
LCOR, NCOR1 (siNCOR1) and NCOR2 (siNCOR2) either alone or in combination (siNCOR1+2) were 
knocked-down in the LXRα luciferase reporter MCF-7 and MDA-MB-468 cells and treated with vehicle 
control (VC) or 26OHC (10 μM) for 16 h. LXRα transactivation was assessed 36 h post silencing in 
luciferase assays (A+B). Statistical significance was established using 2-way ANOVA (*p<0.05, 
**p<0.01, ***p<0.001) and mean of 2-3 independent replicates with SEM are presented.  
 
Furthermore, expression of ABCA1 and APOE was assessed after knockdown of 
LCOR, NCOR1, NCOR2 and NCOR1+2 (Figure 4.15). Expression of the LXR target 
genes ABCA1 and APOE were enhanced in the MCF-7 cells post knockdown of NCOR1 
(1-way ANOVA: ABCA1 and APOE p<0.001) and NCOR1+2 (ABCA1 and APOE 
p<0.001). NCOR2 knockdown enhanced the expression of ABCA1 however not 
significantly, but was able to significantly enhance the expression of APOE (p<0.05). 
Enhanced transcriptional output of LXR target genes was also observed in the MDA-
MB-468 cells post knockdown of NCOR1 (ABCA1; p<0.001., APOE; p<0.001), NCOR2 
(ABCA1; p<0.05., APOE; p<0.05) and NCOR1+2 (ABCA1; p<0.001., APOE; p<0.001). 
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Figure 4. 15 NCOR1, NCOR2 and LCOR knockdown enhances expression of LXR target genes ABCA1 
and APOE in TNBC and Lumina A reporter cells.  
LCOR, NCOR1 (siNCOR1) and NCOR2 (siNCOR2) either alone or in combination (siNCOR1+2) were 
knocked-down in the LXRα luciferase reporter MCF-7 and MDA-MB-468 cells. Gene expression of the 
canonical LXR target genes ABCA1 (A) and APOE (B) were assessed by qPCR 36 h post silencing. 
Statistical significance of gene expression analyses was established using 1-way ANOVA comparing 
knockdown cells to cell line specific siSCR (using ΔΔCt and normalised to HPRT1). Mean of 2-4 
independent replicates with SEM are presented. 
 
Since LXR transcriptional response to ligand was equalized by knockdown of 
corepressors NCOR1, NCOR2 and LCOR between the two BCa subtypes we wanted 
to assess whether corepressor knockdown also made the MCF-7 cells more sensitive 
to ligand in MTT assays (Figure 4.16A). In MCF-7 cells, knockdown of NCOR1 (non-
linear regression comparison of fits: p<0.001), NCOR2 (p,0.001) and LCOR (no p 
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value: ambiguous) made the Luminal A cells more sensitive to treatment with 
26OHC. In MDA-MB-468 cells, knockdown of NCOR1 (p<0.001), NCOR2 (p<0.001) 
and LCOR (p<0.001) also made the TNBC cells more sensitive to treatment with 
26OHC. In summary, corepressors have been shown to be important factors 
dictating the differential transcriptional activity of LXR between BCa subtypes. 
Next, we measured LXR transcriptional output of its target genes after LXRα silencing 
to assess for LXRα control. First, we transfected MDA-MB-468 and MCF-7 LXRα 
luciferase reporter cells with LXRα siRNA complexes and measured LXRα 
transactivation after stimulation with ligands (Figure 4.16B). 26OHC was able to 
induce LXRα transactivation in the MDA-MB-468 and MCF-7 siSCR transfected cells 
but in the MDA-MB-468 and MCF-7 siLXRα cells; ligand driven LXRα activity was 
significantly attenuated (2-way ANOVA, 26OHC; p<0.0001., for both cell lines). After 
validation of successful knockdown, RNA was harvested from MDA-MB-468 and 
MCF-7 cells transfected with siLXRα complexes and expression of ABCA1 and APOE 
was assessed by TaqMan assays (normalized to HPRT1) (Figure 4.16C). In cells 
transfected with siLXRα complexes gene expression of ABCA1 was reduced 
(p<0.0001 for both cell lines), as was APOE expression (p<0.0001 for both cell lines) 
validating these targets as LXRα regulated genes.  
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Figure 4. 16 Knockdown of corepressors increases sensitivity to ligand, and knockdown of LXRα in 
attenuates the expression of LXR target genes ABCA1 and APOE.  
The corepressors LCOR, NCOR1 and NCOR2 were knocked down in MCF-7 and MDA-MB-468 cells and 
their response to ligand assessed relative to the universal negative control. LXRα was knocked-down 
in MCF-7 and MDA-MB-468 LXRα-luciferase reporter cells and were treated with vehicle control (VC) 
or 26OHC (10 μM) for 16 h to validate LXRα specificity (A). After knockdown of LXRα the expression 
of the LXR target genes ABCA1 and APOE were analysed by qPCR. Statistical significance was 
established using 2-way ANOVA (*p<0.05, **p<0.01, ***p<0.001, p<0.0001) and mean of 4 
independent replicates with SEM are presented.. 
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4.3.5  Enhanced LXRα activity and function increases the risk of patient 
relapse. 
Enhanced LXRα activity and function has been shown in the TNBC disease relative to 
the Luminal A disease, but whether this impacts on the patient prognosis, 
independently of subtype is unclear. To assess whether enhanced LXRα activity is a 
signature of poor prognosis in TNBC patients, we assessed tumours for oxysterol 
content, LXRα target gene expression, and gene signatures through correlations 
between gene expression profiles in tumours in 69 breast tumour samples from the 
Leeds Breast Tissue Bank (09H1326/108 - 22 tumours, 15/HY/0025 - 47 tumours). 
First, we assessed whether markers of LXRα activity are associated with worse 
prognosis within the TNBC subtype by assessing patient primary tumours for 
expression of the LXRα target gene ABCA1 in patients who had either suffered an 
event or not. Events are defined as patients who have suffered a breast cancer 
relapse but may still be alive or patients who had died from breast cancer. No events 
are classified as patients who have had no relapse, were disease free and are alive 
after at least 3 years. To test this aim, RNA was extracted from 69 tumours from a 
mixture of breast tumour subtypes (Table 7 – section 3.12.1) and gene expression 
analysed by qPCR. In TNBC tumours, patients who had suffered an event had 
significantly higher expression of ABCA1 (Mann-Whitney U Test; p=0.0036) relative 
to patients who had not suffered an event (Figure 4.17). In the Non-TNBC tumours, 
patients who had suffered an event did not have significantly higher expression of 
ABCA1 (ns) than those who were alive and disease free after at least 3 years (Figure 
4.17). Tumour expression of ABCA1 was then assessed alongside patient survival to 
assess whether expression is predictive of survival in Kaplan Meier graphs (Figure 
4.17B). ROC curves were used to establish the expression cut offs for high and low 
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expression levels. TNBC tumours with higher expression of ABCA1 (>1) were found 
to have worse survival than those with lower ABCA1 expression (<1; Logrank test, 
p=0.031). In non-TNBC tumours however, ABCA1 expression was found to have no 
effect on patient survival (ns). 
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Figure 4. 17 Enhanced expression of ABCA1 was observed in patient tumours who relapsed 
compared to those with primary disease.  
RNA was isolated from 69 breast cancer patient tumours (41 TNBC, 28 HER2 enriched or hormone 
receptor positive [HR+]) and the expression the canonical LXR target gene ABCA1 was analysed by 
qPCR. Expression of the target genes were assessed in patients who had suffered a recurrence or BCa 
related death (Event) and those that had not had (No Event) with at least 3 years follow up from 
diagnosis. Statistical differences were established using Mann-Whitney U Tests. Patient survival is 
shown in a Kaplan Meier graph for the TNBC (28) and Non-TNBC (13) subtypes due to significant 
differences in ABCA1 expression between event and no event groups. Statistical differences were 
established using a Logrank test, expression cut offs established using ROC curves. 
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4.4  Discussion 
The purpose of this study was to establish if a difference in LXRα activity between 
ER-negative and ER-positive subtypes of breast cancer could explain why clinical 
interventions that impact on cholesterol have greater impacts on TNBC than ER-
positive disease [5, 46-48, 122, 220, 221, 258]. In this chapter, it was established that 
although ligand synthesis and concentration were indistinguishable between 
subtypes, the expression of LXRα and its regulatory factors is skewed towards 
insensitivity to ligand in ER-positive breast cancers and a more responsive and 
transcriptionally poised state in the ER-negative breast cancers.  As a transcription 
factor, it would be expected that on balance, and in the absence of other variables, 
LXR target genes should be more highly expressed in the presence of high levels of 
LXR. This was found to be the case in ER-negative, but not ER-positive disease. This 
difference in LXR target gene expression was explained by significantly higher 
expression of the corepressors NCOR1, NCOR2 and LCOR in the ER-positive disease 
and was reversable by genetic knockdown of these factors. These data indicate that 
ER-negative tumours are more sensitive to the increased oxysterols levels that are 
produced by in high cholesterol environments than ER-positive tumours. Given the 
role of LXR-oxysterol signaling in BCa, the observations presented here may explain 
why ER-negative disease is more likely to be ameliorated by cholesterol lowering 
interventions such as statins and nutrition such as plant-based diets and diets low in 
saturated fat [46, 47, 220]. 
Nuclear receptor repression through elevated corepressor expression has been 
observed in other cancers including bladder [242] and prostate [94, 95], as a 
mechanism to reduce antiproliferative effects, but this is the first report of reduced 
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CoR expression that facilitate a NR’s activity and associates with worse prognosis. 
Here, the antiproliferative effects of oxysterol-LXR signaling were assessed though 
MTT assays and surprisingly found a more sensitive environment in the 
antiproliferative response to oxysterols in the aggressive ER-negative disease. The 
ER-positive breast cancer cells MCF-7 have previously been shown to be more 
sensitive to LXR induced cell cycle arrest than the ER-negative MDA-MB-231 breast 
cancer cells after exposure to synthetic LXR ligands [134]. Interestingly, LXR 
stimulation was shown to induce expression of the LXR target gene ABCA1 in the BCa 
cells with a more enhanced transcriptional output observed in the ER-negative cells 
compared to the ER-positive cells, which matches our observations in this study. The 
differences in antiproliferative effects observed in the study by Vedin et al [134], 
compared to our study may be due to the nature of LXR specific synthetic agonists. 
The LXR ligands used in our study were oxysterols, which are estrogenic and show 
the antiproliferative actions of oxysterols on ER and LXR in ER-positive cells. As 
demonstrated in this chapter, there are notable differences in nuclear receptor 
biology between BCa subtypes beyond those of ER and PR expression. Furthermore, 
responsiveness to ligands in the subtypes is controlled by corepressor expression 
and indicates differential cholesterol metabolism between subtypes. 
In some tumour types it appears there may be selective advantages associated with 
the retention of LXR signaling which compensates for the antiproliferative actions of 
the oxysterol-LXR axis. The oxysterol signaling pathway has been associated with the 
metastasis of breast cancer cells in ER-negative disease [21].  It would be interesting 
to determine if repressed LXR activity is required for the initial primary tumour 
development to impair its antiproliferative actions, and in later stage disease returns 
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to support migration. Consistent with this is the observation that 25OHC is elevated 
in serum of breast cancer patients at relapse compared to those with primary disease 
[136]. 
Gene expression patterns and responsiveness to ligand appear to be altered in 
cancer biology. With the use of nuclear receptor cofactor expression as therapeutic 
biomarkers, it may be possible to reinstate pre-cancer gene expression 
responsiveness through targeting of corepressors such as NCOR. NCOR1 for 
example, was identified as an independent prognostic marker in a cohort of mixed 
breast cancer subtypes [259]. Interestingly for the treatment of ER-positive breast 
cancers, tamoxifen depends on NCOR1 recruitment to the ER to repress the activity 
of the receptor and therefore its target genes [260]. Additionally, our data suggest 
corepressor expression levels are high in pre-treatment ER-positive tumours, which 
may be to prevent LXR and other nuclear receptors driving anti-proliferative effects. 
This may cause impacts on oxysterol dependent ER activity, which as several 
oxysterols are estrogenic and pro-proliferative when liganded with the ER, high 
corepressor activity may impede oxysterol-ER dependent proliferation. 
LCOR is another corepressor of great interest in this chapter. LCOR recruitment is 
somewhat different to that of NCOR. LCOR is a ligand recruited corepressor and its 
recruitment to promotors by agonists, and can repress gene expression rather than 
enhance or activate gene transcription [261]. In this study, LCOR expression was 
found to be higher in the ER-positive primary breast tumours as well as the ER-
positive breast cancer cells (MCF-7), which has previously been associated with 
improved survival in BCa patients [262]. In support of the observations where ER-
positive BCa displayed enhanced LCOR expression, LXR ligands also down-regulated 
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the expression of APOE but only in the ER-positive breast cancer cells, implicating 
LCOR as the corepressor recruited in the MCF-7 cells to impair activation of the LXR 
target gene APOE. This was further supported by increased expression of APOE in 
MCF-7 cells that had LCOR silenced/knocked down (Figure 4.15B).  
4.5  Summary 
In this chapter LXRα activity and function has been established as subtype specific. 
Oxysterols have been confirmed as natural LXR agonists in TNBC and Luminal A BCa 
cell lines. Enhanced LXRα activity has been identified in the TNBC tumours and cell 
lines and are poised for response to ligand relative to the Luminal A subtype. These 
findings were established through mining publicly available datasets, qPCR analyses, 
western blot protein analysis, MTT assays and the generation of LXRα-luciferase 
reporter cell lines. We also assessed publicly available datasets to assess correlations 
of potential LXR target genes to validate highly correlated genes by qPCR. 
Furthermore, we performed knockdowns to assess subtype response to ligand after 
co-repressor gene silencing and established NCOR1, NCOR2 and LCOR knockdown 
restored sensitivity to the Luminal A cell line comparable to the TNBC response to 
ligand. And finally, we showed enhanced LXRα activity in patients who had relapsed 
compared to those that had not through methods of LCMS/MS and genes expression 
analyses in patient primary tumours.  
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Chapter 5 
LXR links cholesterol hydroxylation to chemotherapy resistance in 
breast cancer. 
5.1  Introduction 
LXR and oxysterol signalling have been linked to the progression of BCa in multiple 
studies [21, 105, 110]. In the previous chapter, the differential expression of 
cofactors and ligand concentration were explored as mechanistic reasons for why 
TNBC and Luminal A BCa subtypes process and respond to cholesterol differently. In 
TNBC subtype, lower expression of corepressors was identified as a likely reason for 
enhanced LXRα activity relative to the Luminal A BCas. Knockdown of the 
corepressors NCOR1, NCOR2 and LCOR enhanced LXR response to ligand in both 
Luminal A and TNBC cell lines and the response to some ligands was equalised. LXR 
ligands are known to be anti-proliferative in a wide variety of cancer cell lines [68, 
249], so it remains unclear why TNBC, the more aggressive form of BCa, would 
deregulate expression of its co-factors to have enhanced oxysterol signalling.  
In addition to their anti-proliferative actions, oxysterols are also known to have 
proapoptotic and cytotoxic effects on tumour cells. Oxysterols are consequential of 
the enzymatic or non-enzymatic oxidation of cholesterol. The enzymatic conversion 
of cholesterol to oxysterols involves the enzymes belonging to the cytochrome P450 
family (CYPs) and are responsible for the synthesis of 24OHC and 26OHC. The 
synthesis of 25OHC occurs when cholesterol is hydroxylated by CH25H, an enzyme 
that utilises diiron cofactors to catalyse hydroxylation (Figure 5.1). The non-
enzymatic conversion or auto-oxidation involves reactive oxygen and nitrogen 
species (ROS) such as hydroxyl radical or hydrogen peroxide, and an example of this 
includes the synthesis of 7-ketocholesterol. The overproduction of ROS as a 
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biproduct of cholesterol auto-oxidation is linked to the proapoptotic effects of 
oxysterols as shown in 7-ketocholesterol treated RPE cells, which have been shown 
to significantly enhance mitochondrial DNA damage [263]. Furthermore, oxysterol 
induced apoptosis is facilitated by internal mitochondrial pathways [264, 265] and 
an external Fas/Fas death receptor-dependent pathway [266] of which highlight an 
exploitable mechanism through targeting of the LXRs.  
Total cholesterol, LDL-C and oxysterol levels have been shown to be elevated in 
tumours relative to healthy tissue [110, 176-178], yet low total serum cholesterol 
and LDL-C levels have been observed in patients with cancer [179, 180] suggesting 
cholesterol may accumulate within tumours or be synthesised by tumour 
microenvironment support cells. Oxysterols have been shown to promote BCa 
tumour growth [105, 110], metastasis [21], and to induce LXR-dependent EMT in ER-
negative tumours [105]. Furthermore, elevated oxysterol levels have been found in 
patient serum at relapse [136] and knockdown of CYP27A1, the rate-limiting enzyme 
in the synthesis of 26OHC, resulted in the reduction of hypercholesterolemia-
promoted tumour growth in mice [105]. Wu et al, supported these studies by the 
Nelson group [21, 105], demonstrating 26OHC promotes ER-positive BCa growth via 
diminished CYP7B1 expression [110]. Moreover, larger tumours derived from TNBC 
BCa cells were observed in mice with high circulating LDL-C compared to mice with 
low LDL-C [51]. Research so far has shown oxysterols have links to BCa progression 
and the enhanced LXR activity in TNBC may be contributing to the higher risk of 
relapse associated with this subtype. 
Recurrence of cancer is common in the TNBC subtype and relapse often occurs due 
to the failure or lack of response to anticancer therapies resulting in the 
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development of chemotherapy resistance [56]. The active efflux of chemotherapy 
agents from within a cell is a key mechanism of chemoresistance [61]. Several  
members of the ATP-binding cassette transporters (ABC-transporters), including 
BCRP [226, 267], p-gp/ABCB1 [224, 268] and MDRP  [225, 269] are linked with 
unsuccessful drug effect and cancer cell survival. Importantly, 24OHC has been 
shown, via LXRα, to regulate expression of the p-gp/ABCB1 in the BBB [228]. 
Additionally, as oxysterols are known to have cytotoxic and proapoptotic effects it 
may provide insight into oxysterol induced expression of the p-glycoprotein/ABCB1. 
Given the enhanced LXRα activity and function in TNBCs, and that p-glycoprotein is 
an important clinical factor associated with chemotherapy resistance, if p-gp/ABCB1 
is regulated by LXRα in BCa it may be a previously unidentified route of 
chemotherapy resistance in TNBC. 
 
5.2  Hypothesis and Aims 
Oxysterols are moderately reactive with DNA, proteins, and lipids, and if further 
metabolised form bile acids that have increased propensity to react with cellular 
components. A tumour that has developed in a cholesterol rich environment is pre-
equipped (de novo) with detoxification mechanisms that not only allow removal of 
potentially cytotoxic metabolite metabolites but xenobiotics such as chemotherapy 
agents as well. Enhanced LXR activity in TNBC promotes chemoresistance by direct 
activation of drug efflux proteins.  
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Figure 5. 1 Do LXR ligands alter the efficacy of chemotherapy drugs? 
HMGCR is the enzyme responsible for the synthesis of cholesterol. Cholesterol can be modified by 
enzymes such as CYPs (shown are CYP46A1 and CYP27A1) to convert cholesterol to their hydroxylated 
state as oxysterols (24OHC and 26OHC). Other enzymes such as CH25H utilise diiron cofactors to 
catalyse hydroxylation for the conversion of cholesterol to oxysterols (25OHC), or conversion can 
occur through auto-oxidation or non-enzymatic means. Oxysterols can then bind to and activate LXRα 
in breast cancer cells. Further modifications such as sulphonation (SULT2B1) or hydroxylation of the 
B ring (CYP7B1) however, inactivate the oxysterols impairing their ability to interact with LXR. Here 
we hypothesise that oxysterols can reduce chemotherapy efficacy through up-regulation of genes 
involved in chemotherapy drug export. 
 
The aims of this chapter were to: 
• Establish if LXRα regulation alters cancer cell line responses to 
chemotherapy. 
• Determine whether LXR regulates expression of genes implicated in 
chemoresistance. 
• Establish if LXRα activity is associated with worse chemotherapy efficacy in 
breast cancer patients. 
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5.3  Results 
5.3.1  LXR activation protects breast cancer cells from chemotherapy 
assault. 
To establish if LXR ligands alter chemotherapy response in breast cancer cell lines 
colony forming assay, MTT assay, and mouse xenografts were performed. First, we 
performed colony forming assays to assess the effects of LXRα regulation during 
chemotherapy treatments. Luminal A BCa cell cultures (MCF-7) and TNBC cell 
cultures (MDA-MB-468 and MDA-MB-231) were pre-treated with LXR synthetic 
ligands (T0901317, GW3965 and GSK2033) for 24 h before the chemotherapy agent 
epirubicin for a further 24 h. Cells were then counted and 500 live cells/well were 
plated per treatment group and left to recover and form colonies for 12 days. After 
the recovery period colonies were stained with crystal violet and colonies counted 
(Figure 5.2).  
The LXR agonist T0901317 enhanced colony formation and cell survival when given 
as a pre-treatment before epirubicin in all BCa cells (paired t-tests; p<0.01) as did the 
LXR agonist GW3965 (p<0.01). Furthermore, the LXR antagonist GSK2033 decreased 
colony formation and cell survival when given as a pre-treatment before epirubicin 
in TNBC cells (p<0.05), but not in MCF-7 cells (ns). No effects on colony forming 
efficiency were observed in the LXR ligand treatment groups in the absence of 
epirubicin (ns), indicating the increased colony formation is likely due to rescue from 
epirubicin rather than enhanced inherent colony forming capacity. 
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Figure 5. 2 Treatment of breast cancer cell cultures with synthetic LXR ligands protects against 
subsequent exposure to the chemotherapy agent epirubicin.  
ER-positive (MCF-7) and triple negative (MDA-MB-468 and MDA-MB-231) breast cancer cell cultures 
were treated with the synthetic LXR ligands (a) T0901317 (T090), (b) GW3965 (GW), (c) GSK2033 (GSK) 
at 1 μM, or vehicle control, for 24 h before exposure to epirubicin (25 nM) for a further 24 h. Each 
line shows an independently replicated experiment (generated from the mean of 3 technical repeats) 
comparing the effect on colony formation of epirubicin alone (EPI) or first pre-treating cells with 
ligand (EPI + T090/GW/GSK). In (d) cells were treated with LXR ligands but not exposed to epirubicin. 
p-values show results from paired t-tests (a, b and c) or one-way ANOVA (d) after correction for 
multiple testing. Data shown are mean of 4 independent replicates with SEM. 
 
Next, the colony forming assays were repeated to determine if endogenous LXR 
ligands (oxysterols) recapitulated the chemoresistance inducing effects of synthetic 
LXR agonists. Luminal A breast cancer cell cultures (MCF-7) and TNBC cell cultures 
(MDA-MB-468 and MDA-MB-231) were pre-treated with LXR endogenous ligands 
(24OHC, 24,25-EC and 26OHC) for 24 h before the chemotherapy agent epirubicin 
for a further 24 h (Figure 5.3). 24OHC enhanced the number of cells able to establish 
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a colony when given as a pre-treatment before epirubicin in TNBC cells (paired t-
tests; p<0.01), but not in MCF-7 cells (ns). 24,25-EC enhanced colony formation when 
given as a pre-treatment before epirubicin in all BCa cells (paired t-tests; p<0.05), as 
did 26OHC (paired t-tests; p<0.01). These data (Figure 5.2 and 5.3) demonstrate that 
activation of the LXR pathway with synthetic agonists or endogenous ligands, 
increases the ability of several breast cancer cell types to resist chemotherapy and 
form colonies. 
 
Figure 5. 3 Treatment of breast cancer cell cultures with endogenous LXR ligands protects against 
subsequent exposure to the chemotherapy agent epirubicin.  
ER-positive (MCF-7) and triple negative (MDA-MB-468 and MDA-MB-231) breast cancer cell cultures 
were treated with the endogenous LXR ligands (a) 24-hydroxycholesterol (24OHC), (b) 24,25-
epoxycholesterol (24,25-EC), (c) 25,26-hydroxycholesterol (26OHC) at 10 μM, or vehicle control, for 
24 h before exposure to epirubicin (25 nM) for a further 24 h. Each line shows an independently 
replicated experiment (generated from the mean of 3 technical repeats) comparing the effect on 
colony formation of epirubicin alone (EPI) or first pre-treating cells with ligand (EPI + 24OHC/24,25-
EC/26OHC). In (d) cells were treated with LXR ligands but not exposed to epirubicin. p-values show 
results from paired t-tests (a, b and c) or one-way ANOVA (d) after correction for multiple testing. 
Data shown are mean of 3-4 independent replicates with SEM. 
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The next aim was to determine if oxysterols impair the ability of epirubicin to induce 
cell death, by using mitochondrial function as a surrogate marker of cell viability/cell 
number in MTT assays (NB: these experiments were performed and analysed by 
Priscilia Lianto).  
The MTT assays (Figure 5.4) showed significant reductions in epirubicin efficacy after 
exposure to 24OHC in the MCF-7 cells at 1 µM (2-tailed unpaired t-tests; p=0.004) 
and 10 µM (p=0.025), MDA-MB-231 cells at 1 µM (p=0.0026) and 2.5 µM (p=0.0013) 
and MDA-MB-468 cells at 1 µM (p=0.0452) and 2.5 µM (p=0.0198) and 10 µM 
(p<0.0001). Significant reductions in epirubicin efficacy were observed after 
exposure to 25OHC in the MCF-7 cells at 2.5 µM (p<0.0001) only, MDA-MB-231 cells 
at 2.5 µM (p=0.0074) and 10 µM (p=0.0136) and MDA-MB-468 cells at 2.5 µM 
(p=0.002) only. Furthermore, significant reductions in epirubicin efficacy were 
observed after exposure to 26OHC in the MCF-7 cells at 1 µM (p=0.0048) and 2.5 µM 
(p=0.0056), MDA-MB-231 cells at 10 µM (p=0.0167), and in MDA-MB-468 cells at 10 
µM (p<0.0001). In summary these data show oxysterols reduce the efficacy of the 
chemotherapy drug epirubicin. 
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Figure 5. 4 Oxysterols alter the efficacy of the chemotherapy agent epirubicin.  
The anti-proliferative effects of epirubicin alone and in the presence of oxysterols were assessed by 
MTT in MDA-MB-468, MDA-MB-231 and MCF-7 cells over 72 h. Cells were treated with ligand 
treatment for 24 h alone (A: 24OHC, B: 25OHC and C: 26OHC), then with epirubicin for a further 48 h. 
Data are presented as means of 3 independent replicates with SEM and non-linear regression. 
Experiments performed and data analysed by Priscilia Lianto. 
 
5.3.2  The oxysterol-LXR axis regulates genes which promote chemotherapy 
resistance in triple negative breast cancer. 
To establish the molecular mechanisms through which LXR appeared to be exerting 
chemotherapy resistance, hypothesis driven and hypothesis generating approaches 
were taken. The initial candidate for LXR-mediated chemoresistance was p-
gp/ABCB1; previous reports had identified p-gp/ABCB1 was regulatable by the LXR 
ligand 24OHC albeit in the BBB [228]. To identify other molecular effectors of LXR-
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mediated chemotherapy resistance, the following steps were performed: i) a 
systematic review to identify all genes previously implicated in breast cancer 
chemoresistance (Appendix A – A.2); ii) evidence for LXRα binding to the promoters 
of these genes was then sought by mining ChIP-Seq data public databases [231]; iii) 
assessment of correlations between mRNA expression of LXRα and chemotherapy 
resistance target genes; iv) validation of top targets in BCa cell lines. 
5.3.2.1  Systematic Literature Review. 
Pubmed was searched (for search criteria and flow diagram see methods section 
3.11.2) and 130 genes identified as potential candidates (Appendix A - A.2) 
containing a range of chemotherapy mechanisms including DNA repair (BRCA1, 
BRCA2, XRCC1), detoxification (ABCC1, ABCG2, CBR1) and evasion of apoptosis 
(BIRC3, BCL2, TP53).. 
5.3.2.2  LXRα binding.  
ChIP-Seq data was mined from the Cistrome database [231] to check for LXRα 
binding (see Appendix A – A.3 for list of genes and binding scores). 
5.3.2.3  Assessment of chemotherapy resistance gene expression in breast cancer 
patient tumours. 
Genes were then assessed for mRNA expression levels [230] in the CBioportal 
database [229]. The expression of genes implicated in chemoresistance was then 
assessed for any correlations with LXRα and LXRβ. A False Discovery Rate (FDR) of 
what 1 % was used to correct for multiple testing (denoted with a dotted line). The 
analysis is shown as a volcano plot showing correlation coefficient against FDR in ER-
negative BCa tumours (Figure 5.5). We observed that LXRα significantly correlated 
with 11/130 chemoresistance genes in the TNBC tumours which was significantly 
more than 0/130 genes for LXRβ (Fisher’s exact test: p<0.0001). A mixture of 
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previously identified LXR targets (p-gp/ABCB1 and MMP9) and apparently novel, 
aside from their listing in Cistrome ChIP-Seq analyses (SLC31A2, BIRC3, NFKB1, TFPI2, 
TRIM2, ERBB3, GPSM3, FPGS, and CXCL5) were found. Of these, five genes (SLC31A2, 
BIRC3, p-gp/ABCB1, GPSM3 and CXCL5) with the strongest positive correlations were 
followed further to test the in-silico predictions that these genes should be inducible 
in the TNBC cells. Recruitment of LXRα to target gene promoters are shown in 
Appendix 2 – A.2. 
Next, gene correlations were performed individually to show how LXRα and LXRβ 
correlate with genes in the TNBC and Luminal A BCa samples (Figure 5.6). LXRβ failed 
to significantly correlate with the selected chemotherapy resistant genes SLC31A2, 
BIRC3, and CXCL5 in the TNBC and Luminal A patient tumours (Pearson’s correlation 
test: ns), but GPSM3 significantly correlated with LXRβ in the Luminal A patient 
tumours (p<0.0001; R=0.4688) as well as in the TNBC tumours (p=0.0016; R=0.3455). 
Expression of p-gp/ABCB1 only weakly correlated with LXRβ expression in the TNBC 
tumours (p=0.05; R=0.2146) but not with the Luminal A BCas. Interestingly, the 
selected chemoresistance genes (SLC31A2; p<0.0001, p-gp/ABCB1; p<0.0001, 
GPSM3; p<0.0001, and CXCL5; p<0.0001) had much stronger correlations in the 
TNBC tumours except BIRC3 which was equally as strong (p<0.0001) compared to 
the Luminal A tumours genes (SLC31A2; p=0.0085, p-gp/ABCB1; ns, GPSM3; 
p=0.0002, CXCL5; ns). 
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Figure 5. 5 LXRα is significantly more likely to correlate with chemoresistance genes in TNBC.. 
130 genes implicated in chemotherapy resistance in cancer were identified from literature and 
included for analysis if they appeared in the top 50 % of LXRα bound scores and the genes were found 
bound to their promoters in a mouse macrophage ChIP-Seq dataset [256] accessed from Cistrome 
[231]. These genes were then assessed for correlation with LXRα and LXRβ expression in 89 TNBC 
primary breast tumours [229, 230]. Data display the correlation coefficient (R) against correlation 
significance (on a log10 scale). Fishers’ exact test was used to assess significance between LXRα and 
LXRβ correlations with genes implicated in chemoresistance (p<0.0001). Genes marked with a # were 
later validated by qPCR analysis. 
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Figure 5. 6 Examples of the some of the strongest correlating genes with LXRα in TNBC and Luminal 
A BCa patient tumours.  
Expression of genes implicated in chemoresistance were correlated with LXRα  and LXRβ in 89 TNBC 
and 234 Luminal A/ER-positive breast tumours [230] accessed from the patient database CBioportal 
[229]. Statistical significance was assessed using Pearson’s correlation test with linear regression. 
 
 
- 140 - 
5.3.2.4  In vitro validation of chemotherapy resistance genes as LXRα targets. 
To clarify if the chemotherapy resistance genes identified as correlated with LXRα 
expression and had LXRα binding in their promoters, were targets, their 
transcriptional output was assessed after treatment with LXR ligands. Expression of 
the chemotherapy efflux pump p-gp/ABCB1 was significantly increased in MDA-MB-
468 by all agonists (p<0.05) and by all endogenous agonists in MDA-MB-231 cells 
(p<0.01) (Figure 5.7). In MCF-7 cells, agonists either had no effect  or decreased 
expression (p<0.05), which was reminiscent of how APOE responded previously 
(Figure 4.8). GSK2033 prevented 26OHC mediated induction in both TNBC cell lines 
(468 p=0.0038, 231 p=0.0008). 
 
Figure 5. 7 LXR ligands induce expression of the p-glycoprotein/ABCB1 in TNBC cells but 
downregulates its expression in Luminal A cells in an LXR dependent manner.  
TNBC (MDA-MB-468 and MDA-MB-231) and ER-positive (MCF-7) cells were treated with LXR ligands 
(synthetic 1 μM, endogenous 10 μM) for 16 h and expression of p-gp/ABCB1 was assessed by qPCR 
(∆∆ct using HPRT and normalised to vehicle). Data shown are mean of 2-3 independent replicates 
with SD, statistical analysis was established using 1-tailed unpaired t tests.  
 
LXR ligands also regulated three of the remaining four chemoresistance genes 
selected for further analysis (Figure 5.8). In both TNBC lines, GPSM3 and CXCL5 were 
significantly altered (p<0.05) whilst BIRC3 induced in MDA-MB-468 only. In MCF-7 
cells, BIRC3 and CXCL5 expression was altered by LXR ligand (Figure 5.8). In no cell 
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line was SLC31A2 regulated (ns). Taken with the data presented above, p-gp/ABCB1 
was the strongest candidate for LXRs chemotherapy resistance effects. P-gp/ABCB1 
responded to all ligands in both TNBC cell lines, was correlated with LXRα, and had 
demonstrable recruitment of LXR to its promoter. P-gp/ABCB1 was selected for more 
detailed evaluation as the link between LXR and chemotherapy resistance. 
 
Figure 5. 8 LXR ligands also drive transcription of predicted genes involved in chemoresistance in 
TNBC.  
TNBC (MDA-MB-468 and MDA-MB-231) and Luminal A/ER-positive (MCF-7) cells were treated with 
LXR ligands (synthetic 1 μM, endogenous 10 μM) for 16 h and expression of SLC31A2 (A), BIRC3 (B), 
GPSM3 (C), CXCL5 (D) was assessed by qPCR (∆∆Ct using HPRT and normalised to vehicle). Data shown 
are mean of three independent replicates with SD, statistical analysis was established using 1-tailed 
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5.3.3  LXR regulates chemotherapy drug efflux from breast cancer cells. 
As p-gp/ABCB1 expression was shown to be induced by 24OHC in literature (albeit 
in the BBB) [228], and later in TNBC cells (Figure 5.6), our aim was to establish a 
functional role for enhanced p-gp/ABCB1 expression in TNBC. To explore this role, a 
new assay was developed to exploit the natural fluorescence of  epirubicin in a high 
throughput (96-well plate) and time resolved system; epirubicin efflux was 
measurable in time-matched using signal decay rates under different experimental 
conditions. In the TNBC cell lines, pre-treatment with the LXR ligand GW3965 (Figure 
5.9) and endogenous ligands (Figure 5.10) significantly enhanced the export of 
epirubicin relative to control. Verapamil (a p-gp/ABCB1 inhibitor), but not MK571 or 
KO131 (BCRP and MRP1 inhibitors) enhanced epirubicin loading (Figure 5.11) and 
reversed LXR dependent efflux in TNBC cell lines but not MCF-7 and reversed LXR 
dependent efflux (Figure 5.9-11). In summary, these data suggest that LXR can 
increase epirubicin efflux, this was only observed in TNBC cell lines, and it is 
dependent on p-gp/ABCB1. 
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Figure 5. 9 The synthetic LXR ligand GW3965 enhances epirubicin export via p-gp/ABCB1 in TNBC 
cells.  
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MDA MDA-MB-468 (A+B), MDA-MB-231 (C+D) and MCF-7 (E+F) cells were pre-treated with LXR 
ligands GW3965 (A+C) or T0901317 (E), GSK20333 (B, D, F) or vehicle for 16 h. Cells were then treated 
with the p-gp/ABCB1 specific inhibitor verapamil 20 μM (V20) or vehicle for 30 min, before cells were 
loaded with epirubicin (50 μM) for 1h. Fluorescence of epirubicin was measured at 15 min intervals 
for 90 min. Mean and standard error of the mean of 3 independent replicates (performed with 6 
technical replicates) with SEM is shown. The half-life of the intra-cellular epirubicin signal was 
determined using dissociation one phase exponential decay, (n=3). 
 
 
Figure 5. 10 Oxysterols enhance epirubicin export and is reversed by verapamil in TNBC cells.  
MDA-MB-468 (A+B) and MDA-MB-231 (C+D) cells were pre-treated with the LXR ligands 24OHC (A+C) 
and 26OHC (B+D) or vehicle for 16h. Cells were then treated with the p-gp/ABCB1 specific inhibitor 
verapamil 20 μM (V20) or vehicle for 30 min, before cells were loaded with epirubicin (50 μM) for 1h. 
Fluorescence of epirubicin was measured at 15 min intervals for 90 min. Mean and standard error of 
the mean of 3 independent replicates (performed with 6 technical replicates) with SEM is shown. The 
half-life of the intra-cellular epirubicin signal was determined using dissociation one phase 
exponential decay, (n=3).   




















E+26OHC: Half-life; 9.619m, p<0.0001
E+V20: Half-life; 20.67m, p<0.0001
E+26OHC+V20: Half-life; 18.30m, p<0.0001
E+26OHC relative to E+26OHC+V20;
p<0.0001




















E+V20: Half-life; 20.67m, p<0.0001
E+24OHC: Half-life; 8.272m, p<0.0001
E+24+V20: Half-life; 16.06m, p<0.0001
E+24OHC relative to E+24OHC+V20;
p<0.0001




















E+26OHC: Half-life; 12.38m, p<0.0001
E+V20: Half-life; 31.73m, p<0.0001
E+26OHC+V20: Half-life; 28.18m, p<0.0001
E+26OHC relative to E+26OHC+V20;
p<0.0001




















E+V20: Half-life; 31.73m, p<0.0001
E+24OHC: Half-life; 12.28m, p<0.0001
E+24OHC+V20: Half-life; 26.22m,
p<0.0001
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Figure 5. 11 The p-gp/ABCB1 inhibitor verapamil increases intra-cellular retention of epirubicin in 
TNBC cells but not MK571 and KO143 inhibitors.  
TNBC (MDA-MB-468 and MDA-MB-231) and Luminal A/ER-positive (MCF-7) cells were seeded into 
black 96-well plates and after 24 h they were pre-treated with KO143 (BCRP/ABCG2 inhibitor), MK571 
(MRP1/ABCC1 inhibitor) or verapamil [V20] (p-gp/ABCB1 inhibitor) for 30 minutes before a treatment 
of epirubicin (50 μM) for 1 h. Cells were washed with PBS and epirubicin within the cells was measured 
fluorescently. Data shown are mean of three independent replicates with SEM, statistical analysis was 
established using 2-way ANOVA and corrected for multiple tested. 
 
5.3.4  P-gp/ABCB1 dependent chemoresistance is partially dependant on 
LXRα in breast cancer. 
To prove LXRα was responsible for mediating the chemotherapy resistance effects 
of the ligands tested knockdown of LXRα expression was performed (and validated), 
and qPCR and colony forming assays repeated. To further investigate if p-gp/ABCB1 
was an LXRα target gene, co-factors that were previously shown to regulate LXRα’s 
ability to control its target genes (Chapter 4) were also inhibited. 
First, LXRα knockdowns were validated by measuring LXRα and LXRβ mRNA 
expression post gene silencing relative to universal negative control (siSCR) (Figure 
5.12). 48 h after transfection, LXRα expression was reduced by 70 % in MCF-7 cells 
(2-way ANOVA; p<0.0001) and 60 % in MDA-MB-468 cells (Figure 5.12A, p<0.0001). 
LXRβ expression was unaffected (Figure 5.12B, ns).  
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Figure 5. 12 Knockdown of LXRα in BCa cells.  
LXRα was knocked-down in TNBC (MDA-MB-468) and Luminal A (MCF-7) parental cells. Gene 
expression of LXRα (A) and LXRβ (B) were assessed by qPCR 36 h post silencing using ΔΔcT (normalised 
to HPRT1). Statistical analysis was performed using 2-way ANOVA and is representative of 3 
independent replicates with SEM. 
 
 
Figure 5. 13 Knockdown of LXRα attenuates ABCG2 and ABCC1 expression in ER-positive cells. 
LXRα was knocked-down in TNBC (MDA-MB-468) and Luminal A (MCF-7) parental cells. Gene 
expression of ABCG2 and ABCC1 were assessed by qPCR 36 h post silencing using ΔΔCt (normalised 
to HPRT1). Statistical analysis was established using 2-way ANOVA and is representative of 3 
independent replicates with SEM. 
 
Next, we show a series of knockdowns in MCF-7 and MDA-MB-468 cells and the 
expression of the chemoresistance genes p-gp/ABCB1 and BIRC3 post gene silencing 
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LXRα silenced cells, p-gp/ABCB1 and BIRC3 expression was significantly reduced 
relative to the universal negative control in MDA-MB-468 cells (2-way ANOVA: p-
gp/ABCB1 p<0.0001, BIRC3 p=0.0024) as was BIRC3 expression in the MCF-7 cells 
(p=0.0004). p-gp/ABCB1 expression however, was significantly enhanced in the LXRα 
silenced MCF-7 cells (p<0.0001). In LCOR silenced cells, p-gp/ABCB1 and BIRC3 
expression was significantly enhanced in the MDA-MB-468 cells (p-gp/ABCB1 
p<0.0001, BIRC3 p=0.0002) and in the MCF-7 cells (p-gp/ABCB1 p=0.0252, BIRC3 
p=0.0001). In NCOR1+2 silenced cells, p-gp/ABCB1 expression was also significantly 
enhanced relative to the universal negative control in the MDA-MB-468 cells (p-
gp/ABCB1 p<0.0001, BIRC3 p=0.0002) but only BIRC3 expression was enhanced in 
the  MCF-7 cells (p-gp/ABCB1 ns, BIRC3 p<0.0001).  
 
Figure 5. 14 Knockdown of LXRα, LCOR and NCOR alters p-gp/ABCB1 and BIRC3 expression.  
LXRα, LCOR, NCOR1+2 was knocked-down in TNBC (MDA-MB-468) and Luminal A/ER-positive (MCF-
7) parental cells. Gene expression of p-gp/ABCB1 and BIRC3 were assessed by qPCR 36 h post silencing 
using ΔΔCt (normalised to HPRT1). Statistical analysis was established using 2-way ANOVA and is 


















































































- 148 - 
Finally, we assessed LXRα dependent chemoresistance by silencing LXRα in MDA-
MB-468 and MCF-7 cells followed by colony forming assays (Figure 5.15). In universal 
negative control MDA-MB-468 cells, pre-treatment with GW3965 significantly 
improved cancer cell survival and colony formation during chemotherapy treatment 
(paired t-tests; p=0.0022). In LXRα silenced MDA-MB-468 cells, pre-treatment of 
GW3965 before epirubicin treatment restored TNBC cell sensitivity to chemotherapy 
treatment (ns). In universal negative MCF-7 cells, pre-treatment with GW3965 also 
significantly improved cancer cell survival and colony formation during 
chemotherapy treatment (p=0.0034). However, in LXRα silenced MCF-7 cells, pre-
treatment of GW3965 before epirubicin treatment not only restored TNBC cell 
sensitivity but was able to enhance cell sensitivity to chemotherapy treatment 
(p=0.0171). 
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Figure 5. 15 Knockdown of LXRα increases chemotherapy efficacy demonstrating chemoresistance 
is LXR dependent.  
LXRα was knocked-down in TNBC (MDA-MB-468) and Luminal A (MCF-7) parental cells. Post gene 
silencing cells were plated into colony forming assays and pre-treated with either VC or GW3965 (1 
μM) for 24 h. Cells were then treated with either VC or a dose of the chemotherapy agent epirubicin 
(25 nM) for a further 24 h, before 500 cells/treatment were plated in triplicate wells and incubated 
for 12 days. Colonies were then stained with crystal violet and counted. Statistical analysis was 
established using paired t-tests. Data shown are of 3 independent replicates with SEM. 
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5.3.5  Enhanced p-gp/ABCB1 expression correlates with LXRα expression in 
breast cancer patient tumours. 
 
To establish if enhanced LXRα activation is a marker of worse prognosis, BCa tumours 
were assessed for increased expression of p-gp/ABCB1 in patients who had suffered 
an event (relapse) and those who had not (no event). The expression of p-gp/ABCB1 
was also correlated with LXRα expression to assess the relationship between 
expression of the genes. 
First, we established whether patient tumours displayed enhanced p-gp/ABCB1 
expression, and if this is altered in patients who had relapsed compared to those 
who had not. RNA was extracted from the 69 patient primary tumours and gene 
expression analysed by Taman assays (normalised to HPRT1). In Non-TNBC tumours, 
patients who has suffered an event did not have significantly altered expression of 
p-gp/ABCB1 (Mann-Whitney U Test; ns) when compared to patients who had not 
suffered an event (Figure 5.16). Interestingly, in the TNBC tumours, patients who has 
suffered an event had significantly higher expression of p-gp/ABCB1 (p=0.003) 
relative to patients who had not suffered an event (Figure 5.16A). Tumour 
expression of ABCB1 was then assessed alongside patient survival to assess whether 
expression is predictive of survival in Kaplan Meier graphs (Figure 5.16B). ROC curves 
were used to establish the expression cut offs for high and low expression levels. 
TNBC tumours with higher expression of p-gp/ABCB1 (>0.175) were found to have 
worse survival than those with lower p-gp/ABCB1 expression (<0.175; Logrank test, 
p=0.018). In non-TNBC tumours however, p-gp/ABCB1 expression was found to have 
no effect on patient survival (ns). 
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Figure 5. 16 Increased expression of p-gp/ABCB1 was observed in TNBC breast tumours.   
RNA was isolated from 69 breast cancer patient tumours (41 TNBC, 28 HER2 enriched or hormone 
receptor positive [non-TNBC]). mRNA expression p-gp/ABCB1 was analysed by qPCR. Expression of p-
gp/ABCB1 was assessed between patients who had suffered a recurrence or death (Event) and those 
that had not had (No Event). Statistical differences were established using Mann-Whitney U Tests. 
Patient survival is shown in a Kaplan Meier graph for the TNBC (28) and Non-TNBC (13) subtypes due 
to significant differences in p-gp/ABCB1 expression between event and no event groups. Statistical 
differences were established using a Logrank test, cut offs established using ROC curves. 
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After measuring p-gp/ABCB1 expression in the patient primary tumours, LXRα and 
LXRβ expression were tested for correlation with the expression of p-gp/ABCB1 
(Figure 5.17A and Figure 5.17B) to establish if patient tumours with higher LXRα 
expression are likely to have higher expression of p-gp/ABCB1. First, LXRα expression 
was correlated with p-gp/ABCB1 expression (Figure 5.17A). In the TNBC patients 
who had suffered an event LXRα was found to have a particularly strong correlation 
with p-gp/ABCB1 expression (Pearson correlation; p<0.0001). In the TNBC tumours 
which did not have an event, LXRα did not significantly correlate with the expression 
of p-gp/ABCB1 (ns). LXRα also correlated with p-gp/ABCB1 expression in the Non-
TNBC patients who had suffered an event (p=0.0235) but did not correlate with those 
who had not had an event (ns). 
Next, LXRβ expression was tested for correlation with p-gp/ABCB1 expression 
(Figure 4.17B). In the TNBC patients who had suffered an event, LXRβ expression 
strongly correlated with p-gp/ABCB1 expression (p<0.0001). In the TNBC patient 
tumours who had not had an event, LXRβ failed to significantly correlate with the 
expression of p-gp/ABCB1 (ns).  In the Non-TNBC patients who had relapsed, LXRβ 
expression also correlated with p-gp/ABCB1 expression (p=0.017) however the 
correlation was not as strong as in the TNBC tumours. In the Non-TNBC patients who 
had not had an event, LXRβ expression also weakly correlated with p-gp/ABCB1 
expression (p=0.0321).  
In summary, patient tumours from those who had suffered an event (BCa death or 
relapse) had strong LXRα and correlations with p-gp/ABCB1 expression in the TNBC 
group, and a weak but significant correlation in the non-TNBC group. Furthermore, 
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patient tumours from those who had not suffered any event (healthy and alive) had 
no LXRα correlations with p-gp/ABCB1 expression in the TNBC or Non-TNBC group. 
  
Figure 5. 17 LXRα and LXRβ expression strongly correlates with ABCB1 in TNBC patient tumours 
who have relapsed. . 
RNA was isolated from 69 breast cancer patient tumours (41 TNBC, 16 HER2 enriched and 12 hormone 
receptor positive [non-TNBC]) and the expression of p-gp/ABCB1 was analysed by qPCR. Statistical 
differences were established using Mann-Whitney U Tests. Expression of LXRα and LXRβ were then 
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5.3.6 LXR ligands reduce the efficacy of the chemotherapy agent epirubicin 
in vivo. 
To validate the hypothesis proposed above that LXR activation confers 
chemotherapy resistance, an animal model was developed.  
The 4T1 TNBC cells were orthotopically grafted into the axial mammary fat pad of 
BALB/C mice and split into four treatment groups: placebo, GW3965 (daily, 
30mg/kg), epirubicin (every other day, 2.5mg/kg) and GW3965+epirubicin (Full 
details in M+M). Tumour size was measured daily, and after 12 days tumours 
harvested, weighed and markers of LXR activation and chemotherapy resistance 
measured. The tumours in mice treated with GW3965+epirubicin were larger than 
the tumours in mice treated with epirubicin (p=0.03) (Figure 5.18) and had 
significantly higher expression of chemotherapy resistance gene ABCB1 and 
canonical LXR target gene ABCA1 (Figure 5.19). As expected GW396, which is 
antiproliferative, slowed tumour growth compared to placebo. In summary, 
treatment with LXR agonist concurrently with chemotherapy reduces epirubicin 
efficacy in mice. 
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Figure 5. 18 LXR agonists reduce anti-tumoural efficacy of epirubicin in TNBC cells grafted into mice.  
4T1 cells (TNBC) were grafted orthotopically into the axial mammary fat pad of BALB/C mice. Mice 
were treated with either placebo or the LXR ligand GW3965 (daily, 30 mg/kg) 24 h post-graft. 
Treatments with placebo or epirubicin (every other day, 2.5 mg/kg) commenced 48 h post-graft. 
Tumour volumes measured by direct calliper (A), plasma, liver and tumour were harvested after 12 
days. Statistical analysis was assessed using non-linear regression. Tumours were dissected out and 
weighed (B). Statistical analysis was assessed using 1 Way ANOVA with SNK test, with 10 mice per 
group and shown with SD. Different letters denote statistical differences. Mouse study completed in 
Chicago in the lab group of Erik Nelson. 
 

























Treatment (slope) Compared to Treatment (slope) P value null hypothesis
Placebo (76.69) > GW3965 (63.80) 0.0305 reject
> Epirubicin (43.36) <0.0001 reject
> GW+EPI (55.15) 0.0002 reject
GW+EPI (55.15) > Epirubicin (43.36) 0.0297 reject
> GW3965 (63.80) 0.1837 accept
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Figure 5. 19 Mice treated with LXR agonists have enhanced expression of Abca1 and Abcb1b.  
4T1 cells (TNBC) were grafted orthotopically into the axial mammary fat pad of BALB/C mice. Mice 
were treated with either placebo or the LXR ligand GW3965 (daily, 30 mg/kg) 24 h post-graft. 
Treatments with placebo or epirubicin (every other day, 2.5 mg/kg) commenced 48 h post-graft. 
Tumours were dissected out and weighed after 12 days. Total RNA was isolated from tumour tissue 
and expression of Abca1 (A), Abcb1b (B), Abcg2 (C), and Cxcl5 (D) was assessed by qPCR analysis. 
Statistical analysis was assessed using 1 Way ANOVA with SNK test, with 10 mice per group and shown 
with SD. Different letters denote statistical differences. Mouse study completed in Chicago in the 
laboratory group of Erik Nelson. 
5.4  Discussion 
New roles for oxysterol-induced LXR targets in the progression of breast cancer are 
emerging. The purpose of this study was to establish if LXRα activity was linked to 
chemotherapy resistance in TNBC. In this chapter oxysterol activation of LXR was 
found to reduce the efficacy of epirubicin, a common anthracycline given to TNBC 
patients, via activation of the membrane bound drug efflux pump p-gp/ABCB1. 
Regulation by LXRα of p-gp/ABCB1 and several other genes implicated in 
chemotherapy resistance (BIRC3, GPSM3 and CXCL5) was identified by combining 
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data mined from public databases, with cell biology and mouse xenograft 
experiments and analysis of primary tumours from TNBC patients. BCa subtype 
specific differences were observed, with p-gp/ABCB1 appearing the dominant efflux 
pump in TNBC, whereas BCRP and MRP1 were dominant in Luminal A BCa. LXRα 
control of p-gp/ABCB1 expression was confirmed by siRNA knockdown of LXRα, as 
expression of p-gp/ABCB1 was attenuated in the TNBC cells but not in the MCF-7 
cells, and knockdown of LXRα in colony forming assays restored epirubicin efficacy 
in both TNBC and Luminal A cells.  
In the present study, LXR agonists reduced the efficacy of epirubicin, a common 
chemotherapy agent given to TNBC patients to either down-stage tumours before 
breast conserving surgery, or after surgery to eliminate residual tumour. The data 
presented are consistent with the hypothesis that activation of LXRα by excessive 
oxysterol production that results from high LDL-cholesterol levels may therefore 
promote a de novo chemotherapy resistance during tumour growth. The analysis of 
gene expression in primary tumours, mouse xenograft models and in cell lines 
suggested this chemotherapy resistance could be due to upregulation of the 
xenobiotic transporter p-gp/ABCB1. The fluorescence-based efflux assay developed 
during this chapter demonstrated that LXR dependent epirubicin efflux was entirely 
driven by p-gp/ABCB1. P-gp/ABCB1 expression was higher in TNBC when patients 
went on to relapse or die from their disease, but interestingly, p-gp/ABCB1 and LXRα 
expression only correlated (suggesting functional regulation of p-gp/ABCB1 by LXRα) 
in patients who relapsed or died.  
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5.4.1 Enhanced p-gp/ABCB1 expression predicts reduced survival in triple 
negative breast cancer patients 
A key finding of this chapter showed enhanced expression of p-gp/ABCB1 in BCa 
tumours from patients who had relapsed relative to those that had not. Reassuringly, 
Kim et al, made similar observations of  enhanced p-gp/ABCB1 expression in breast 
tissues post neoadjuvant chemotherapy which was associated with reduced survival 
by 20 % [270]. Kim et al, also showed a significant 40 % reduction in survival in 
patients who had high BCRP expression post neoadjuvant chemotherapy relative to 
those with low expression [270]. In another study, the expression of p-gp/ABCB1 was 
assessed in two MDA-MB-231 cell lines, one which was doxorubicin resistant and the 
other doxorubicin sensitive. Immunocytochemical staining of the doxorubicin 
sensitive MDA-MB-231 cells for p-gp/ABCB1 was undetected, however the 
doxorubicin resistant MDA-MB-231 cells showed strong cytoplasmic and nuclear 
staining of p-gp/ABCB1 expression [271]. These data support our findings of a p-
gp/ABCB1 enhanced chemotherapy resistance mechanism in ER-negative breast 
cancers which could provide useful as a prognostic marker for poor response to 
treatment and increased risk of relapse.  
So far attempts at targeting p-gp/ABCB1 in clinic have failed due to side effects such 
as, cardiotoxicity [272], unwanted interactions with drug metabolizing enzymes 
[273] and altered pharmacokinetics of anti-cancer drugs [274]. Failures in targeting 
p-gp/ABCB1 suggest cancer specific mechanisms of regulation are required to 
successfully reverse the reduced chemotherapy efficacy caused by up-regulation of 
p-gp/ABCB1.  
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5.4.2 Oxysterols regulate the p-glycoprotein via LXRα in the blood brain barrier 
LXR ligand upregulation of p-gp/ABCB1 in TNBC is a novel finding of this study. So 
far, LXRα regulation of p-gp/ABCB1 has only been identified in the BBB in a study by 
Saint-Pol et al [228]. Saint-Pol et al, showed treatments of 24OHC and 26OHC 
enhanced expression of the LXR target gene ABCA1 in BCECs and the apical-to-
basolateral transport (influx) of Aß peptides across BCECs. Furthermore, the ABCA1 
inhibitor probucol failed to significantly alter the apical-to-basolateral transport 
(influx) of Aß peptides across BCECs suggesting ABCA1 was not directly involved in 
the influx. The expression of p-gp/ABCB1 was assessed and found to be significantly 
induced by the treatment with both oxysterols. Although no other studies have 
shown LXRα regulation of p-gp/ABCB1 there are other studies that have found 
enhanced p-gp/ABCB1 expression in breast cancers [270, 271]. As my finding is 
unique, confirmatory reports will be required to allow subsequent follow up, 
although the work by Saint-Pol [228], and the support of enhanced p-gp/ABCB1 in 
breast tumours [270, 271] supply circumstantial evidence for oxysterol:LXRα 
regulation of p-gp/ABCB1. For follow up experiments, validation of LXRα regulation 
of p-gp/ABCB1 by means of ChIP-Seq is required – see future work in Section 8.6.  
5.4.3 P-gp/ABCB1 is regulated in triple negative breast cancer and BCRP in ER-
positive breast cancer cells 
Through the development of a chemotherapy efflux assay, p-gp/ABCB1 was shown 
to be upregulated by LXR agonists which was attenuated by treatment with 
verapamil in the TNBC cells. In ER-positive cells, verapamil had no effect on 
chemotherapy efflux but the BCRP and MDRP inhibitors MK571 and K0143 
respectfully enhanced the chemotherapy loading. Encouragingly, Kim et al, observed 
similar results when they investigated the effects of MK571 on the loading of another 
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chemotherapy drug doxorubicin, which is also often used for the treatment of breast 
cancer [269]. Intracellular doxorubicin was significantly enhanced by treatment with 
MK571 in the ER-positive T47D cells when measured by flow cytometry [269]. These 
findings support those observed in the current study but in the ER-positive MCF-7 
cells. This suggests BCRP inhibitors may increase the chemotherapy drug load of 
other similar chemotherapy drugs and in other ER-positive BCa cells. This suggestion 
warrants further cell line comparisons and clinical testing. 
5.4.4 Oxysterols promote in vivo tumour growth and LXR-dependent metastasis 
Other novel findings in this chapter include the in vitro and in vivo experiments 
showing LXR agonists reduce the efficacy of the chemotherapy drug epirubicin and 
enhance expression of p-gp/Abcb1b in BCa cells and mice treated with the LXR 
agonist GW3965. A similar study by Nelson et al,  demonstrated GW3965 treatments 
retarded the growth of primary tumours in MMTV-PyMT mice (which is in line with 
our observations), but was able to promote the formation of metastatic cancers in 
the mice lungs [105]. LXR-dependent metastatic tumour growth was established 
through pre-treatment with 26OHC prior intravenous injection readily metastasized 
in ER-negative Met1 cells to the mice lungs [105]. LXR agonists have not been shown 
to reduce the efficacy of epirubicin, however reduced efficacy of other BCa therapies 
have been identified. Bougaret et al, showed co-cultures of mature adipocytes with 
breast cancer cells in overweight and obese patients reduced the efficacy of 
Tamoxifen therapy in the ER-positive MCF-7 cells [275]. The observations in this 
chapter showing LXR agonists reduce the efficacy of epirubicin in both BCa cells and 
a mouse study are strongly supported by the findings in mice grafted with the same 
ER-negative 4T1 cells by Nelson et al [105], and the reduced efficacy of Tamoxifen in 
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adipocytes [275]. Furthermore, the observations of the enhanced p-gp/ABCB1 
expression from this chapter further develop the research implicating p-gp/ABCB1 
and LXRα activity in chemotherapy failure and the development of chemotherapy 
resistance. 
 
5.5  Summary 
In this chapter we have shown LXRα activation leads to chemoresistance in BCa 
through a series if colony forming assays, MTT assays and gene expression analysis. 
We have also identified subtype specific LXRα-regulation of p-gp/ABCB1 in TNBC 
cells and ABCG2 and ABCC1 in Luminal A cells through the development of a 
chemotherapy efflux assay, gene silencing and data mining. Furthermore, LXRα-
dependent chemoresistance has been demonstrated through knockdown of LXRα 
followed by colony forming assays and gene expression analyses. Finally, we showed 
enhanced p-gp/ABCB1 expression leads to poorer prognosis through the means of 
gene expression analyses and correlations in RNA from patient tumours who had 
relapsed and those who had not. And this was further supported through the design 
and execution of a mouse study which demonstrated LXR agonists reduce the anti-
tumoural efficacy of epirubicin in TNBC cells grafted into mice also through enhanced 
p-gp/ABCB1 expression. 
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Chapter 6 
Fibroblasts activate LXRα in adjacent triple negative breast cancer 
epithelial cells. 
6.1  Introduction 
The tumour microenvironment can be diverse with large variations between host 
cell (macrophages, fibroblasts and adipocytes) presence at the site of breast cancers. 
In vitro cell studies suggest that tumour growth is influenced by the tumour stroma 
[276], which includes the extracellular matrix (ECM). The deposition of the ECM is 
one of the key functions of fibroblasts along with regulation of inflammation, 
epithelial differentiation, and wound healing [277, 278]. Many of the constituents of 
the ECM, such as collagen and fibronectin, are synthesised by fibroblasts [278, 279]. 
Fibroblasts are also known to regulate expression of CYP enzymes responsible for 
the synthesis of oxysterols [142], but whether these support cells are generating 
oxysterols for epithelial cells is unknown. Fibroblasts have been linked to the 
progression of cancer [280, 281], and CAF-promoted tumour growth [282]. 
Furthermore, patients who have tumours with enhanced support cell 
microenvironments often have a poor prognosis, allowing the cancer cells to employ 
TME-driven metastatic and proliferative behaviours via paracrine signalling [143-
145]. 
Given that tumours supported by cancer-associated fibroblasts tend to have poorer 
prognosis and fibroblasts have been shown to regulate the expression of CYP 
enzymes and produce 24OHC, 26OHC , 25OHC and 24,25-EC it may be plausible to 
suggest cancer-associated fibroblasts may be able to regulate LXRα through the 
synthesis and secretion of oxysterols.  
- 163 - 
6.2  Hypothesis and Aims 
Cancer-associated fibroblasts not only have migratory capacities but they have been 
shown to promote tumour growth and progression. In this chapter, the hypothesis 
that cancer-associated fibroblasts activate LXRα in BCa cells was tested. 
 
Figure 6. 1 Fibroblasts may secrete oxysterols into the tumour microenvironment. 
Cancer associated fibroblasts (CAFs) have the ability to synthesise and secrete oxysterols into to the 
tumour microenvironment (TME). Oxysterols may be sequestered into the BCa cells activating LXRα 
and driving LXR target genes. 
 
The aims of this chapter were to: 
• Measure oxysterol concentrations in cell lines to relative contributions to the 
tumour microenvironment.  
• Determine if fibroblasts can drive LXRα dependent transcription in adjacent 
cancer cells in co-culture. 
• Differentiate between juxtracrine and paracrine activation of LXRα 
investigate origins.   
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6.3  Results 
6.3.1 Cancer-associated fibroblasts have high concentrations of oxysterols. 
Epithelial cancer cells create a tumour microenvironment around the site of cancer 
made up of all different kinds of support cells [140]. To establish whether fibroblasts 
can activate LXRα in epithelial breast cancer cells, oxysterol content in epithelial cells 
and fibroblasts was measured and a series of co-cultures of fibroblasts and epithelial 
breast cancer cells were performed. 
First, to identify if fibroblasts (cancer-associated and non-cancer associated) have 
high levels of oxysterols relative to epithelial cancer cells oxysterol concentrations 
were measured in breast cancer cells lines (MCF-7, MDA-MB-468 and MDA-MB-231) 
a healthy breast cell line (HB2) and two fibroblast cell lines (LaCAF; cancer-associated 
fibroblast, NF2; non-cancer associated fibroblast) by methods of fast liquid 
chromatography LCMS/MS (completed by Dr Hanne Roberg-Larsen, Oslo) (Figure 
6.2). In general, results showed LaCAFs had significantly higher concentrations of 
oxysterols  (24OHC, 26OHC and 24,25-EC) than epithelial breast cells (1 way ANOVA, 
at least p<0.05). NF2 cells did not have higher concentrations of oxysterols compared 
to epithelial (ns), with the exception of 25OHC (at least p<0.01 for all epithelial cells). 
Finally, LaCAFs had significantly higher oxysterol concentrations than the NF2 cells 
(at least p<0.05 for 24OHC, 26OHC and 24,25-EC) with the exception of 25OHC (ns). 
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Figure 6. 2 Cancer-associated fibroblasts have high concentrations of oxysterols relative to 
epithelial cells.  
Epithelial cells (HB2, MCF-7, MDA-MB-468 and MDA-MB-231) and fibroblasts (non-cancer associated 
NF2 and cancer-associated LaCAF) were individually cultured. 500,000 cells of each cell line (in 
triplicate from different passages) were pelleted and sent to Oslo to be measured by LCMS/MS 
(LCMS/MS completed by HRL). Statistical analysis was assessed by 1-way ANOVA, grey lines represent 
comparisons between NF2 cells and epithelial cells, black lines for comparisons between LaCAFs and 




6.3.2  Fibroblasts activate adjacent LXRα epithelial triple negative breast 
cancer cells 
To establish if cancer-associated fibroblasts can activate LXRα in breast cancer 
epithelial cells co-culture experiments were performed with epithelial breast cancer 
luciferase reporter cell lines. Conditioned media from CAFs and non-cancer 
associated fibroblasts was collected and epithelial breast cancer luciferase reporter 
cell lines exposed to increasing percentages to assess if LXRα is possible without cell 
to cell contact.  
To identify if cancer-associated fibroblasts can regulate LXRα in breast cancer 
epithelial cells we co-cultured cancer-associated fibroblasts with epithelial breast 
cancer luciferase reporter cell lines and measured the LXRα transactivation after 16 
h by luciferase assay (Figure 6.3). MDA-MB-468 and CAF co-cultures showed as the 
fibroblast percentage relative to the epithelial breast cell reporters increased so did 
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the LXRα activation plateauing around 80 % then a reduction in LXRα activation was 
observed (1-way ANOVA: 20-120 %; 1.5-2 fold increase, at least p<0.05). MDA-MB-
231 and CAF co-cultures also showed as the fibroblast percentage relative to the 
epithelial breast cell reporters increased so did the LXRα activation (20-120 %; 1.4-2 
fold increase, at least p<0.001). Surprisingly, MCF-7 and CAF co-cultures showed no 
matter what the fibroblast percentage relative to the epithelial breast cell reporters, 
fibroblasts failed to regulate LXRα activity (ns for all percentages). 
 
Figure 6. 3 Fibroblast co-cultures with epithelial cells activate LXRα in TNBC luciferase reporters but 
not ER+ luciferase reporters.  
Cancer associated fibroblasts (LaCAFs) were seeded into 96 white walled clear bottomed plates 48 
hours before epithelial cells were added. Epithelial cells were incubated for the 8 h cells are usually 
given to attach and regain usual morphology plus a further 16 h to represent treatment/stimulation 
time. LXRα transactivation was measured by luciferase assay and normalised to total epithelial cells 
(0). Statistical analysis was assessed by 1-way ANOVA with the Holm-Sidak multiple correction test.  
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To establish if CAF conditioned media could regulate LXRα in breast cancer epithelial 
cells, LXRα breast cancer reporter cells and the liver cell line HepG2 [control] were 
exposed to CAF conditioned media for 16 h and LXRα transactivation measured by 
luciferase assay. (Figure 6.4). MDA-MB-468 cultures showed as the fibroblast 
conditioned media percentage increased so did the LXRα activation plateauing 
around 20-30 % then a reduction in LXRα activation was observed (1-way ANOVA: 
10-40 %; 1.3-1.5 fold increase, at least p<0.05, 50 %, 75 % and 100 %; no increase, 
ns). MDA-MB-231 cultures also showed as the fibroblast conditioned media 
percentage increased so did the LXRα activation plateauing around 20-30 % then a 
reduction in LXRα activation was observed (10-30 %; 1.3-1.4 fold increase, at least 
p<0.01., 40 %; no increase ns, 50-100 %; decrease, at least p<0.001). Again, MCF-7 
cultures showed no matter what the fibroblast conditioned media percentage, 
fibroblasts failed to regulate LXRα activity (ns for all percentages). HepG2 cultures 
however, showed as the fibroblast conditioned media percentage increased so did 
the LXRα activation plateauing around 75-100 % with response significantly more 
robust (10-100 %; 3-6 fold increase, at least p<0.01). 
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Figure 6. 4 LaCAF conditioned media activates LXRα in TNBC and liver HepG2 cell reporters. 
Cancer associated fibroblasts (LaCAFs) and parental epithelial cells were seeded into T75 flasks 24 h 
before conditioned media was collected. Epithelial reporter cells were seeded into 96 white walled 
clear bottomed plates incubated for 8 h. Fresh conditioned media was added for 16 h before LXRα 
transactivation was measured by luciferase assay and normalised to complete epithelial conditioned 
media (0). Statistical analysis was assessed by 1-way ANOVA with the Holm-Sidak multiple correction 
test. Data shown are of 3 independent replicates with SEM. 
 
Next, NF2 conditioned media was assessed to see if it could also regulate LXRα in 
breast cancer epithelial cells, so LXRα breast cancer reporter cells and the liver cell 
line HepG2 [control] cells were exposed to NF2 conditioned media for 16 h and 
measured LXRα transactivation by luciferase assay. (Figure 6.5). MDA-MB-468 
cultures showed as the NF2 conditioned media percentage increased so did the LXRα 
activation plateauing around 50-75 % then a reduction in LXRα activation was 
observed (1-way ANOVA: 10-100 %; 1.4-1.8 fold increase, at least p<0.01). MDA-MB-
231 cultures also showed as the NF2 conditioned media percentage increased so did 
the LXRα activation plateauing around 50-75 % then a reduction in LXRα activation 
was observed (20-100 %; 1.4-1.5-fold increase, p<0.01). Interestingly, MCF-7 







































































































LACAF conditioned media, n=3
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cultures also showed as the NF2 conditioned media percentage increased so did the 
LXRα activation plateauing around 50-75 % then a reduction in LXRα activation was 
observed (30-75 %; 1.2-1.3 fold increase, at least p<0.01., and 100 %; no increase 
ns). HepG2 cultures also showed as the NF2 conditioned media percentage increased 
so did the LXRα activation plateauing around 50-75 % with response more moderate 




Figure 6. 5 NF2 conditioned media activates LXRα in Luminal A, TNBC and liver HepG2 cell reporters.  
Non-cancer associated fibroblasts (NF2s) and parental epithelial cells were seeded into T75 flasks 24 
h before conditioned media was collected. Epithelial reporter cells were seeded into 96 white walled 
clear bottomed plates incubated for 8 h. Fresh conditioned media was added for 16 h before LXRα 
transactivation was measured by luciferase assay and normalised to complete epithelial conditioned 
media (0). Statistical analysis was assessed by 1-way ANOVA with the Holm-Sidak multiple correction 
test. Data shown are of 3 independent replicates with SEM. 
 










































































































NF2 - conditioned Media SEM (n=3)
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6.4  Discussion 
The purpose of this study was to establish if cancer associated fibroblasts could 
activate LXRα in BCa cells.  LXRα activation was assessed after co-culture with the 
fibroblasts or after exposure to conditioned media taken from the cultured 
fibroblasts.  
In this chapter fibroblasts were found to have higher levels of oxysterols than breast 
cancer epithelial cells and non-cancer associated fibroblasts when measured by 
LCMS/MS. Strangely there have been no reports published showing the comparison 
of oxysterol concentrations between epithelial BCa cells and fibroblasts. There have 
been a few reports where fibroblast production of oxysterols has been validated 
[283, 284] and concentrations reported for 24,25-EC (56 ng/mg/h), 25OHC 
(11ng/mg/h) and 26OHC (14 pmol/mg/h) in fibroblast conditioned media and/or 
fibroblast cells [146-148]. Interestingly, a recent study by Shi et al, measured protein 
expression of CYP27A1 in the breast cancer cell lines MCF-7 and MDA-MB-231, 
showing enhanced expression in the MDA-MB-231 cells relative to the MCF-7 cells 
[285]. Furthermore, the same study also measured the oxysterol concentrations in 
THP-1 monocytes/macrophages and found expression of CYP27A1 to be at least x10 
higher in the support cells than the epithelial cells [285]. This study supports the 
hypothesis that TNBC cells require/benefit from oxysterols relative to Luminal A, but 
also the hypothesis that support cells in the TME have higher concentrations of 
oxysterols than epithelial cells.    
Oxysterol concentrations have not been previously measured in the breast cancer 
cell lines before, as such no direct comparison to published data can be made. 
However, comparison to oxysterols in other epithelial cells can be made. A recent 
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study by Hong et al, measured the oxysterol concentrations in GES-1 and GES-
1SULT2B1−/− cells. After conversion to match the units of this study, oxysterols 
concentrations were found to be within the range of concentrations identified in the 
breast epithelial cells measured in this chapter [in bold]. 24OHC was found to 
average at 2 pmol/100,000 cells in GES-1 cells and 20 pmol/100,000 cells in GES-
1SULT2B1−/− cells [this study BCa cells average: 10 pmol/100,000 cells], 24,25-EC at 35 
pmol/100,000 cells in GES-1 cells and 200 pmol/100,000 cells in GES-1SULT2B1−/− cells 
[BCa cells range: 100-1000 pmol/100,000 cells], 25OHC at 2 pmol/100,000 cells in 
GES-1 cells and 5 pmol/100,000 cells in GES-1SULT2B1−/− cells [BCa cells average: 20 
pmol/100,000 cells], and 26OHC at 2 pmol/100,000 cells in GES-1 cells and 10 
pmol/100,000 cells in GES-1SULT2B1−/− cells [BCa cells average: 10-100 pmol/100,000 
cells] [286]. Interestingly, the GES-1SULT2B1−/− cells have comparable oxysterol 
concentrations to those measured in the BCa cell lines, but the GES-1 cells appear to 
have lower amounts. To date, there has been no direct comparison between 
oxysterol concentrations in non-cancer associated fibroblasts and cancer-associated 
fibroblasts, may be because the hypothesis has not been considered. As the higher 
concentrations of oxysterols in fibroblasts relative to epithelial cells is a unique 
finding, confirmatory studies in isolated primary fibroblasts (non-cancer associated 
and CAFs) and primary breast cancer cells including LCMS/MS with matched tumour 
section immunohistochemistry analysis of the oxysterol synthesis enzymes will be 
required to allow subsequent follow up. Additionally, the oxysterol concentrations 
in epithelial and fibroblasts co-cultures should be assessed as cross-talk between 
cells may increase the demand for oxysterol production. Finally, knockout of the 
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oxysterol synthesis enzymes in fibroblasts would be interesting to assess whether 
production of oxysterols is compensated for in epithelial cells. 
Another key finding in this chapter was that CAFs drive LXRα signalling in MDA-MB-
468 and MDA-MB-231 cells by CAFs. Camp et al showed similar findings where TNBC 
co-cultures with fibroblasts enhanced the expression of ABCA1 but did not in the 
Luminal BCa co-cultures [287]. The similar findings in the study by Camp et al and 
this one gives great confidence in the results, particularly as the data presented by 
Camp et al, included the same MCF-7 cell used in this chapter. Camp et al also used 
alternative cell lines to the ones used in this study (SUM102, SUM149, HCC1937, ZR-
75-1, T47D), and found that TNBC co-cultures with fibroblasts enhanced the 
expression of ABCA1 but failed to do so in the Luminal BCa co-cultures. This means 
we can suppose epithelial cell co-cultures with fibroblasts activate LXRα in multiple 
TNBC and therefore further testing would be warranted. However, this chapter has 
expanded the findings of Camp and colleagues as the data from conditioned media 
experiments show paracrine rather than juxtacrine signalling is the most likely form 
of communication and a secreted factor, most likely oxysterol(s), is responsible.  
There is increasing recognition that the tumour microenvironment support cells can 
influence the behaviour of tumour epithelial cells contributing to and defining 
patient outcomes [281, 288]. In response to tumourigenesis, breast stromal 
arrangement changes increasing the numbers of cancer-associated fibroblasts 
within the tumour site [289, 290], which has been shown to increase tumour cell 
proliferation and angiogenesis [291]. Although there is limited research that has 
been published showing LXRα modulation in BCa epithelial cells by fibroblasts there 
is evidence showing fibroblasts have the capacity to produce oxysterols [146-148] 
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which are known LXR ligands. In this chapter we have presented data supporting the 
hypothesis that fibroblasts activate LXRα in epithelial BCa cells when cultured with 
fibroblasts and when exposed to fibroblast conditioned media suggesting cell-to-cell 
contact is not required or is dispensable. The study by Camp et al, performed two 
methods of epithelial BCa cell co-cultures with fibroblasts, through direct contact co-
culture and through the use of transwell to impair cell-to-cell contact. As discussed 
above, direct contact co-culture of TNBC cells with fibroblasts enhanced the 
expression of ABCA1 but failed to do so in the Luminal BCa co-cultures. Co-cultures 
of TNBC cells with fibroblasts using the transwell method enhanced the expression 
of ABCA1 in both the fibroblast and the epithelial cells. Co-cultures of Luminal A BCa 
cells with fibroblasts using the transwell method enhanced the expression of ABCA1 
in the epithelial cells but failed to do so in the fibroblasts. This study by Camp and 
colleagues strengthens the hypothesis that fibroblasts activate LXRα in epithelial BCa 
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6.5  Summary 
In this chapter we have established that fibroblasts support LXRα enhanced TNBC 
cancer cells through the secretion of oxysterols. We have also identified that 
fibroblasts produce almost x10 higher amounts of oxysterols than breast epithelial 
cells. Through co-culture assays we discovered cancer-associated fibroblasts were 
not able to activate MCF-7 LXRα-driven reporters but significantly increased LXRα 
activity in the TNBC reporters. Furthermore, CAF and NF2 conditioned media were 
also able to increase LXRα activity in the TNBC and HepG2 liver luciferase reporters 
showing cell-to-cell contact is not essential and oxysterol activation of the reporters 
is secretion dependent. Finally, MCF-7 co-cultures with CAFs and CAF conditioned 
media were not able to alter Luminal A LXRα activity, however the NF2 conditioned 
media was able to increase LXRα activation suggesting cross-talk between CAFs and 
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Chapter 7 
Phytosterols antagonise oxysterol-mediated LXRα activation and 
chemosensitize triple negative breast cancer cells. 
Data presented in this chapter have in part been published in a peer-reviewed article 
[131]. Journal article included in Appendix B - 1.2.  
7.1  Introduction 
Plant based diets that are rich in phytosterols are known to lower LDL-C and are 
associated with reduced risk of primary and recurrent breast cancer [48]. In normal 
biology however, phytosterols are essential components of plant cell membranes 
and have equivalent cellular functions in plants to those of cholesterol in mammals. 
At the molecular level, relatively little is known about the biological functions of 
phytosterols (outside of their role as cholesterol lowering sterols) in normal or 
diseased tissues. In animal models and in vitro studies, anti-cancer properties for 
phytosterols have been suggested including the inhibition of BCa growth and 
metastasis [292-294]. Furthermore, plant rich diets [220] and healthy dietary 
patterns associated with PSS intake have lower cancer incidence and improved 
survival [219]. 
7.1.1 Phytosterol intake is associated with a reduction in cancer risk 
Recently Jiang et al, published a systematic evaluation of the existing research 
focusing on dietary total phytosterols [295]. The meta-analysis consisted of 11 case-
control and case-cohort studies assessing the relative risk associated with 
phytosterol intake and cancer risk. The relative risk (RR) for the highest intake 
compared to the lowest intake for total phytosterol intake RR=0.63 (95 % CI = 0.49-
0.81) [295]. Individual phytosterol intake was also assessed, with β-sitosterol 
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RR=0.74 (95 % CI = 0.54-1.02), campesterol RR=0.72 (95 % CI = 0.51-1.00) 
stigmasterol RR=0.83 (95 % CI = 0.60-1.16), β-sitostanol RR=1.12 (95 % CI = 0.96-1.32) 
and campestanol RR=0.77 (95 % CI = 0.65-0.90 [295]) but due to large heterogeneity 
no individual associations could be made. Data shown suggest that high total 
phytosterol intake is inversely associated with cancer risk.  
Other studies have also looked at cancer risk and dietary patterns. Results from the 
Women’s intervention nutrition study (WINS) showed dietary patterns that lower fat 
intake were associated with reduced risk of BCa relapse [48]. The WINS design 
included two groups, one was a control group and the other a low-fat (15 % energy 
from fat) group which were asked to lower their consumption of oils, high fat 
dressings and spreads, opt for low fat dairy products , fish, poultry, meat and egg 
whites, consume smaller portions and substitute low fat beverages, desserts and 
snacks with high fat items. The intervention group were also asked to increase their 
fruit, vegetables, grain products and legume intake. Results from the intervention 
showed a significant (p<0.001) decrease in dietary fat (33.3 fat grams/per day) at 12 
months [95 % CI = 32.2-34.5] in the intervention group relative to the control group 
(51.3 fat grams/per day) at 12 months [95 % CI = 50.0-52.7] which was maintained 
through the 5 years of observations. In line with reduced dietary fat intake the 
intervention group had a mean body weight which was 6 pound lighter than the 
control group after the 5 years of observations (p<0.005). Dietary patterns were 
designed to reduce dietary fat intake and increase consumption of fruit and 
vegetables. Furthermore, implemented dietary patterns were associated with a 
reduction in the hazard ratio (HR) for BCa relapse events when compared to the 
control group, HR=0.76 (95 % CI, 0.60-0.98, adjusted Cox model analysis p=0.034). 
- 177 - 
When groups were further classified by ER status, HR for relapse events was further 
reduced in the intervention group with ER-negative BCas, HR=0.58 (95 % CI, 0.37-
0.91, adjusted Cox model analysis p=0.018) compared to the control group however, 
significance was lost in ER-positive BCas relative to the control group, HR=0.85 (95 % 
CI, 0.63-1.14, adjusted Cox model analysis p=0.277).  
 
7.1.2 Phytosterol effects on cells 
PSS intake has been associated with reduced BCa risk, but the exact mechanism 
behind the reduced relapse rates is not clear. Other researchers have performed in 
vitro experiments to assess the response to phytosterol treatments in various cell 
line models. For example, the tumour growth of multiple human cancer cell lines has 
been shown to be inhibited by treatments of β-sitosterol, such as; colon [296], liver 
[297], lung [298],prostate [292, 299] and breast [300]. Additionally, rats treated with 
β-sitosterol 20 mg/kg three times per week for 24 weeks had induced apoptosis in 
renal cancer cells [301]. Furthermore, treatments of β-sitosterol also inhibited 
proliferation and metastasis in renal cancer cells in the rats [301], which is in support 
of other similar observations where high intakes of phytosterols has anticancer 
effects [302-305]. The anti-cancer properties of phytosterols are thought to be acting 
through induced apoptosis [306], inhibition of cholesterol synthesis [307], 
promotion of cell cycle arrest [308, 309] and through inhibition of cell invasion and 
migration [308, 309].  
7.1.3 Phytosterols alter oxysterol signalling 
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Phytosterols alter oxysterol signalling in several ways as summarised in Figure 7.1. 
First, phytosterols have been shown to alter oxysterol signalling through inhibition 
of cholesterol uptake. Lutjohann et al, showed patients given 0.5 g sitostanol (three 
times a day) had an average reduction in cholesterol absorption by 34 % and 
increased cholesterol content in faecal matter [210]. Furthermore, there was no 
significant rise in cholesterol synthesis following sitostanol mediated reductions in 
cholesterol absorption [210]. Second, phytosterols alter oxysterol signalling through 
inhibition of HMGCR, the rate limiting enzyme in cholesterol synthesis. Yang et al, 
showed significant reductions in HMGCR at the protein level after treatment with 
campesterol and stigmasterol in cultured Y1-BS1 adrenal cells [172]. Furthermore, 
no significant changes were observed in cells after treatment with phytosterols 
showing changes in HMGCR levels were not due to changes in cholesterol levels 
[172]. And finally, phytosterols can also alter oxysterol signalling through inhibition 
of CYP family members, which are required for the conversion of cholesterol to 
oxysterols. Brauner et al, showed co-incubation of cholesterol with either 
campesterol (77 ± 9 pmol x mg protein/min) or sitosterol (106 ± 16 pmol x mg 
protein/min) significantly inhibited the generation of 26OHC when compared to 
treatment of cholesterol alone (285 ± 23 pmol x mg protein/min) [211]. 
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Figure 7. 1 Phytosterols alter oxysterol signalling in several ways. 
Phytosterol intake can alter oxysterol signalling in three ways: 1) inhibition of HMGCR the enzyme 
required to synthesise cholesterol, 2) Inhibition of cholesterol uptake from the diet and 3) inhibition 
of CYP family members required to convert cholesterol to oxysterols and therefore reduce LXRα 
activity. 
 
7.1.4 Phytosterols have tissue specific effects. 
Phytosterols have been shown to behave as selective LXR modulators (SLiM) which 
is defined as LXR ligands that have diverse effects in different tissues. Phytosterols 
are very similar in structure to oxysterols and cholesterol and it appears they can 
alter mammalian physiology if accumulated at sufficient concentrations. 
Interestingly, phytosterol treatments have been shown to induce [66] and repress 
LXR target gene expression [109, 211, 213, 214]. For example, Kaneko et al showed 
SITO, CAMP, BRASS and STIG were able to activate LXRα driven luciferase HEK293 
cells at 10 μM [66] however in CHO-7 cells, SITO was unable to effectively activate 
LXR [172]. Plat, Nichols and Mensink, showed the expression of canonical LXR target 
gene ABCA1 is enhanced by treatment of phytosterols (SITO, STAN and CAMP) in 
Caco-2 cells [212] but Brauner et al, found that co-treatment of cholesterol with 
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either CAMP or SITO attenuated cholesterol mediated ABCA1 expression, suggesting 
phytosterols may be able to moderate LXR’s response to ligand [211] but in a 
tissue/cell specific manner. 
7.2  Hypothesis and Aims 
PSS are able to impact on the oxysterol:LXRα axis at multiple points, including 
direct binding to LXRα as selective LXR modulators (SLiM) leading to changes in 
transcription targets. In this chapter the hypothesis that PSS could inhibit LXRα 
signalling in breast cancer was tested, and if through this altered transcriptional 
activity PSS are able to counteract the chemotherapy resistance mechanisms 
observed in chapter 5.  
The aims of this chapter were to: 
• Identify whether phytosterols act as selective modulators of LXRα in BCa 
cell lines. 
• Determine whether phytosterols can alter LXR target gene transcription. 
• Establish if phytosterols can reduce LXR-driven chemoresistance in 
TNBC. 
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Figure 7. 2 Graphical abstract. 
In the presence of oxysterols, oxysterols can bind to LXR and are able to regulate LXR target genes in 
breast cancer cells. In the presence of oxysterols and phytosterols however, phytosterols will 
compete with oxysterols for LXRα binding in breast cancer cells suppressing the LXR activity. Image 
previously published by Hutchinson et al [131]. 
7.3  Results 
7.3.1 Phytosterols weakly modulate LXR. 
In the literature, phytosterol interactions with LXR have shown a variety of results. 
For example, in HEK293 cells phytosterols (SITO, CAMP, BRAS and STIG at 10 µM) 
were shown to behave as LXR agonists [66] but in other cell types such as CHO-7 cells 
failed to activate LXRα reporters [172]. MTT assays (see methods section 3.14) were 
performed to assess the anti-proliferative effects of phytosterol treatments and 
luciferase reporter systems (see methods section 3.2) were used to assess LXRα 
response after phytosterol treatments alone and in combination with oxysterols in 
BCa cell lines. 
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First, MTT assays were performed to assess the anti-proliferative effects in BCa cell 
lines after treatment with a range of phytosterol concentrations (Figure 7.3). All cell 
lines were unaffected by phytosterol treatments below 100nM (NB: MTT assays 
performed by Priscilia Lianto). 
 
Figure 7. 3 Phytosterols are anti-proliferative in breast cancer cell cultures.  
The anti-proliferative effects of STIG, SITO, CAMP, BRASS and STIG over 48 h was assessed by MTT in 
MDA-MB-468, MDA-MB-231, and MCF-7 cells. Cell viability relative to vehicle control was measured 
after treatment with plant sterols and stanols (PSSs) at indicated concentrations. Data are presented 
as mean of three independent replicates (open circles) with SEM. For assessing changes between 
individual concentrations and vehicle, one-way ANOVA with Holm-Sidak correction for multiple 
testing and post-test for linear trend was performed. Significance levels are indicated by € = p < 0.05 
and # = p < 0.0001. Linear trend was significant for all PSS in all cell lines except for BRAS in MCF-7 
(ns). Data generated and analysed by Priscilia Lianto. 
 
At 100nM and above there were differences between the cell lines in their response 
to the phytosterols. MDA-MB-468 cells were the most sensitive to phytosterol 
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treatment with significant reductions in cell viability after treatment with STAN, 
SITO, CAMP and BRAS at 100 µM (1 way-ANOVA: p<0.0001), 10 µM (at least p<0.05) 
and 1 µM (at least p<0.05). MCF-7 cells were the most resistant to phytosterol 
treatment with complete resistance to BRAS at all concentrations tested (ns). SITO 
most effective phytosterol at altering cell viability across all three cell lines (p<0.0001 
at 100 µM and 10 µM, p<0.05 for 1 µM in 468 and MCF-7 cells).  The MDA-MB-231 
cells were more sensitive to phytosterol treatments that the MCF-7 cells, but not as 
sensitive as the MDA-MB-468 cells. 
Next, we assessed phytosterol regulation of LXRα luciferase reporters.  MDA-MB-
468, MDA-MB-231 and MCF-7 reporter cells were treated with a panel of 
phytosterols at a range of concentrations for 16 h and LXRα transactivation 
measured by luciferase assay (Figure 7.4). The range of phytosterols failed to 
significantly alter LXRα activity in the MDA-MB-468 cells at all concentrations except 
for STAN at 100 nM (1 way-ANOVA; p<0.05). The range of phytosterols failed to 
significantly alter LXRα activity in the MDA-MB-231 cells at all individual 
concentrations. However, in the MCF-7 cells BRAS (50 μM, p<0.05) and STIG (1 pM, 
100 nM., 5 μM, 10 μM and 50 μM., p<0.05) were able to activate LXRα by a small 
fraction. Linear trends were assessed for each phytosterol; MDA-MB-468 (SITO; 
slope=0.017, R2=0.09, p=0.038), MDA-MB-231 (STAN; slope=-0.03, R2=0.025, 
p=0.002., SITO; slope=-0.015, R2=0.063, p=0.03., and BRAS; slope=0.018, R2=0.061, 
p=0.033) and MCF-7 (BRAS; slope=0.049, R2=0.25, p=0.0002., STIG; slope=0.023, 
R2=0.15, p=0.0049). Overall, the range of phytosterols were not able to sufficiently 
alter LXRα activation. 
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Figure 7. 4 LXRα is only weakly modulated by PSSs treatment in breast cancer cell lines.  
A luciferase reporter driven by an LXR alpha (LXRα) responsive promoter was stably transfected into 
MDA-MB-468, MDA-MB-231, and MCF-7. Relative luciferase activity was measured after treating with 
PSSs at indicated concentrations for 16 h and is shown normalised to vehicle control (VC). Data are 
presented as mean of three independent replicates (open circles) with SEM. For assessing changes 
between individual concentrations and vehicle, one-way ANOVA with Holm-Sidak correction for 
multiple testing and post-test for linear trend was performed. Significance levels are indicated by € = 
p < 0.05 and # = p < 0.0001, or for linear trend Slope, R2 and p value are indicated. 
 
7.3.2  Phytosterols antagonise oxysterol-LXRα activation. 
The phytosterol treatments were not able to strongly alter LXRα activity in the breast 
cancer reporters. Phytosterols when taken to reduce LDL-C, have an effect when 
cholesterol and oxysterol levels are high. So, to test their ability to alter LXRα activity 
when stimulated by the cholesterol derivatives oxysterols, we used luciferase 
reporter systems and gene expression analyses to assess cell LXRα response after co-
treatment with oxysterols and phytosterol in BCa cell lines. 
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First, we assessed LXRα response after co-treatment with oxysterols and 
phytosterols in BCa reporter cell lines. MDA-MB-468, MDA-MB-231 and MCF-7 LXRα 
reporter cell lines were treated with oxysterols and phytosterols alone and in 
combination for 16 h and LXRα transactivation measured by luciferase assay.  In the 
MDA-MB-468 reporters (Figure 7.5) treatment with oxysterols at 1 μM (2-way 
ANOVA: p<0.05) and 10 μM (p<0.0001) increased LXRα activity. When oxysterols  
were given as co-treatments with phytosterols, the phytosterols antagonised the 
oxysterol activation of LXRα at 1 μM (24OHC; all PSS, p<0.0001., 25OHC; all PSS, 
p<0.0001., 24,25-EC; all PSS, p<0.0001., 26OHC; all PSS, p<0.05) and 10 μM (24OHC; 
all PSS, p<0.0001., 25OHC; all PSS at least, p<0.05., 24,25-EC; all PSS except CAMP 
(ns), p<0.0001., 26OHC; all PSS except STIG (ns) at least, p<0.05). 
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Figure 7. 5 Phytosterols antagonise oxysterol-LXRα activation in TNBC MDA-MB-468 cell cultures. 
Oxysterol-mediated LXRα activity was measured in the presence of oxysterols alone (24OHC, 25OHC, 
26OHC, 24,25-EC) or in combination with PSS (STAN, SITO, CAMP, BRAS, STIG) or the synthetic LXR 
antagonist GSK2033. PSS were applied to TNBC cells in doses of 10  M, and oxysterols in 1 M and 
10 M as indicated. Error bars show SEM of four biological replicates. Two-way ANOVA used for 
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In the MDA-MB-231 reporters (Figure 7.6) treatment with oxysterols at 1 μM 
(p<0.05) and 10 μM (p<0.0001) increased LXRα activity. When oxysterols were given 
as co-treatments with phytosterols, the phytosterols antagonised the oxysterol 
activation of LXRα at 1 μM (24OHC; all PSS except STAN (ns) at least, p<0.05., 25OHC; 
all PSS, p<0.05., 24,25-EC; all PSS, p<0.05, 26OHC; only STAN, p<0.05) and 10 μM 
(24OHC; all PSS, p<0.0001, 25OHC; all PSS except BRAS (ns), p<0.0001, 24,25-EC; all 
PSS except BRAS (ns), p<0.0001, 26OHC; all PSS, p<0.0001). 
In the MCF-7 reporters (Figure 7.7) treatment with oxysterols at 1 μM (all OHC 
except 26OHC p<0.05) and 10 μM (p<0.0001) increased LXRα activity. When 
oxysterols were given as co-treatments with phytosterols in the MCF-7 cell line, the 
phytosterols were also able to antagonise the oxysterol activation of LXRα at 1 μM 
(24OHC; all PSS except SITO (ns) at least, p<0.05, 25OHC; all PSS at least, p<0.05., 
24,25-EC; all PSS except STAN (ns), p<0.05, 26OHC; all PSS except SITO (ns), p<0.05) 
and 10 μM (24OHC; all PSS, p<0.0001, 25OHC; all PSS except BRAS and STIG (ns), 
p<0.0001, 24,25-EC; all PSS at least, p<0.05, 26OHC; all PSS except BRAS and STIG 
(ns), p<0.0001). 
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Figure 7. 6 Phytosterols antagonise oxysterol-LXRα activation in TNBC MDA-MB-231 cell cultures. 
Oxysterol-mediated LXRα activity was measured in the presence of oxysterols alone (24OHC, 25OHC, 
26OHC, 24,25-EC) or in combination with PSS (STAN, SITO, CAMP, BRAS, STIG) or the synthetic LXR 
antagonist GSK2033. PSS were applied to TNBC cells in doses of 10  M, and oxysterols in 1 M and 
10 M as indicated. Error bars show SEM of four biological replicates. Two-way ANOVA used for 
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Figure 7. 7 Phytosterols antagonise oxysterol-LXRα activation in ER-positive MCF-7 cell cultures. 
Oxysterol-mediated LXRα activity was measured in the presence of oxysterols alone (24OHC, 25OHC, 
26OHC, 24,25-EC) or in combination with PSS (STAN, SITO, CAMP, BRAS, STIG) or the synthetic LXR 
antagonist GSK2033. PSS were applied to ER-positive cells in doses of 10  M, and oxysterols in 1 M 
and 10 M as indicated. Error bars show SEM of four biological replicates. Two-way ANOVA used for 
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Additional to the luciferase oxysterol and phytosterol co-treatments, phytosterols 
were also included as single treatments as controls (Figure 7.8). Treatments of 
phytosterols (STAN, SITO, CAMP, BRAS and STIG) in MDA-MB-468, MDA-MB-231 and 
MCF-7 luciferase reporters were unable to regulate LXRα activity at 10 μM as single 
treatments (Two-way ANOVA; ns). The LXR antagonist GSK2033 was included as a 
control to compare reduced LXRα activity in the three BCa cell lines (p<0.0001). 
 
Figure 7. 8 LXRα activity when treated with phytosterols at 10 μM.  
Hormone receptor negative (a) MDA-MB-468 and (b) MDA-MB-231 luciferase reporter cells, and 
hormone receptor positive (c) MCF-7 luciferase reporter cells were treated with PSS (10 μM) for 16 h 
and LXRα activity was assessed by luciferase assay and normalised to VC. Data shown are mean of 
four independent replicates with SEM. Two-way ANOVA with Holm-Sidak correction for multiple 
testing was used to determine statistical significance. 
 
Next, the data were analysed to establish efficiency of inhibition. (Figure 7.9). First 
the percentage efficiency that each phytosterol impairs the activation of LXRα by 
each oxysterol in each cell line at 1 μM and 10 μM were calculated and presented as 
boxplots. Results showed that in the co-treatments treated with 1 μM oxysterol and 
10 μM phytosterol there was no significant difference (Two-way ANOVA, ns) 
between phytosterols for the breast cancer cell lines (Figure 7.9A). In the co-
treatments treated with 10 μM oxysterol and 10 μM phytosterol (Figure 7.9B) 
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however, STAN and SITO were significantly more efficient at antagonising oxysterol 
activation of LXRα in the three BCa cell lines (Two-way ANOVA) .  
 
 
Figure 7. 9 Inhibition of oxysterol induced LXRα activity by PSS and cell lines.  
The percentage efficiency with which each PSS impairs activation of LXRα by each oxysterol was 
calculated in each cell line for both low (1 μM (a)) and high (10 μM (b)) dose PSS treatment. Individual 
oxysterols are represented by circles with range and mean shown in box plots. Statistical differences 
in the abilities of different PSS to impair oxysterol mediated LXRα activation are denoted by different 
letters (shared letters indicate no significant difference between PSS). Statistical significance was 
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After phytosterols were found to inhibit oxysterol mediated activation of LXRα, 
oxysterol and phytosterol co-treatments were repeated in the parental cell lines to 
determine whether co-treatment altered LXR transcriptional output of its target 
genes ABCA1 (Figure 7.10) and APOE (Figure 7.11).  
MDA-MB-468, MDA-MB-231 and MCF-7 parental cell lines were exposed to co-
treatments of 24OHC, 26OHC and GW3965 alone and in combination with SITO and 
STAN for 16 h. RNA was harvested, and gene expression analysed with Taqman 
assays. In MDA-MB-468 cells, treatment with LXR agonists enhanced expression of 
ABCA1 (1-way ANOVA, p<0.0001) which was attenuated by co-treatment of 24OHC, 
26OHC and GW3965 with phytosterols (SITO and STAN, p<0.0001, all co-treatments). 
In MDA-MB-231 cells, treatment with LXR agonists enhanced expression of ABCA1 
(p<0.0001) which was also attenuated by co-treatment of 24OHC, 26OHC and 
GW3965 with phytosterols (SITO and STAN, p<0.0001, all co-treatments). And finally 
in MCF-7 cells, treatment with LXR agonists enhanced expression of ABCA1 
(p<0.0001) which was also attenuated by co-treatment of 24OHC, 26OHC and 
GW3965 with phytosterols (SITO and STAN, p<0.0001, all co-treatments). 
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Figure 7. 10 Phytosterols antagonise oxysterol-LXR activation of the canonical target genes ABCA1. 
TNBC MDA-MB-468 and MDA-MB-231 cells, and Luminal A MCF-7 cells were treated with LXR ligands 
24OHC (A), 26OHC (B) and GW3965 (C) (synthetic 1 μM, oxysterol 10 μM) for 16 h alone or in 
combination with SITO or STAN and expression of ABCA1 was assessed by qPCR (∆∆Ct using HPRT and 
normalised to vehicle). Data shown are mean of three independent replicates (circles) with SEM. One-
way ANOVA with Holm-Sidak correction for multiple testing was performed. 
 
In MDA-MB-468 cells, treatment with LXR agonists enhanced expression of APOE 
(p<0.0001) which was attenuated by co-treatment of 24OHC, 26OHC and GW3965 
with phytosterols (SITO and STAN, p<0.0001, all co-treatments). In MDA-MB-231 
cells, treatment with LXR agonists enhanced expression of APOE (p<0.0001) which 
was attenuated by co-treatment of 24OHC with phytosterols (SITO, p<0.05., STAN, 
p<0.0001), 26OHC with phytosterols (SITO and STAN, p<0.0001) and GW3965 with 
phytosterols (SITO and STAN, p<0.0001). In MCF-7 cells, treatment with LXR agonists 
drastically decreased expression of APOE (p<0.0001) which was not able to be 
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further attenuated by co-treatment of 24OHC, 26OHC and GW3965 with 
phytosterols (SITO and STAN, ns, all co-treatments). 
 
Figure 7. 11 Phytosterols antagonise oxysterol-LXR activation of the canonical target genes APOE. 
TNBC MDA-MB-468 and MDA-MB-231 cells, and Luminal A MCF-7 cells were treated with LXR ligands 
24OHC (A), 26OHC (B) and GW3965 (C) (synthetic 1 μM, oxysterol 10 μM) for 16 h alone or in 
combination with SITO or STAN and expression of APOE was assessed by qPCR (∆∆Ct using HPRT and 
normalised to vehicle). Data shown are mean of three independent replicates (circles) with SEM. One-
way ANOVA with Holm-Sidak correction for multiple testing was performed. 
 
Furthermore, expression of ABCA1 and APOE was measured after single treatment 
of phytosterols SITO and STAN (Figure 7.12). In MDA-MB-468 cells individual 
treatments of SITO and STAN were unable to alter the expression of ABCA1 or APOE 
(1-way ANOVA; SITO and STAN, ns). In MDA-MB-231 cells individual treatments of 
SITO and STAN increased the expression of ABCA1 (SITO, p=0.016., STAN, p=0.03) 
and APOE (SITO and STAN, p<0.0001). And finally, in MCF-7 cells individual 
treatments of SITO and STAN were unable to alter the expression of ABCA1 (SITO 
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Figure 7. 12 Phytosterols weakly regulate of LXR target genes. 
TNBC MDA-MB-468 and MDA-MB-231 cells, and Luminal A MCF-7 cells were treated with PSS (10 μM) 
for 16 h and expression of ABCA1 (A) and APOE (B) was assessed by TaqMan assays (ΔΔCt using HPRT 
and normalised to vehicle). Data shown are mean of three independent replicates with SEM. One-
way ANOVA with Holm-Sidak correction for multiple testing was used to determine statistical 
significance. 
 
7.3.3  Phytosterols attenuate the oxysterol-LXR driven expression of the p-
glycoprotein/ABCB1. 
Phytosterols have been shown to antagonise LXRα activity and the transcriptional 
output target genes involved in cholesterol efflux in the TNBC cells. As shown in 
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chemoresistance such as p-gp/ABCB1 in TNBC cells, which when knocked down or 
silenced was able to reverse the chemoprotective effects. To establish if phytosterols 
can impair oxysterol-mediated expression of LXRα driven expression of p-gp/ABCB1 
and therefore reduce the chemoprotective effects previously demonstrated, we 
treated cells with co-treatments of phytosterols and oxysterols and assessed the 
regulation of p-gp/ABCB1 through gene expression analyses and chemotherapy 
efflux assays.  
To assess if phytosterols can inhibit oxysterol-LXR expression of the chemotherapy 
efflux pump p-gp/ABCB1, co-treatments of the phytosterols SITO and STAN were 
administered to MDA-MB-468, MDA-MB-231 and MCF-7 cells with either 24OHC, 
26OHC or GW3965 and expression of p-gp/ABCB1 measured using qPCR (Figure 
7.13). In MDA-MB-468 cells, treatment with LXR agonists enhanced expression of p-
gp/ABCB1 (1-way ANOVA, p<0.0001) which was attenuated by co-treatment of 
24OHC, 26OHC and GW3965 with phytosterols (SITO and STAN, at least p<0.001 for 
all co-treatments). In MDA-MB-231 cells, treatment with LXR agonists enhanced 
expression of p-gp/ABCB1 (p<0.0001) which was attenuated by co-treatment of 
24OHC with phytosterols (p<0.0001), 26OHC with phytosterols (p<0.0001) and 
GW3965 with phytosterols (p<0.0001). In MCF-7 cells however, treatment with LXR 
agonists decreased expression of p-gp/ABCB1 (p<0.0001) which was not able to be 
further attenuated by co-treatment of 24OHC, 26OHC or GW3965 with phytosterols 
(ns). 
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Figure 7. 13 Phytosterols antagonise oxysterol-LXR activation of p-gp/ABCB1. 
TNBC (a) MDA-MB-468 and (b) MDA-MB-231 cells, and Luminal A (c) MCF-7 cells were treated with 
LXR ligands (synthetic 1 μM, oxysterol 10 μM) for 16 h alone or in combination with SITO or STAN and 
expression of p-gp/ABCB1 was assessed by qPCR (∆∆Ct using HPRT and normalised to vehicle). Data 
shown are mean of three independent replicates (circles) with SEM. One-way ANOVA with Holm-
Sidak correction for multiple testing was performed. 
 
Furthermore, we measured expression of p-gp/ABCB1 after single treatment of 
phytosterols SITO and STAN (Figure 7.14). In MDA-MB-468 cells individual 
treatments of SITO and STAN were unable to alter the expression of p-gp/ABCB1 (1-
way ANOVA, ns) or in MDA-MB-231 cells (ns). In MCF-7 cells however, individual 
treatments of SITO and STAN significantly reduced the expression of p-gp/ABCB1 
(p<0.0001). 
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Figure 7. 14 Phytosterols downregulate the expression of p-gp/ABCB1 in Luminal A cells. 
TNBC MDA-MB-468 and MDA-MB-231 cells, and Luminal A MCF-7 cells were treated with PSS (10 μM) 
for 16 h and expression of p-gp/ABCB1 was assessed by qPCR (ΔΔCt using HPRT and normalised to 
vehicle). Data shown are mean of three independent replicates with SEM. One-way ANOVA with 
Holm-Sidak correction for multiple testing was used to determine statistical significance. 
 
As gene expression of p-gp/ABCB1 was significantly reduced by co-treatment of 
phytosterols with oxysterols in the TNBC cells, chemotherapy efflux assays were 
performed to identify if the reduction in p-gp/ABCB1 expression by the co-
treatments also reduced the export of epirubicin (Figure 7.15). MDA-MB-468 and 
MDA-MB-231 cells were pre-treated with phytosterols and oxysterols in 
combination and alone for 16 h before epirubicin for 1 h. Figure 7.15 shows 
oxysterols in co-treatment with sitosterol (SITO) and (Figure 7.16) shows oxysterols 
in co-treatment with sitostanol (STAN).  
In TNBC cells (MDA-MB-468 Figure 7.15A, MDA-MB-231 Figure 7.15B), oxysterol 
treatment with 24OHC and 26OHC before chemotherapy treatment enhanced the 
export of epirubicin (dissociation one phase exponential decay; p<0.0001) relative 
to the epirubicin only treated cells. Treatment with SITO before chemotherapy 
treatment slowed down the export of epirubicin (p<0.001). Interestingly, co-
treatment of oxysterols with SITO reversed the enhanced expression of epirubicin 
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oxysterols with SITO further slowed down the export of epirubicin in the MDA-MB-
468 cells (p<0.0001) but was only able to in MDA-MB-231 cells with co-treatment of 
26OHC+SITO (p<0.0001). 
 
Figure 7. 15 Sitosterol reverses the OHC-LXR effects of enhanced epirubicin exportation. 
MDA-MB-468 (A) and MDA-MB-231 (B) cells were pre-treated with LXR ligands (24OHC, 26OHC) alone 
or combination with a phytosterol (β-sitosterol) or vehicle for 16 h. Cells were then exposed to 
epirubicin (50 μM) for 1 h. Fluorescence of epirubicin was measured at 15 min intervals for 90 min. 
Statistical analysis of half-life was assessed using dissociation one phase exponential decay. Data 
shown are of 3 independent replicates with SEM. 
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In  TNBC cells (MDA-MB-468 Figure 7.16A, MDA-MB-231 Figure 7.16B), oxysterol 
treatment with 24OHC or 26OHC before chemotherapy treatment enhanced the 
export of epirubicin (dissociation one phase exponential decay; p<0.0001) relative 
to the epirubicin only treated cells. Treatment with STAN in both TNBC cell lines 
before chemotherapy treatment slowed down the export of epirubicin (at least 
p=0.001). In MDA-MB-468 and MDA-MB-231 cells co-treatment of 24OHC with STAN 
reversed the enhanced expression of epirubicin slowing down the rate of 
exportation (p<0.0001) as did the co-treatment of 26OHC with STAN (p<0.0001). 
Additionally, the co-treatment of 24OHC with STAN further slowed down the export 
of epirubicin (at least p<0.01) relative to the treatment of E+STAN, as did the co-
treatment of 26OHC with STAN (p<0.0001).  
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Figure 7. 16 Sitostanol reverses the OHC-LXR effects of enhanced epirubicin exportation. 
MDA-MB-468 (A) and MDA-MB-231 (B) cells were pre-treated with LXR ligands (24OHC, 26OHC) alone 
or combination with  a phytosterol (β-sitostanol) or vehicle for 16 h. Cells were then exposed to 
epirubicin (50 μM) for 1 h. Fluorescence of epirubicin was measured at 15 min intervals for 90 min. 
Statistical analysis of half-life was assessed using dissociation one phase exponential decay. Data 
shown are of 3 independent replicates with SEM. 
 
In summary, phytosterols antagonise oxysterol-mediated expression of p-gp/ABCB1 
in TNBC. Phytosterols have also been shown to reverse the oxysterol-LXR effects of 
enhanced epirubicin export when given as a co-treatment. 
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7.4  Discussion 
Plant based diets that are rich in phytosterols are known to lower LDL-C and are 
associated with reduced risk of primary and recurrent breast cancer [48]. Typically, 
0.04-5 % of consumed PSSs are absorbed [210, 310-312] but this can vary from 
person to person based on the individual genetics or pathologies [210, 311], but also 
on the chemistry of specific PSSs [210, 312]. Absorption of dietary cholesterol is more 
efficient than the absorption of phytosterols however, phytosterols circulate in 
much higher concentrations than cholesterol derivatives. In the general population 
phytosterols circulate at around 20 μM, although in some high PSS intake individuals 
PSS concentrations have been found to be in excess of 100 μM [204]. Cholesterol 
circulates at concentrations between 4-5 mM [313] which is around 50-200 times 
higher than PSS concentrations. Although lower than cholesterol concentrations, PSS 
circulating concentrations are around 5,000-20,000 times higher than 17β-estradiol 
(1 nM), 20-100 times higher than Vitamin D (50 nM) and up to 1000 times higher 
than most oxysterols [314].  
In this chapter, cells have been treated with phytosterols in the concentrations of 1 
μM and 10 μM which is below the mean physiological serum concentration of 20uM 
from serum [204]. Within this range PSSs have been shown to have modest effects 
on LXRα activity and cell proliferation in TNBC and Luminal BCa cell cultures and were 
unable to repress or induce LXRα when not in competition for binding. However, 
phytosterols when given as a co-treatment were able to significantly attenuate the 
oxysterol-LXRα activation as measured by luciferase and analysis of LXR target genes 
ABCA1 and APOE by qPCR. These changes were further influenced by cell line. 
Furthermore, phytosterols when given as a co-treatment were able to significantly 
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attenuate the oxysterol-LXR activation of p-gp/ABCB1. And finally, phytosterols were 
able to antagonise oxysterol:LXR enhanced export of epirubicin in TNBC cells in a 
manner similar to the p-gp/ABCB1 inhibitor verapamil suggesting an alternative 
route for reducing p-gp/ABCB1 mediated chemotherapy resistance. 
From these data, we have shown that categorising phytosterols as LXR agonists or 
antagonists is too simplistic when key factors such as the presence of other ligands 
and cell type can alter how the ligand interacts with LXRα. In these BCa cell lines, 
phytosterols have been found to behave as competitive inhibitors of LXRα. 
Furthermore, these data may have implications for the development of novel 
therapeutic drugs targeting LXRα as PSS rich diets may alter the efficacy of LXRα 
targeting. 
In the three breast cancer cell lines MDA-MB-468, MDA-MB-231 and MCF-7, the 
extent to which phytosterols attenuated the oxysterol:LXRα pathway depended on 
which oxysterol they were competing with. The most efficient inhibitors of oxysterol-
driven LXR activation were SITO and STAN. The most effective drivers of LXRα 
activations were 24,25-EC and 24OHC (which is in agreement with previous reports 
[241]). Interestingly Ras et al, previously reported no differences in the ability of 
phytosterols and phytostanols at lowering LDL-cholesterol [315]. SITO and STAN are 
almost identical in structure except for a single double bond in the B-ring structure. 
Given that no significant differences were observed between SITO and STANs 
percentage efficiency with which each PSS impaired oxysterol activation of LXRα, 
suggests the double bond on the B-ring structure does not impact on interactions 
with LXR. For example, SITO and STIG are almost identical except for the unsaturated 
bond between the 22nd and 23rd carbon in the side chain (Figure 1.4) which appears 
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to be an adequate change altering the ability of STIG to compete with oxysterols for 
LXRα binding. Plat, Nichols and Mensink, measured ABCA1 expression after exposure 
to SITO, STAN and CAMP and found all three PSSs to induce ABCA1 expression in 
Caco2 cells [212]. Furthermore, they found SITO and STAN significantly increased 
ABCA1 expression by approximately 3.5 fold and CAMP by 3 fold which is in line with 
the observations shown in this chapter demonstrating SITO and STAN as the most 
efficient LXR ligands tested [212]. Hac-Wydro et al, specifically compared SITO and 
STIG and their interactions with 2-oleoyl-1-palmitoyl-3-phosphocholine (POPC) 
molecules, finding SITO had stronger affinity for the molecules than STIG as a 
consequence of their structure, namely the double bond in the side chain of STIG 
[316].  Furthermore, unsaturated bonds in the side chain like the one in STIG, makes 
the side chain bulkier and less flexible and allows for decreased rotational freedom 
[316]. Additionally, unsaturated bonds in the side chain makes the ligand more prone 
to enzymatic attack or oxidation. Supporting this, one study used a series of synthetic 
STIG derivatives with alterations on either carbon 22 or carbon 23 and found the 
altered STIG derivatives were able to selectively regulate the LXR target gene ABCA1 
[317]. Furthermore, robust activation of ABCA1, SCD1 and FASN was observed by 
altered stigmastane ligands (addition of a hydroxyl group at C24) [318]. A study by 
Yang et al however, showed STIG was able to regulate ABCA1 in culture mouse 
adrenal cells but SITO failed to alter ABCA1 levels [319]. Furthermore, they 
investigated the structural requirements for ligand LXR activation and found 
unsaturation of the cholesterol side chain was required for LXR activation by sterols 
[319]. There are clear research gaps in the understanding of phytosterols and their 
selective modulation of LXR, particularly in understanding why some phytosterols 
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appear to be more efficient ligands than others and in a tissue dependent manner.  
This is a critical factor for the successful therapeutic targeting of LXR which has 
disease promoting and disease prevention capacities through the LXR-oxysterol 
signalling cascades.  
Oxysterols and phytosterols are closely related, both displaying similar structures 
and functions in their natural host. It is in part the reason we suspected phytosterols 
to behave in a selective manner combined with other evidence supporting this 
selective modulator hypothesis include the work completed by Kaneko et al, who 
showed SITO, CAMP, BRASS and STIG were able to activate LXRα driven luciferase 
HEK293 cells at 10 μM [66]. In CHO-7 cells however, SITO was unable to successfully 
activate LXRα [172]. Plat, Nichols and Mensink performed qPCR analysis after 
treatments with phytosterols and showed SITO, CAMP and STAN were able to 
enhance ABCA1 expression in Caco2 cells [212], but contrary to this Brauner et al, 
showed co-treatment of cholesterol with CAMP or SITO attenuated cholesterol 
driven ABCA1 expression in the same cell line [211]. Furthermore, in HepG2 cells 
phytosterols were found to downregulate the expression of LXR target genes 
(HMGCR, LDLR, SR-BI and NPC1L1) [109] and downregulate expression of ABCG5 and 
ABCG8 in Caco2 cells [214]. These findings support the conclusion that 
understanding the modulation of LXR in conjunction with other factors such as cell 
type and the presence of other ligands is essential for therapeutic targeting of LXR. 
In this study oxysterols have been shown to have the capacity to robustly regulate 
LXRα. As isolated ligands, phytosterols were unable to significantly alter LXRα activity 
but as a co-treatment with oxysterols were able to attenuate oxysterol-driven LXRα 
luciferase BCa reporters. Furthermore, co-treatment of oxysterols with phytosterols 
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were also able to significantly attenuate transcription of LXR target genes. One gene 
in particular, p-gp/ABCB1 is a well-known chemotherapy efflux pump which we 
showed to be under the control of LXRα in chapter 5. In this chapter the expression 
of p-gp/ABCB1 was assessed after co-treatment of phytosterols with oxysterols and 
was found to reduce the expression of p-gp/ABCB1. Additionally, co-treatment of 
phytosterols with oxysterols slowed down the export of epirubicin in chemotherapy 
efflux assays, reversing the effects of pre-treatment with just the oxysterols. These 
results suggest a phytosterol rich diet may have beneficial effects for patients 
undergoing chemotherapy treatment. 
 
7.5  Summary 
In this chapter we have demonstrated that phytosterols as single treatments are able 
to weakly modulate LXRα in luciferase reporters and they are anti-proliferative at 
micromolar concentrations. Although phytosterols do not appear to do much in the 
absence of oxysterols, in the presence of oxysterols they impair oxysterol mediation 
of LXRα and its target genes ABCA1 and APOE. Furthermore, we identified a 
therapeutic method to silence the chemoprotective effects in TNBC cells caused by 
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Chapter 8 
8.0  Discussion 
8.1 LXRα activity is enhanced in triple negative breast cancer 
The purpose of this research was to explore and identify new therapeutic targets in 
TNBC. Chapter 4 of this thesis has focused on identifying a therapeutic target that is 
altered between BCa subtypes. LXRα was found to be expressed at much higher 
levels in TNBC primary patient tumours along with its alternative binding partner 
RXRβ, suggesting altered cholesterol pathways in BCa subtypes. Presented in chapter 
4 are results showing enhanced LXRα activity and response to ligand in the TNBC 
subtype relative to the Luminal/ER-positive subtype, which appears to be influenced 
by lower levels of corepressors relative to the Luminal A subtype. Interestingly, LXR 
stimulation in BCa cells has been shown to induce expression of ABCA1 with 
enhanced transcriptional output observed in ER-negative cells compared to the ER-
positive cells, which matches the observations in this chapter with those of Vedin et 
al [134]. Reassuringly, Vedin and colleagues also observed enhanced transcriptional 
output of LXR target genes (ABCA1 and SREBP1c) in ER-negative MDA-MB-231 cells 
relative to ER-positive MCF-7 and T47D cells, which strongly agrees with our findings 
as two of the cell lines used in the Vedin study were the same cell lines used here. 
Furthermore, they observed the same findings in the T47D and SK-BR3 cells 
suggesting the enhanced ER-negative response to ligand may be true for many ER-
negative cell lines.  
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8.2 Fibroblasts can activate LXRα in BCa cells. 
Through a series of fibroblast co-cultures and conditioned media experiments, 
fibroblasts have been shown to activate LXRα BCa reporters successfully. Oxysterol 
concentrations within CAFs and non-cancer associated fibroblasts were measured by 
LCMS/MS (completed by Dr. Hanne Roberg-Larsen, Oslo) and were found to have 
significantly higher concentrations of oxysterols (except 25OHC) than epithelial BCa 
cells. Conditioned media taken from fibroblast cultures were exposed to LXRα BCa 
reporters and LXRα transactivation measured by luciferase assay. Results showed 
that CAF conditioned media successfully activated LXRα TNBC reporters and the 
control liver HepG2 reporter but failed to activate the Luminal A BCa reporter. 
Conditioned media from the non-cancer associated fibroblasts successfully activated 
all LXRα BCa reporters as well as the control liver HepG2 reporter. These data imply 
fibroblasts do not require direct cell-to-cell contact with BCa epithelial cells to active 
LXRα, but in fact secrete factors to interact with LXRα in the BCa reporters. The study 
by Camp et al, performed two methods of epithelial BCa cell co-cultures with 
fibroblasts, through direct contact co-culture and through the use of transwell insert 
culture dishes to impair cell-to-cell contact. Both methods of TNBC cells co-culture 
with fibroblasts enhanced the expression of ABCA1 but contact culture failed to do 
so in the Luminal BCa co-cultures. Co-cultures of Luminal A BCa cells with fibroblasts 
using the transwell method enhanced the expression of ABCA1 in the epithelial cells 
but failed to do so in the fibroblasts. This study by Camp and colleagues strengthens 
the hypothesis that fibroblasts activate LXRα in epithelial BCa cells and supports the 
observations in this chapter of LXRα induced paracrine signalling. 
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Further research is needed to establish whether fibroblasts secrete enhanced levels 
of oxysterols to cancer epithelial cells in the TME enabling the activation of LXRα.  A 
study by Axelson et al, measured the production of oxysterols in normal human 
fibroblasts after incubation in media containing 10 % FCS for 24 h [146]. 
Measurements of 24OHC, 25OHC and 26OHC in fibroblast cells and the conditioned 
media were assessed. After subtracting the oxysterol content observed in the FCS 
control cell measurements showed no production of 24OHC, 3 pmol of 25OHC and 5 
pmol of 26OHC. In fibroblast conditioned media oxysterols concentrations increased 
to 77 pmol of 26OHC but no secretion of 24OHC and a decrease in 25OHC. The 
concentrations of oxysterols in the human fibroblasts are much lower than observed 
in the breast fibroblasts in this chapter, but it does provide evidence that fibroblasts 
secrete oxysterols. To follow up this study, samples of conditioned media from 
multiple types of TME cells (fibroblast, macrophages and adipocytes) could be 
assessed for oxysterol content by LCMS/MS from single cultures and co-cultures 
(cell-to-cell and using transwell) with epithelial BCa cells.  
The role of macrophages in the TME [320] is also an area of interest as they too 
possess the ability to synthesise and secrete oxysterols [321], and LXR ligands have 
been shown to induce ABCA1 in macrophages [322]. Shi et al, measured protein 
expression of CYP27A1 in the breast cancer cell lines MCF-7 and MDA-MB-231 and 
the THP-1 human monocytes/macrophages. Western blot analysis showed epithelial 
BCa cell expression of CYP27A1 to be relatively low compared to the THP-1 
monocytes/macrophages, and enhanced expression of CYP27A1 in the MDA-MB-231 
cells relative to the MCF-7 cells [285]. Both the findings in this chapter and the 
literature that support our LCMS/MS analysis results provide confidence in the data 
- 210 - 
collected and pave the way for further analysis of other TME support cells and their 
role in oxysterol synthesis and secretion contributing to the ER-negative/TNBC 
enhanced LXRα activity. 
 
8.3 Enhanced LXR activity predicts poorer patient outcome and reduced 
treatment efficacy  
In chapter 5, LXRα was shown to have a central role in the development of 
chemotherapy resistance. LXR ligands, the oxysterols, were identified as mediators 
of reduced chemotherapy drug efficacy in TNBC and Luminal A BCas. Through a 
series of knockdowns and chemotherapy efflux assays LXRα was shown to regulate 
p-gp/ABCB1 in TNBC but not Luminal A BCas.  Supporting these findings was a study 
by Saint-Pol et al, who showed oxysterol induction of p-gp/ABCB1 increasing efflux 
across the BBB [228]. Other than this one study showing regulation by LXRα in the 
brain no other published records exist. This may not be a complete novel discovery, 
but it is a novel finding for BCa with clinical implications particularly for those with 
high LDL-C. The LXRα regulation of p-gp/ABCB1 in BCa is of great importance, and 
although no other studies can be directly compared due to the novelty of this 
discovery other studies can support aspects of this research. For example, Kim et al, 
made similar observations of  enhanced p-gp/ABCB1 expression in breast tissues 
post neoadjuvant chemotherapy which was associated with reduced survival by 20 
% [270]. Furthermore, Kim and colleagues also showed a significant 40 % reduction 
in survival in patients who had high BCRP expression post neoadjuvant 
chemotherapy relative to those with low expression which links in with the LXRα 
regulation of BCRP in Luminal A BCa [270]. In another study, the expression of p-
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gp/ABCB1 was assessed in two MDA-MB-231 cell lines, one which was doxorubicin 
resistant and the other doxorubicin sensitive. Immunocytochemical staining of the 
doxorubicin sensitive MDA-MB-231 cells for p-gp/ABCB1 was undetected, however 
the doxorubicin resistant MDA-MB-231 cells showed strong cytoplasmic and nuclear 
staining of p-gp/ABCB1 expression [271]. These data support our findings of a p-
gp/ABCB1 enhanced chemotherapy resistance mechanism in ER-negative breast 
cancers which could provide useful as a prognostic marker for poor response to 
treatment and increased risk of relapse. To follow up on these novel findings, 
validation studies showing LXRα control of p-gp/ABCB1 are required in these and 
other cell lines using ChIP-Seq techniques. 
 
8.4 Phytosterols antagonise the oxysterol:LXR axis 
Data presented in chapter 7 explore the role of phytosterols as selective LXRα 
modulators. Phytosterols were shown to have little effect on LXRα in the absence of 
ligand but when in the presence of ligand, they were able to antagonise oxysterol-
mediated LXRα activation and expression of its targets ABCA1, APOE and P-
gp/ABCB1. Brauner et al, showed the induction of HEK293 LXRα reporters by 
treatment of 26OHC but not by phytosterols (CAMP and SITO), but co-cultures of 
26OHC with either SITO or CAMP increased the LXRα response [211]. In contrast, 
Brauner et al, also found no change in ABCA1 expression by phytosterol treatment 
in Caco2 cells but co-treatment of cholesterol with either CAMP or SITO in the same 
cell line attenuated cholesterol mediated ABCA1 expression[211], therefore 
phytosterols may be able to moderate LXR’s response to ligand but in a tissue/cell 
specific manner. This is further supported by their oxysterol production experiments 
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where Brauner and colleagues showed co-incubation of cholesterol with either 
campesterol (77 ± 9 pmol x mg protein/min) or sitosterol (106 ± 16 pmol x mg 
protein/min) significantly inhibited the generation of 26OHC when compared to 
treatment of cholesterol alone (285 ± 23 pmol x mg protein/min) in HepG2 cells 
[211]. Additionally, in Caco2 cells CYP27A1 was shown to be increased by treatment 
with cholesterol and attenuated by co-treatment with either SITO or CAMP [211]. 
 
8.5 Future prospective 
The design of this study was split into four key sections; i) to identify a therapeutic 
target in TNBC, ii) to assess the targets role in chemotherapy resistance, iii) to assess 
the regulation of the target in the TME, and iv) to identify compounds that can be 
used to impair and reduce the activity of the target in TNBC. The research presented 
in this thesis, have highlighted LXRα activity is enhanced in TNBC, LXRα activation 
reduced the efficacy of chemotherapy treatment through up-regulation of p-
gp/ABCB1, fibroblasts activate LXRα through cell-to-cell contact and paracrine 
signalling and finally that phytosterols antagonise oxysterol-mediated LXRα 
activation.  
LXRα activity and cholesterol status is increasingly recognised as important in patho-
biology, particularly in the field of cancer. Understanding mechanisms that reduce 
treatment and chemotherapy efficacy is important to be able to predict better 
patient outcomes. Identifying enhanced LXRα activity in the TNBC subtypes and their 
readiness to respond to ligand has the potential to assess individual cholesterol 
status alongside the standard tumour classification to identify individuals who may 
be at a higher risk. This is supported by the WCRF-CUP report which assessed intake 
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of non-starchy vegetables (which are high in phytosterols) and the associated risk of 
BCa. The report found no significant difference between high and low non-starchy 
vegetable intake and risk of unspecified BCa, RR=0.95 (95 % CI, 0.88-1.33) per 200 g 
per day [37]. However, when phytosterol intake was assessed in 3950 cases of ER-
negative BCas specifically, there was a significant inverse association RR=0.79 (95 % 
CI, 0.63-0.98) per 200 g per day. Furthermore, when non-starchy vegetable intake 
was assessed in 1,229 cases of ER-positive BCas there was no significant association 
[37]. Similar observations from the Women’s intervention nutrition study (WINS) 
support these findings, in which dietary patterns that lower fat intake were 
associated with reduced risk of BCa relapse [48]. Although phytosterol intake was 
not directly measured, diets rich in fruit and vegetables and low in fat are more likely 
to have higher levels of phytosterols than diets which are low in fruit and vegetables. 
Implemented dietary patterns in the WINS intervention when classified by estrogen 
receptor status show HR for relapse events was reduced in the intervention group 
with ER-negative BCas, HR=0.58 (95 % CI, 0.37-0.91, adjusted Cox model analysis 
p=0.018) compared to the control group however, no  significance was observed in 
ER-positive BCas relative to the control group, HR=0.85 (95 % CI, 0.63-1.14, adjusted 
Cox model analysis p=0.277) [48]. Data presented in chapter 4 of this thesis show 
TN/ER-negative BCas are more susceptible than Luminal A/ER-positive BCas at the 
molecular level to modulation by LXRα, which explains how these reports by 
Chlebowski [48] and the WCRF-CUP [37] show reductions in fat intake and increases 
in non-starchy vegetables are protective against TNBC/ER-negative disease but not 
ER-positive disease.  
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Based on these findings, clinical trials with phytosterols in the lead up to and during 
chemotherapy treatments for BCa patients are warranted. The evidence supplied in 
this thesis with the supporting evidence already published suggest the inclusion of 
phytosterols to treatment plans before and during chemotherapy treatment has the 
potential to improve BCa outcomes, particularly those belonging to the TNBC 
subtype.  The most recent study by Jiang et al showed relative risk for the highest 
phytosterol intake compared to the lowest for total phytosterol intake was 
associated with a reduction in cancer risk, RR=0.63 (95 % CI = 0.49-0.81) [295]. This 
study included multiple different cancer types and therefore shows phytosterol 
intake to reduce cancer risk is applicable to other cancers not just BCa.  
Kumar et al, conducted one of the largest retrospective ER-negative tumour studies 
during which they analysed data from 2,141 female participants who had a BCa 
incident. The study assessed statin use among the women previous to the BCa 
incidence and identified women taking lipophilic statins for more than a year had 
proportionally fewer ER/PR-negative tumours OR=0.63 (95% CI 0.43-0.92: p=0.02) 
relative to women who did not use statins or had been for less than a year [122]. 
Phytosterols are already given to patients at higher risk of cardiovascular disease and 
are therefore known to be safe and not have cytotoxic side effects. The daily intake 
guidelines given to CVD patients is 2-3 g/day which is achievable through a diet rich 
in fruit, vegetables and nuts. This highlights the simplicity of changing patient diets 
to include manageable amounts of phytosterols per day to improve their response 
to chemotherapy treatments and reduce their risk of relapse.  
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8.6 Future work 
To further support the findings of this PhD project a number of experiments remain 
to validate LXRα control of p-gp/ABCB1. This project has mainly focused on LXRα 
control of p-gp/ABCB1 at the RNA level and therefore control at the protein level 
would be the obvious next steps. This includes treatment of cells with LXR ligands 
(oxysterols and phytosterols alone and in combination), protein extraction and 
western blot analyses with a p-gp/ABCB1 antibody and a HPRT1 housekeeping 
antibody. The remaining patient tumour samples obtained from the Leeds Breast 
Tissue bank should also have protein extracted and western blot analyses performed 
with a p-gp/ABCB1 antibody and a HPRT1 housekeeping antibody to assess whether 
p-gp/ABCB1 protein expression is predictive of survival using Kaplan Meier plots. 
Furthermore, tissue for immunohistochemistry was also acquired from the Leeds 
Breast Tissue bank to validate the cBioportal datasets.  
In this project siRNA knockdowns were used for targeted gene silencing at the RNA 
level. This could be strengthened using techniques such as CRISPR which knocks out 
the target gene at the DNA level. The CRISPR method is much more specific and is a 
guaranteed gene knockout, whereas siRNA knockdown gives only a partial 
knockdown and has the potential to have non-specific effects.  
The final future suggestion to strengthen this project is to perform a ChIP-Seq 
experiment in TNBC cells after treatment with a VC and LXR ligands for 16 h. After 
crosslinking and chromatin shearing, the chromatin can be incubated with protein-
specific antibodies to immunoprecipitate the DNA-protein complex. The DNA can 
then be extracted and sequenced, providing sequences of the protein-binding sites 
with the gene of interest promotor (p-gp/ABCB1). This experiment would provide 
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the validation necessary to show LXRα binds in the promotor region of p-gp/ABCB1 
controlling the expression. 
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Chapter 9 
9.0  Conclusion 
TNBCs have been shown to have enhanced LXRα activity and are poised for response 
to ligand relative to Luminal A breast cancers. TNBC patients who had relapses were 
shown to have enhanced LXRα activity. LXRα regulates the expression of p-gp/ABCB1 
in TNBC but not in Luminal A BCa, and LXRα regulates the expression of ABCG2 and 
ABCC1 in Luminal A BCa but not TNBC. Oxysterols are endogenous LXR ligands which 
reduced the efficacy of epirubicin in BCa cell cultures and in ER-negative grafted 4T1 
BCa cells in BALB/C mice. Phytosterols were shown to have little effect on LXRα in 
the absence of ligand, but when in the presence of ligand antagonised oxysterol-
mediated LXR expression of ABCA1, APOE and p-gp/ABCB1. Furthermore, 
phytosterols when given as a co-treatment were able to decrease the export of 
epirubicin in a similar manner to that of the p-gp/ABCB1 inhibitor verapamil 
suggesting possible new roles for phytosterols in improving BCa patient response to 
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Figure 9. 1 LXRαs role as a therapeutic target – a summary of key findings.  
The overall enhanced expression of LXRα in TNBC (shown in the top left box) has protective effects on tumour cells when pre-treated with oxysterols (OHC) during 
chemotherapy treatment (top right). This protective effect resulted in larger tumours in mice when treated with LXR ligands and was associated with worse survival. In 
addition to enhanced LXRα expression in TNBC, fibroblasts were also found to activate TNBC LXRα reporters through paracrine signalling. Finally, phytosterols (PSS) inhibit 
oxysterol-mediated expression of LXRα and reduces the export of epirubicin through attenuation of the p-glycoprotein. 
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Appendix A 
A.1  Table of LXRα target genes and their genomic binding scores 
(identified using the Cistrome database). 
The top 100 scoring genes for 7 different LXRα ChIP-Seq datasets are shown. Each of the 7 datasets 
(which include mouse macrophages, human adipocytes and human colorectal cancer cells) are shown 
in columns with the appropriate reference and the cell line at the top. The genes are listed in the first 
column on the left in alphabetical order  and their corresponding binding scores for each study in the 
following 7 columns. Scores that are in black text are scores that were within the top 100 scoring 
genes for that dataset. Scores that are in grey text are scores that were not within the top 100 scoring 
genes for that dataset. Each gene has at least two binding scores that successfully appeared in the 
top 100 scoring genes. 
 
  Oishi, Y., et al, 2017. Galhardo, 
M., et al., 
2013. 
Savic, D., et al., 2016. 

















A130077B15RIK 1.88 3.512 2.019 3.097 0 0 0 
ABCA1 3.58 3.29 3.865 3.332 0.948 1.981 2.382 
ABCG1 2.58 2.922 2.266 3.073 1.652 2.21 2.0945 
ABLIM3  0 0 0 0 0 3.1305 3.5665 
ADAMTSL4 3.818 4.073 3.281 1.974 0 1.3845 1.1115 
AFF1 3.423 3.556 1.849 3.958 0 1.761 2.3825 
AIM1L 0.396 0.437 0.343 0.343 0 3.023 3.3815 
AMZ2 3.215 2.785 3.644 3.95 0 0.4725 0.847 
ANKRD22 0.683 1.636 1.24 0.706 0.603 2.754 3.383 
AP2S1 0.725 0.728 0.626 0.726 0 3.1435 3.0865 
APBB1IP 3.033 3.747 2.462 2.407 0 0.107 0.152 
ARHGAP25 3.596 4.148 2.676 3.394 0 0.319 0.643 
ARHGAP26-AS1 0 0 0 0 0 2.9995 2.667 
ASPH 1.855 4.37 2.822 2.944 0 2.1115 2.15 
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ATG2A 1.616 2.342 1.572 2.431 0 2.078 3.343 
B330016D10RIK 2.336 3.478 3.71 3.18 0 0 0 
BCL3 2.421 3.108 3.292 2.807 0 4.512 3.878 
BMF 1.58 2.439 2.388 1.242 0 3.408 3.9315 
C14ORF182 0 0 0 0 0 2.028 2.119 
C1ORF159 0 0 0 0 0 2.795 3.32 
C1QTNF1-AS1 0 0 0 0 0 3.3795 3.4415 
C6ORF222 0 0 0 0 0 3.5385 3.133 
CAPN2 1.459 1.931 1.558 1.661 0 3.889 3.3725 
CAPN5 0.508 1.931 1.568 1.091 0 4.036 3.1095 
CCDC19 0 0 0 0 0 1.5575 3.647 
CCL3 2.979 2.949 3.086 3.237 0 0.2015 0.352 
CCL6 3.403 4.196 3.416 3.304 0 0 0 
CCL9 3.16 3.875 2.839 3.578 0 1.593 0 
CD14 3.055 3.463 2.708 3.845 0.486 2.3265 2.247 
CD300A 4.041 4.719 1.777 3.602 0 1.367 1.6455 
CD300C 3.206 2.986 1.799 3.069 0 0.074 0.1225 
CD300LB 3.664 3.376 1.664 3.325 0 0.169 0.217 
CLCF1 1.453 3.264 3.114 2.473 0 3.299 2.672 
CLDN7 1.831 1.662 1.505 1.143 0.294 2.075 3.568 
CTDNEP1 2.132 2.243 1.959 1.461 0.187 2.0865 3.375 
CTDSP1 3.398 2.552 2.789 2.027 0 2.4175 2.346 
CYTH4  3.783 3.311 2.335 3.074 0 0.497 0.6645 
DDX47 1.023 0.88 0 0 0 3.348 3.582 
DNAJC17 0.959 0.19 0.152 0.756 0 2.9305 3.0395 
DOK2 1.759 2.843 2.747 3.306 0 0.512 0.512 
DUSP1 2.593 2.63 2.496 2.319 0 3.3765 3.9665 
E230016K23RIK 3.231 3.942 2.995 3.607 0 0 0 
E230025N22RIK 3.103 3.22 2.269 3.469 0 0 0 
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EHD1 1.794 2.368 1.529 2.866 0 2.802 3.472 
EHF 0 0 0 0 0 3.8045 2.903 
ELF3 0.744 1.155 0.744 1.314 0 3.42 3.346 
ELP5 2.132 2.244 1.959 1.464 0.189 2.094 3.39 
FAM83E 1.473 1.743 0.942 1.7 0 3.515 3.3635 
FCGR2B 2.136 4.169 3.928 2.687 0 0.409 0.4555 
FCRLA 2.328 3.889 2.757 2.435 0 0.899 1.3235 
FEM1A 2.693 3.623 3.101 2.425 0.595 1.3795 1.7125 
FIZ1 0.256 1.773 0.79 1.105 0 3.169 3.292 
FLOT1 1.678 2.642 2.549 2.901 0 3.308 3.189 
FYB 3.254 3.948 3.119 3.076 0 0.7515 0.5905 
GM13031 2.687 3.679 2.792 1.809 0 0 0 
GM14005 1.858 2.989 3.501 4.307 0 0 0 
GM19510 3.025 3.425 4.473 3.341 0 0 0 
GM2848 1.679 3.618 2.845 2.845 0 0 0 
GPRC5C 1.231 2.793 0.428 2.113 0 3.4955 3.229 
HCG27 0 0 0 0 0 3.1945 3.5385 
IER3 1.699 2.677 2.639 2.976 0 3.343 3.23 
IL1B 1.506 2.671 2.748 3.021 0 2.4235 2.1675 
IL21R 3.381 4.466 3.09 3.984 0 0.3435 0.4955 
ITGB6 0.059 0.029 0.033 0.209 0 3.287 3.1685 
JUP 1.07 1.823 0.566 0.498 0 3.3015 2.966 
KRT7 0.383 0.667 0.759 0.653 0 3.416 3.4625 
LCP2 2.711 3.765 2.77 3.961 0 0.0135 0.5135 
LINC00880         0 3.819 3.545 
LINC01226         0 2.352 3.4795 
LOC100503496 2.582 2.471 2.755 3.229 0 0 0 
LOC100506499 0 0 0 0 0 3.8165 1.94 
LOC101928093 0 0 0 0 0 3.0705 3.1675 
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LOC254099 0 0 0 0 0 3.4 1.9805 
LOC731656 0 0 0 0 0 3.6505 3.606 
LTBR 1.653 2.152 1.422 1.884 0 3.4655 3.2635 
LY9 3.46 3.665 1.806 2.926 0 0.756 0.7805 
MAPK6 0.812 1.723 1.028 1.419 0.135 3.331 3.7225 
MCL1 4.279 4.495 3.655 2.297 0 1.2855 1.5605 
MGRN1 3.456 4.423 3.16 3.353 0 1.283 1.448 
MIR101C 4.51 2.906 4.317 3.499 0 0 0 
MIR192 1.641 2.166 1.541 2.528 0 2.9125 3.733 
MIR194-2 1.635 2.16 1.535 2.518 0 2.912 3.7315 
MIR26B 3.394 2.451 2.787 1.977 0 2.442 2.354 
MIR6076 0 0 0 0 0 3.6895 2.779 
MIR6749         0 2.4065 3.397 
MIR6750         0 2.5795 3.508 
MIR8085 0 0 0 0 0 3.9775 3.497 
MPEG1 3.952 5.67 2.183 3.195 0 1.6755 1.7955 
MSL1 1.905 3.241 3.265 3.088 0 1.981 2.2855 
N4BP1 3.185 3.073 2.214 3.151 0 1.363 1.591 
NDST1 4.492 3.72 1.577 2.665 0 1.552 1.9775 
NINJ1 2.954 3.484 2.441 2.619 0 1.442 2.606 
NR1D1 1.991 3.211 3.659 3.259 0 2.3405 2.442 
OMP 0.385 0.898 1.23 0.515 0 3.808 3.276 
PDE4B 2.176 2.776 3.329 3.392 0 0.03 0.017 
PGC 1.275 1.949 0.416 1.486 0 3.3635 3.287 
PIGC 1.298 1.549 0.434 1.62 0 3.6525 3.406 
PIK3CG 2.286 3.206 3.416 3.956 0.552 0.519 0.742 
PILRA 3.799 2.98 3.319 2.347 0 0.296 0.5855 
PILRB1 3.737 2.891 3.06 2.359 0 0.3405 0.4225 
PLA2G7 2.649 3.452 2.784 3.047 0 0.3365 0.4055 
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PLAU 2.942 2.493 2.301 3.535 0 1.938 2.1345 
PLXND1 2.017 3.61 2.541 3.5 0 0.9205 0.863 
PNPLA2 4.061 3.586 1.942 2.232 0 2.0065 1.9595 
PPM1N 1.587 2.016 1.709 3.105 0 2.3235 2.8845 
PRKCD 2.956 3.829 3.205 2.869 0 2.154 2.33 
PTK2B 3.399 3.037 2.382 3.366 0 1.7165 1.8775 
RALB 1.796 1.457 0.185 1.797 0 3.0205 3.4605 
RALGDS 2.782 3.06 2.138 3.286 0 2.6305 3.2175 
RHOV 1.876 1.752 1.271 1.717 0 3.282 3.259 
RPL18 1.654 1.963 1.069 1.79 0 3.362 3.2965 
RPLP2 3.605 3.533 1.682 2.159 0 1.846 1.7275 
RTN2 1.52 2.081 1.666 3.041 0 2.3765 2.9505 
SBSN 1.093 1.463 0.561 0.527 0.039 1.9105 3.483 
SCNN1A 1.589 2.267 1.278 1.862 0 3.4695 3.2685 
SDHB 2.85 3.865 3.069 1.901 0 0.693 1.379 
SLA 3.115 2.811 1.966 3.294 0 0.229 0.6185 
SLC2A4 2.275 1.766 1.675 1.278 0.596 1.9825 3.204 
SLFN2 2.381 3.811 2.057 3.409 0 0 0 
SMAD3 1.235 1.206 1.921 1.875 0 3.695 3.4055 
SMIM5 0 0 0 0 0 3.638 3.5235 
SMIM6 0 0.027 0.296 0.256 0 3.689 3.5365 
SNAR-E 0 0 0 0 0 3.5265 3.46 
SNORA52 3.652 3.519 1.711 2.158 0 1.8605 1.761 
SNRNP35 2.964 3.157 2.319 3.293 0.014 1.4695 1.2415 
SOCS3 1.542 2.541 1.914 3.162 0.662 2.499 2.6945 
SPACA4 1.24 1.469 0.784 1.607 0 3.5865 3.3715 
SPHK2 1.658 2.131 1.146 1.884 0 3.367 3.3025 
ST6GAL1 3.009 3.593 3.023 2.83 0 0.684 0.2845 
SULT2B1 0.644 0.603 0.199 1.145 0 3.968 3.8135 
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SYK 1.535 3.545 2.991 3.575 0 0.945 0.7315 
SYNJ2 3.049 3.515 1.844 2.089 0 2.55 1.8535 
TAGLN2 2.45 2.304 2.309 2.473 0 3.033 3.542 
TANK 1.808 3.528 1.457 1.104 0.594 2.368 1.9025 
TEC 3.44 3.953 2.71 3.579 0 1.1565 1.686 
TFEB 2.443 2.668 1.567 1.989 0 3.4555 3.4055 
TGFB1 3.797 3.099 2.846 2.793 0 1.0155 0.707 
TGFBI 2.365 3.847 1.462 1.411 0.543 2.6185 2.4415 
TGM2 3.658 3.647 4.156 2.886 0.172 3.179 2.8655 
THEMIS2 2.897 3.848 1.854 3.383 0.067 1.092 1.078 
TICAM1 2.225 3.758 2.829 2.435 0.12 1.0705 1.599 
TMCO6 2.486 3.059 1.999 3.309 0.602 2.3785 2.3185 
TMEM154 4.251 3.55 2.661 2.319 0 0.3375 0.461 
TMEM185B 1.121 1.471 0.434 1.121 0 2.7235 3.539 
TMEM72 1.468 2.243 3.042 4.138 0 1.1515 0.7675 
TNFAIP2 2.33 2.221 2.022 1.991 0 3.947 3.645 
TREML2 2.112 4.558 1.575 3.257 0 1.078 0.586 
TRIM31 0.661 0.79 0.646 0.648 0 4.728 3.652 
TRIM40 0.514 0.691 0.503 1.091 0 4.378 3.4775 
TRNFRSF1B 3.183 3.911 4.32 3.843 0 0.891 1.416 
TRP53COR1 1.885 2.604 2.883 3.262 0 0 0 
TSKU 0.947 1.673 0.72 0.166 0.411 2.9435 3.674 
TXNDC2 2.661 4.012 2.997 3.222 0 2.0835 2.202 
UBALD1 3.179 4.162 3.048 3.167 0 1.3075 1.29 
VASP 1.955 2.23 1.97 3.204 0 2.4965 3.0555 
ZFYVE19 0.956 0.189 0.152 0.754 0 2.93 3.034 
ZNF524 0.261 1.821 0.811 1.132 0 3.1485 3.296 
ZNF598 1.289 0.905 1.344 1.662 0 2.867 3.1385 
ZNRF1 1.883 1.862 4.023 3.055 0 1.0075 1.01 
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5031414D18RIK 3.344 4.637 1.512 2.904 0 0 0 
A.2  Table of genes associated with chemotherapy resistance. 
A systematic review was completed to identify a list of genes associated with chemotherapy 
resistance. The first column includes the genes listed in alphabetical order. The second and third 
column include the type of associated resistance and the reference for each article describing the 
resistance. For genes with multiple types of resistance are labelled multidrug resistance and those 
that do not state the exact chemotherapy drug are labelled chemotherapy resistance. 
Gene Type of resistance Reference 
ABCB1 Anthracyclines [323] 
ABCC1 Anthracyclines [323] 
ABCC3 Anthracyclines [323] 
ABCC5 Anthracyclines [323] 
ABCC9 Anthracyclines [323] 
ABCG1 Multidrug Resistance [324] 
ABCG2 Anthracyclines [323] 
ADD3 Multidrug Resistance [325] 
AGER Chemotherapy Resistance [326] 
AKAP11 Multidrug Resistance [325] 
AKR1A1 Anthracyclines [323] 
AKT1 Cisplatin [327] 
AOX1 Multidrug Resistance [325] 
APAF1 Cisplatin [328] 
APOBEC3 Tamoxifen [329] 
ASK1 Platinum [330] 
ATP7A Cisplatin [331] 
ATP7B Platinum [332] 
BCL2 Platinum [330] 
BIRC2 Multidrug Resistance [325] 
BIRC3 Chemotherapy Resistance [333] 





BRCA1 Cisplatin [335] 
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BRCA2 Cisplatin [335] 
CAT Multidrug Resistance [325] 
CAV1 Doxorubicin [336] 
 
Gemcitabine [336] 
CBR1 Anthracyclines [323] 
CCNB2 Multidrug Resistance [325] 
CDK2 Multidrug Resistance [325] 
CDKN1A Multidrug Resistance [337] 
CDKN2A Multidrug Resistance [337] 
CHEK1 Gemcitabine [338] 
CHEK2 Gemcitabine [338] 
COL1A1 Sorafenib [339] 
 
Cisplatin [339] 
COX17 Platinum [340] 
CTH Multidrug Resistance [325] 
CXCL12 Gemcitabine [341] 
CXCL5 Chemotherapy Resistance [342] 
DDIT4 5-fluorouracil [343] 
DKK3 Multidrug Resistance [325] 
DRAP1 Multidrug Resistance [325] 
DUSP4 Multidrug Resistance [325] 
EGFR Multidrug Resistance [344] 
EMP2 Multidrug Resistance [325] 





ERBB3 Multidrug Resistance [346] 
ERCC1 Cisplatin [347] 
ERCC2 Cisplatin [348] 
ERK1 Platinum [330] 
ERK2 Platinum [330] 
FAM129A Multidrug Resistance [349] 
FANCL Cisplatin [350] 
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FBLN1 Anthracyclines [351] 
 
Taxanes [351] 
FBXO32 Multidrug Resistance [337] 
FDFT1 Multidrug Resistance [325] 
FPGS Methotrexate [352] 
FYN Multidrug Resistance [325] 
GPSM3 Multidrug Resistance [325] 
HMCN1 Multidrug Resistance [353] 
HMGA2 Multidrug Resistance [325] 
HMGN3 Multidrug Resistance [325] 
HSP90 Cisplatin [354] 
IGFBP7 Multidrug Resistance [325] 
IL24 Multidrug Resistance [337] 
JNK Cisplatin [355] 
KRAS Cisplatin [356] 
LAMC1 Multidrug Resistance [357] 
LTBP2 Multidrug Resistance [325] 
MCAM Multidrug Resistance [358] 
MEST Multidrug Resistance [325] 
MLH1 Cisplatin [338] 
 
Carboplatin [338] 
MMP13 Chemotherapy Resistance [359] 
MMP9 Multidrug Resistance [360] 
MMRN2 Chemotherapy Resistance [361] 





MXI1 Multidrug Resistance [325] 
NFKB1 Cisplatin [364] 





NMT2 Multidrug Resistance [325] 
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NOS3 Anthracyclines [323] 
NQO1 Anthracyclines [323] 
NUDT4 Multidrug Resistance [325] 
P83/RHOBTB2 Chemotherapy Resistance [366] 
PAR4 Chemotherapy Resistance [367] 
PDCD4 Multidrug Resistance [337] 
PTEN Cisplatin [368] 
RAB20 Multidrug Resistance [325] 





RAF1 Doxorubicin [370] 
 
Etoposide [370] 
RASSF1 Multidrug Resistance [337] 
RRM1 Gemcitabine [371] 
S100PBP Chemotherapy Resistance [326] 
SCD1 Chemotherapy Resistance [372] 
SERPINB2 Multidrug Resistance [325] 
SERPINE1 Multidrug Resistance [325] 
SKP2 Paclitaxel [373] 
SLC22A1 Cisplatin [374] 
SLC22A12 Anthracyclines [323] 





SLC28A3 Anthracyclines [323] 
SLC31A2 Chemotherapy Resistance [376] 
SLCO1B3 Docetaxel [377] 
SRC Anthracyclines [378] 
SRD5A1 Multidrug Resistance [325] 




Chemotherapy Resistance [381] 
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SULF1 Multidrug Resistance [382] 
SULT1A1 Tamoxifen [352] 
SULT2B1 Anthracyclines [323] 
TFPI2/RAGE 5-fluorouracil [383] 
TIP60 Doxorubicin [334] 
TMEM97 Multidrug Resistance [384] 
TOP1 Gemcitabine [385] 
 
Platinum [385] 
TOP2A Multidrug Resistance [386] 





TP73 Multidrug Resistance [337] 
TRIM2 Tamoxifen [388] 
TUBB3 Gemcitabine [385] 
 
Platinum [385] 
TYMP 5-fluorouracil [352] 
UCHL1 Multidrug Resistance [325] 
WWOX Multidrug Resistance [337] 





XPA Cisplatin [348] 
XRCC1 Cisplatin [348] 
ZFP36L2 Multidrug Resistance [325] 
 
- 233 - 
A.3  LXRα binding in the promotor of genes associated with 
chemotherapy resistance. 
 
LXR recruitment to the promotors of genes associated with chemotherapy resistance.  
Images of LXR binding in gene promotor regions were generated using the Cistrome database [1]. 
LXRα binding was assessed in a ChIP-Seq mouse macrophage dataset provided by Oishi, Y., et al, 2017 
[2] with no treatment (ID: 72545) and after GW3965 treatment for 24 h (ID: 72544). These datasets 
were selected out of the available 11 datasets as these were the only datasets that had paired 
datasets comparing no treatment and treatment with an LXR agonist. Genes of interest were then 
individually assessed for LXRα binding in the gene promotor regions. Each gene was visualised using 
the UCSC genome browser function in Cistrome, aligned and cropped to only include the gene of 
interest and 10 kb immediately upstream of the gene sequence representing the promotor region. 
Datasets were presented showing no treatment sequences placed above the LXR agonist treatment 
sequences for direct comparison. Arrows are used to suggest/predict areas of LXR binding (the largest 
peak within the promotor region that shows an increase with the LXR treatment compared to no 
treatment). 
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Abstract: Interventions that alter cholesterol have differential impacts on hormone 
receptor positive and negative-breast cancer risk and prognosis. This implies 
differential regulation or response to cholesterol within different breast cancer 
subtypes. We evaluated differences in side-chain hydroxycholesterol and liver X 
nuclear receptor signalling between Oestrogen Receptor (ER)-positive and ER-
negative breast cancers and cell lines. Cell line models of ER-positive and ER-
negative disease were treated with Liver X Receptor (LXR) ligands and 
transcriptional activity assessed using luciferase reporters, qPCR and MTT. Publicly 
available datasets were mined to identify differences between ER-negative and ER-
positive tumours and siRNA was used to suppress candidate regulators. Compared 
to ER-positive breast cancer, ER-negative breast cancer cells were highly responsive 
to LXR agonists. In primary disease and cell lines LXRA expression was strongly 
correlated with its target genes in ER-negative but not ER-positive disease. 
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Expression of LXR’s corepressors (NCOR1, NCOR2 and LCOR) was significantly 
higher in ER-positive disease relative to ER-negative, and their knock-down 
equalized sensitivity to ligand between subtypes in reporter, gene expression and 
viability assays. Our data support further evaluation of dietary and pharmacological 
targeting of cholesterol metabolism as an adjunct to existing therapies for ER-
negative and ER-positive breast cancer patients. 
Keywords: cholesterol; hydroxycholesterol; breast cancer; LXR; oestrogen 
receptor status; corepressors 
 
1. Introduction 
Cholesterol is predominantly synthesized de novo in the liver with lesser amounts 
obtained from the diet. Dietary intake, de novo synthesis, metabolism and excretion, 
combine to balance circulating cholesterol levels ensuring extra-hepatic tissues are 
sufficiently equipped to produce a range of metabolites including steroid hormones, 
bile acids and seco-steroids. Side-chain hydroxycholesterols (scOHCs) are typically 
formed through hydroxylation of cholesterol by specialized members of the 
Cytochrome P450 family, which bind and activate the Liver X Receptor-alpha (LXRA; 
gene name NR1H3) and beta (LXRB; gene name NR1H2) transcription factors [1,2]. 
LXR target genes are typically involved in cholesterol and fatty acid metabolism. In 
normal tissue, expression of LXRA is inducible in the liver, intestine, macrophages 
and adipocytes, whilst expression of LXRB is more ubiquitous. As well as differences 
in expression of LXRA and LXRB, local concentrations of the scOHCs differ 
Nutrients 2019, 11, 2618; doi:10.3390/nu11112618 www.mdpi.com/journal/nutrients 
considerably between tissues, and relative to each other, sometimes by as much as 
1000-fold [3] and variance can also depend on disease status [4]. Furthermore, the 
different scOHCs have varying capacities to activate LXR-mediated transcription, 
imposing an element of selective modulation onto signalling. 26-OHC (commonly 
referred to as 27-OHC [5]) for example is the most abundant scOHC, but is a relatively 
weak LXR agonist [1,6]. Moreover, there is little difference in scOHC concentrations 
between breast cancer subtypes [7]. 
Transcriptional activity of the LXRs, like the other members of the Nuclear Receptor 
(NR) superfamily, is not just regulated by ligand bioavailability; chromatin 
environment, cross-talk and competition for response element binding [8] with other 
NRs, as well as cell- and tissue-type dependent expression of cofactors are also key 
mediators. For example, the expression of corepressors such as NCOR1 and 
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NCOR2/SMRT determine how several cancers respond to nutritive ligands [9–11]. 
LXRA has a 100-fold higher binding affinity than LXRB for the corepressors NCOR1 
and NCOR2 [12] and deregulation of these corepressors allows prostate and bladder 
cancer cells to evade cancer suppressive signals of Vitamin D (through repression of 
Vitamin D Receptor (VDR)) and omega-3 fatty acids (through repression of 
peroxisome proliferator-activated receptors (PPARs)) by impairing sensitivity to ligand 
[10,11,13]. Simply measuring scOHC concentrations does not sufficiently determine 
their contributions to LXR signalling; concentration and activation potential should be 
assessed in combination. 
In cancer, the function of the scOHC-LXR signalling axis appears site specific as both 
tumour suppressive and promoting roles have been described. For example, scOHC-
LXR signalling impairs invasion and angiogenesis in melanoma [14] and is anti-
proliferative in lung cancer in vivo [15], as it is in almost every cancer cell line studied 
in vitro [13]. In Oestrogen Receptor (ER)-positive Breast Cancer (BCa) however 26-
OHC promotes growth in vivo via ER-alpha [4,16]. In ER-negative BCa 26-OHC drives 
the epithelial-to-mesenchymal transition [16] and promotes colonization of metastatic 
sites in through mobilization of γδ-T cells [17]. Furthermore, concentrations of several 
scOHCs are altered in BCa relative to normal tissue [4], and 25-OHC is elevated in 
the circulation of BCa patients who have relapsed compared to those with primary 
disease [18]. 
We recently evaluated LXR ligand bio-availability in a small BCa cohort [7] and found 
large inter tumoural heterogeneity in oxysterol content, but no difference in ligand 
concentrations between tumour subtypes. Systematic evaluation of scOHC 
bioavailability and activation potential, coupled 
with analysis of NR cofactor expression between BCa subtypes has not been 
performed previously. Given the prognostic and therapeutic value of stratifying BCa 
by hormone receptor status, further delineation of the pathways that are altered 
between these subtypes, such as scOHC-LXR signalling, may help advance 
understanding about the emerging roles of cholesterol metabolism in cancer and 
improve outcomes for patients.  
2. Materials and Methods 
2.1. Cell Culture and Transfections 
MCF7, T47D, MDA-MB-468 and MDA-MB-231 cell lines were originally obtained from 
ATCC. All cells were maintained at 37 ◦C with 5% CO2 in a humidified incubator and 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher, Altrincham, 
UK Cat: 31966047) supplemented with 10% fetal calf serum (FCS) (Thermo Fisher, 
UK, Cat: 11560636). Routine passaging of cells was completed every 3–4 days, and 
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seeded at 1 × 106 live cells per T75 tissue culture treated flask (Nunc, Thermo Fisher, 
UK, Cat: 10364131) to maintain confluence between 20% and 80%. 
For transfection with siRNA, cells were plated in 6-well plates (MDA-MB-468 cells: 1.5 
× 105 cells/well; MCF7 cells: 1 × 105 cells/well) and incubated overnight. Lipofectamine 
RNAiMAX (Thermo Fisher, Cat: 13778030), siNCOR1 (Cat: SR306392), siNCOR2 
(Cat: SR306393) or siLCOR (Cat: SR313532), or the scrambled siRNA (Cat: 
SR30004) were diluted in OptiMeM (Thermo Fisher, Cat: 31985062), combined 
according to manufacturer’s instructions, and added to the cells at a final 
concentration of 30 nM. The cells were incubated for 20 h and the media was changed 
for fresh DMEM. Cells were plated for luciferase or qPCR assays after 36 h, and for 
MTT at 24 h, knockdown was confirmed at mRNA level at 36 h. 
2.2. Drugs and Reagents 
 Drugs stocks were stored at −20 ◦C as follows: GSK2033 (gift from Dr Carolyn 
Cummings—University of Toronto, Toronto, ON, Canada) at 20 mM diluted in DMSO. 
GW3965 (Cayman, Ann Arbor, MI, USA, Cat: 71810) at 100 mM diluted in DMSO. 
Hydroxycholesterols were sourced from Avanti Polar Lipids (Alabaster, AL, USA): 7-
ketocholesterol (7-KETO) (Cat: 700015), 22R-hydroxycholesterol (22-OHC) (Cat: 
700058), 24S-hydroxycholesterol (24-OHC) (Cat: 700071), 25-hydroxycholesterol 
(25-OHC) (Cat: 700019), 26-hydroxycholesterol (26-OHC) (Cat: 700021) and 
24(R/S),25-epoxycholesterol (24,25-EC) (Cat: 700037). Stocks of 10 mM were 
prepared in nitrogen flushed ethanol (NFE) to prevent auto-oxidation. Puromycin 
Hydrochloride (Santa Cruz, CA, USA; Dallas, TX, USA, Cat: sc-108071) stocks diluted 
in Nuclease Free Water and stored as 25 mg/mL aliquots. 
2.3. Luciferase Reporter Assay 
This method has been reported previously [19]. Briefly, 3 × 104 cells were plated in 
each well of a 24-well plate and incubated overnight. Cignal Lentiviral particles (LXRA) 
were purchased from Qiagen, Manchester, UK (Cat: CLS-7041L) and transduced into 
the cells using 8 µg/mL SureEntry transduction reagent at MOI at manufacturer’s 
recommendations. After 18 h the particles were removed and fresh DMEM 
supplemented with 0.1 mM Non Essential Amino Acids (Thermo Fisher, Cat: 
12084947) and 100 U/mL penicillin and 100 µg/mL streptomycin (Thermo Fisher, Cat: 
10378016) were added to the cells. Cells were passaged and puromycin used to 
select successfully transduced cells. For luciferase quantitation, 30,000 transfected 
cells/well were seeded into 24-well plates, and allowed to attach under normal culture 
conditions for 8 h. Cultures were treated with ligands, inhibitors or vehicle control as 
indicated in figure legends for 16 h. Luciferase assays were carried out by transferring 
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cell lysates to white-walled 96-well plates and luminescence was assessed using the 
Tecan Spark 10M. 
2.4. qPCR 
Cells were plated in 6-well plates (2.5 × 105 cells/well) and incubated overnight before 
treatment with Vehicle Control (ETOH) or LXRA ligands. mRNA analysis was 
performed as described previously [20,21]. Briefly, Promega ReliaprepTM RNA Cell 
Miniprep System was used for the RNA extraction (Promega, Southampton, UK, Cat: 
#Z6012), and product guidelines were followed using approximately 5 × 105 cells. On 
column DNase 1 digestion was performed and RNA was eluted in 30 µL nuclease free 
water. RNA was stored at −80 ◦C. GoScriptTM Reverse Transcription kit (Promega, UK, 
Cat: A5003) was used for the cDNA synthesis, and product guidelines followed 
(TM316), using 500 ng total RNA/reaction and 0.5 µg/µL random primers. cDNA 
produced was then diluted 1 in 5 in nuclease free water and stored at −20 ◦C. For gene 
expression analysis, Taqman Fast Advanced Mastermix (Thermo Fisher, Paisley, UK, 
Cat: 4444557) was used with Taqman assays (Thermo Fisher, Paisley, UK, Cat: 
4331182) on a QuantStudio Flex 7 (Applied Biosystems Life Tech, Thermo Fisher, 
Paisley, UK) in 384-well plates. Taqman assays and Mastermix were stored at −20 ◦C. 
Taqman ID’s used were HPRT1: Hs02800695_m1; ABCA1: Hs01059137_m1; APOE: 
Hs00171168_m1; DOK2: Hs00929587_m1; LCP2: Hs01092638_m1; TNFRSF1B: 
Hs00961750_m1; LCOR: Hs00287120_m1; NCOR1: Hs01094540_m1; NCOR2: 
Hs00196955_m1. Gene expression was analysed using the ∆∆cT method and 
normalised to HPRT1. HPRT1 was confirmed as the most suitable housekeeping gene 
from a panel of 18 housekeeping genes tested in MCF7 and MDA-MB-468 cell lines 
treated with a panel of sterols at various time points and in various concentrations 
(Thermo Fisher, Paisley, UK, Cat: 4367563). 
2.5. MTT Assays 
The human BCa cell lines (MCF7, MDA-MB-468) were cultured in DMEM (glucose 4.5 
g/L) supplemented with 10% fetal bovine serum (FBS) at 37 ◦C in a humidified 5% 
CO2 incubator. Seeding density was determined empirically for each cell line and for 
each time point. Then, 2 × 104 cells/well for MDA-MB-468 cell line and 3 × 104 cells/well 
for MCF7 were seeded in 96-well plates. After overnight incubation, media was 
removed and replaced with the fresh media (200 µL) with vehicle control (0.1% ethanol 
flushed with N2) or 10 µM, or 100 µM 26-OHC (in vehicle) for indicated time points. 
Cells were washed with PBS and 90 µL phenol-red free DMEM was added with 10 µL 
of diluted MTT reagent at 37 ◦C for 4 h incubation. Media was removed and 100 µL of 
DMSO was added, absorbance was read using a CLARIOstar plate reader at 540 nm. 
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2.6. The Cancer Genome Atlas Gene Expression Analysis 
To establish the possible regulators of LXR activity, cofactors were included if they 
physically interacted with LXR in a previously performed NR/cofactor scan [22], and 
if the interaction had been reported in at least one other study. Based on these criteria, 
a total of six coactivators and three corepressors were selected for further analysis. 
mRNA expression of was assessed using the array-median centered gene expression 
obtained from http://cBioportal.org [23], deposited by The Cancer Genome Atlas 
(TCGA) BCa dataset [24]. Data collection and analysis was performed as described 
previously [25,26]. Expression data were obtained for 81 Basal (ER-/PR-/Her2-) and 
234 Luminal A (ER+/PR+/Her2-) tumours and were compared using two-tailed Mann–
Whitney U tests using Bonferroni correction for multiple testing where indicated [27]. 
2.7. Transcription Factor-Target Gene Correlation Analysis 
NR1H3/LXRA binding to gene promoters was assessed in all available ChIP-Seq 
datasets deposited into the http://cistrome.org portal [28]. LXRA binding scores were 
obtained from seven ChIP-Seq datasets, from three publications that had deposited 
LXRA binding information for mouse monocytes either untreated or exposed to LXRA 
agonist GW3965 [29], human colorectal cancer cells treated with GW3965 at 2 or 48 
h [30] (both time points had duplicate ChIP-Seq datasets associated with them, which 
were averaged to give a 2 h list and a 48 h list), and untreated human adipocytes [31]. 
Processed ChIP-Seq data were accessed and the 100 genes with the highest LXRA 
binding scores in each of the seven datasets were included for further analysis. If a 
gene was present in the top 100 bound genes in only one dataset it was excluded 
from further analysis (resulting in 148 genes appearing in multiple lists). Eleven genes 
(from mouse datasets) were excluded as they did not have human orthologs, and a 
further 26 were excluded as they were not expressed in the TCGA dataset resulting 
in a 111 gene list. To this list, 24 canonical LXR targets identified from the literature 
were included in analysis, even if they did not necessarily reach the cut-off criteria 
outlined above. The entire list of 135 genes was then assessed for Pearson correlation 
with NR1H3/LXRA in the 81 ER-negative and 234 ER-positive breast tumours from 
TCGA [24]. The Pearson’s correlation coefficient was calculated between each of the 
135 genes and LXRA and the resulting p values were corrected for False Discovery 
Rate (FDR). Lastly, Fisher’s exact test was used by building a contingency table to 
test the null hypothesis that the number of genes with FDR of 1% is the same in the 
two diseases. Flow diagram of gene selection and exclusion methodology can be 
found in Supplementary Materials (Figure S1). 
3. Results 
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3.1. LXR Activation Potential Is Retained in ER-Negative Disease but Dampened in 
ER-Positive Disease 
Previous studies examining differences in LXR signalling across BCa ER-subtypes 
have reported strong anti-proliferative actions of synthetic LXR agonists in ER-positive 
cell lines, but enhanced transcription from canonical gene loci such as ABCA1 and 
SREBP1c in ER-negative cell lines [32]. To explore differences in how breast cancer 
cells respond to LXR stimulation by synthetic and endogenous ligands, we generated 
LXRA-regulated luciferase reporter cell lines representing ER-negative (MDA-MB-
468, MDA-MB-231) and ER-positive (MCF7, T47D) BCa, as well as a control liver cell 
line (HEPG2). Dose-response experiments were performed with synthetic LXR 
ligands (agonists: T0901317 and GW3965 [33]; inhibitor: GSK2033 [34]). At 
nanomolar and micromolar concentrations in MDA-MB-468 cell culture, GW3965 
treatment resulted in up to a 25-fold induction of LXR driven luciferase activity and 
T0901317 resulted in up to 10-fold induction (Figure 1a). When attempting to stimulate 
LXR-mediated transcription in the ER-positive MCF7 cell line activation was restricted 
to less than 5-fold above vehicle control for both synthetic agonists (Figure 1a). We 
repeated GW3965 treatment in additional ER-positive (T47D) and ER-negative (MDA-
MB-231) lines confirming our observation that ER-negative cells were significantly 
more responsive to LXR agonist than ER-positive cells in LXR-reporter assay (one-
tailed students t-test: p < 0.0001 (Figure S2a)). GSK2033 suppressed basal LXR 
dependent transactivation similarly in both MCF7 and MDA-MB-468 cell cultures 
(Figure 1a). We then applied a panel of endogenous LXR ligands (7-KETO, 22-OHC, 
24-OHC, 25-OHC, 26-OHC and 24,25-EC) and found LXR was activated in both cell 
lines by all ligands but to varying amounts. Similarly to the synthetic ligands, activation 
was more robust in MDA-MB-468 compared to MCF7 cells, across all ligands and all 
concentrations tested (Figure 1b). In the MDA-MB-468 reporter cells, 24,25-EC 
induced the greatest fold change in LXR dependent luciferase expression (×40-fold 
increase), followed by 22-OHC (×19-fold) and 24-OHC (×18-fold). Induction by 26-
OHC (×9-fold), 25-OHC (×6-fold) and 7-KETO (×5-fold) were relatively attenuated 
(Figure 1b). In contrast, the maximum induction by any scOHC observed in MCF7 
cells was <5-fold. As control experiments we first generated a stable luciferase 
reporter liver cell line HEPG2 and activation by agonists and repression by antagonists 
in HEPG2 was comparable to that observed in MDA-MB-468 cells (Figure S2b). In the 
absence of LXRA (following siRNA knockdown) basal luciferase activity was lowered 
and neither 26-OHC (Figure S2c) or 24,25-OHC (Figure S2d) treatment elicited any 
induction of luciferase activity, demonstrating the dependence on LXRA. As scOHC-
LXR signalling is known to be anti-proliferative and pro-apoptotic in an array of cell 
lines, we applied MTT assays to test whether ER-negative MDA-MB-468 cells were 
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more sensitive to ligands than their ER-positive MCF7 counterparts in an alternative 
assay. MCF7 cells were significantly more resistant than MDA-MB-468 cells to 
treatment with 24-OHC (non-linear regression comparison of fits: non-converged for 
MCF7), 25-OHC (p < 0.0001) and 26-OHC (p < 0.0001) (Figure 1c). 
To confirm the luciferase LXRA reporter was representative of regulation within a 
normal chromosomal context, we next examined expression at two endogenous 
canonical LXR target loci, ABCA1 [35] and APOE [36]. Vehicle control, GW3965, 26-
OHC (the most abundant scOHC in breast tumour tissue [7]) or 24,25-EC (the scOHC 
that elicited the greatest fold induction in reporter cells (Figure 1b)) were added to 
MDA-MB-468 or MCF7 cells for 4 or 16 h and changes to ABCA1 and APOE expression 
determined. At 4 h ABCA1 was induced in both cell lines by GW3965 and 24,25-EC but 
not by 26-OHC in MCF7 cells (Figure 2a). Induction was greater after treatment in 
MDA-MB-468 compared to MCF7 cells (multiple t-tests with FDR < 1% and Holm–
Sidak correction: GW3965 p = 0.0097; 26-OHC p = 0.0092; 24,25-EC p = 0.0086; 
Figure 2a). GW3965, but not other agonists, induced APOE induction at 4 h in MDA-
MB-468 cells (Figure 2b). At 16 h ABCA1 was induced by all ligands in both cell lines, 
but again, to a significantly greater level in MDA-MB-468 cells (multiple t-tests with 
FDR < 1% and Holm–Sidak correction: GW3965 p < 0.01; 26-OHC p < 0.01; 24,25-EC 
p < 0.01; Figure 2c). At 16 h APOE was also induced by all ligands in MDA-MB-468 
cells but interestingly, was repressed by 26-OHC and 24,25-EC (but not synthetic 
ligand) in MCF7 cells (compare columns 3 and 4 against vehicle; Figure 2d), and by 
24,25-EC at 4 h (multiple t-tests with FDR < 1% and Holm–Sidak correction: p = 0.003). 
We repeated GW3965 treatment in second ER-positive (T47D) and ER-negative 
(MDA-MB-231) lines confirming our observations that ABCA1 (two-way ANOVA: p < 
0.05 (Figure S3a)) and APOE (two-way ANOVA: p < 0.001 (Figure S3b)), were 
significantly more induced in ER-negative cells compared to the ER-positive ones. 
Accumulation of ABCA1 mRNA was LXR dependent, as the LXR inhibitor GSK2033 
abrogated the scOHC response in both cell lines (Figure S4a) and knockdown of LXRA 
impaired ABCA1 expression (Figure S4b). From these findings we concluded that at 
the transcriptional level, ER-negative cells are more responsive to LXR stimulation 
than their ER-positive counterparts. 
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 Figure 1. Synthetic ligands and side-chain hydroxycholesterols (scOHCs) activate Liver X 
Receptor-alpha (LXRA) dependent transcription in Oestrogen Receptor (ER)-negative but not ER-
positive breast cancer cell culture. ER-negative (MDA-MB-468) and ER-positive (MCF7) cell lines were 
stably transfected with LXRA-Luciferase reporter constructs and treated with synthetic LXR agonists or 
the antagonist GSK2033 (a), or endogenous LXR ligands (b) at indicted concentrations. The anti-
proliferative effects of scOHC over 48 h was assessed by MTT in MDA-MB-468 and MCF7 cells (c) 
with EC50 given in µM. Data are presented as means of 2–4 independent replicates with SEM. 
We next set out to establish if the enhanced LXR transcriptional activity observed in 
cell line models extended to primary tumours. To test this, we examined whether 
expression of NR1H3/LXRA or NR1H2/LXRB correlated with expression of canonical LXR 
target genes (ABCA1 and APOE) in 81 ER-negative or 234 ER-positive primary breast 
tumours (obtained from TCGA dataset [24]). ABCA1 correlated with LXRA (Pearson’s 
correlation: R = 0.502: p < 0.0001) in ER-negative but not in ER-positive tumours 
(Figure 2e). APOE correlated with LXRA in both subtypes (Figure 2f), but the correlation 
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was much weaker in ER-positive than in ER-negative disease (Pearson correlation: 
ER-positive: R = 0.27, p < 0.0001; ER-negative: R = 0.65: p < 0.0001). Both ABCA1 and 
APOE were assessed for correlation with NR1H2/LXRB and whilst APOE weakly 
correlated with NR1H2/LXRB in ER-positive tumours (R = 0.25) it was not correlated in 
ER-negative tumours; ABCA1 was not correlated with NR1H2/LXRB in either tumour type 
(Figure S5). From these observations we concluded that ER-status was inversely 
associated with the ability of LXR to induce canonical target gene expression. 
 
Figure 2. Ligand dependent transcriptional output of LXR target genes is enhanced in ER-negative 
relative to ER-positive breast cancer cell cultures. ER-negative (MDA-MB-468) and ER-positive (MCF7) 
cell lines were treated with a panel of ligands (Vehicle control, GW3965 (1 µM), 26-OHC or 24,25-EC 
(both 10 µM)) for 4 (a,b) and 16 h (c,d). Expression of the canonical LXR target genes ABCA1 (a,c) and 
APOE (b,d) were assessed by qPCR using ∆∆cT (normalised to HPRT1). Statistical analysis was 
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established using multiple t-tests and data are derived from three independent replicates with SEM. 
mRNA-Seq data from TGCA for 81 ER-negative and 234 Luminal A tumours was assessed using 
Pearson correlation between NR1H3/LXRA and ABCA1 (e) or APOE (f). * p < 0.05, ** p < 0.01, *** p < 
0.001. Lines represent linear regression. 
3.2. Expression of LXRA Correlates with Expression of Its Target Genes in Primary 
ER-Negative Tumours but not in ER-Positive Tumours 
We then set out to test if expression of a wider and unbiased set of LXR target genes 
correlated with NR1H3/LXRA or NR1H2/LXRB expression in ER-positive or ER-negative 
tumours. A list of LXRA target genes was generated ‘agnostically’ by repeated 
interrogation of publicly available ChIP-Seq data sets as described above (full gene 
list in ST1 and example promoters shown in Figure S6 [29]) using cistrome.org [28]. 
Then, we assessed correlation of expression of each of these LXRA bound gene 
targets with NR1H3/LXRA and NR1H2/LXRB expression in publicly available RNA-Seq 
datasets from TCGA, as previously for ABCA1 and APOE. In ER-negative tumours 
NR1H3/LXRA significantly correlated with 48/135 genes (Figure 3a), compared to 8/135 
in ER-positive tumours (Figure 3b). This was a statistically significant difference in the 
number of correlating genes (Fisher’s exact test: p < 0.0001). Three genes that had 
not previously been validated as bona fide LXR target genes (TNFRSF1B, LCP2 and 
DOK2) were selected from the top 10 strongest correlations, to test the in silico 
prediction that these genes should be inducible in MDA-MB-468 cells, but not (or less 
so) in MCF7 cells. qPCR analysis on cells exposed for 16 h to 1 µM GW3965 revealed 
that all three genes were induced to significantly greater extent in the MDA-MB-468 
cell line than in MCF7 (multiple t-tests with FDR < 1% and correction for multiple 
testing with Holm–Sidak: TNFRSF1B p = 0.033; LCP2 p = 0.006; DOK2 p = 0.015) (Figure 
3c). We concluded that retention of LXRA’s transcriptional potential was associated 
with more stringent correlations between LXRA and its target genes in vivo, and more 
robust activation of target genes in vitro. 
3.3. LXR Is Poised for Transcription in ER-Negative BCa but Repressed in ER-
Positive BCa 
The capacity for NRs to regulate their target genes depends on multiple factors, 
including receptor expression, ligand bioavailability and coactivator/corepressor 
expression. As we previously found no difference in ligand concentrations [7], we 
hypothesized that the balance of functional regulators of LXR would be different 
between ER-positive and ER-negative BCa. Expression of relevant genes was 
assessed in 234 ER-positive and 81 ER-negative human tumours from TCGA [24]. 
First, as a control, we show that as expected oestrogen receptor alpha (ESR1) and 
progesterone receptor (PGR) were significantly different between these groups, with 
median expression in ER-negative tumours dramatically lower than in ER-positive 
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tumours (Figure 4a). Next, more interestingly, NR1H3/LXRA was expressed at higher 
levels in ER-negative than in ER-positive tumours (two-tailed Mann–Whitney U test: p 
< 0.01 (Figure 4a)). NR1H2/LXRB was unchanged between subtypes. In the absence of 
agonist, LXRA but not LXRB, is primarily repressed by corepressors NCOR1 and 
NCOR2/SMRT [12] and previous reports demonstrate elevated corepressor 
expression helps prostate [9,10] and bladder [11] cancer cells to evade anti-
proliferative actions of NRs through compromising the ligand response. Both NCOR1 
and NCOR2/SMRT were expressed at significantly lower levels in ER-negative 
tumours compared to ER-positive tumours (two-tailed Mann–Whitney U test: p < 0.001 
(Figure 4b)). Interestingly, expression of LCOR, a corepressor that is recruited to LXR 
upon agonist binding [37], was even more drastically reduced in primary ER-negative 
tumours (two-tailed Mann–Whitney U test: p < 0.0001, (Figure 4b)). We repeated these 
measurements in vitro and found the cell line models recapitulated these features of 
the primary tumours; MDA-MB-468 expressed significantly more LXRA but not LXRB 
(Figure 4c), and significantly less NCOR1, NCOR2/SMRT and LCOR transcript than the 
ER-positive cell line MCF7 (two-tailed student’s t-test: p < 0.0001 for all corepressors 
(Figure 4d)). In a reanalysis of a previously published expression dataset of BCa cell 
lines [38], we found that NCOR2/SMRT and LCOR (but not NCOR1) were also expressed 
at significantly lower levels in ER-negative cell lines generally compared to ER-
positive cell lines (Mann–Whitney-U test: p < 0.05 for NCOR2 and LCOR (Figure S7)). 
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Figure 3. LXRA expression correlates with target genes in ER-negative tumours but not in ER-positive 
BCa. Genes with top LXRA occupancy scores from the seven NR1H3/LXRA ChIP-Seq datasets 
available at cistrome.org were identified along with 24 canonical LXR targets identified from the 
literature, and correlation with LXRA/NR1H3 expression in 81 ER-negative and 234 Luminal A tumours 
from The Cancer Genome Atlas (TCGA) determined. Dotted line denotes false discovery rate corrected 
for multiple testing of expression of 135 genes. Data presented are correlation coefficients against 
correlation significance in ER-negative (a) and ER-positive (b) breast tumours. Genes marked with # 
were validated by qPCR analysis in (c) where ER-negative (MDA-MB-468) and ER-positive (MCF7) cell 
lines were treated with either Vehicle control or GW3965 (1 µM) and expression of three highly 
significant genes (TNFRSF1B, LCP2 and DOK2) determined. Statistical significance was tested for 
using multiple t-tests (corrected with Holm–Sidak) and shows three independent replicates with SEM. * 
p < 0.05, ** p < 0.01. 
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Figure 4. LXRA and its corepressors are differentially expressed between primary ER-negative and ER-
positive breast cancers. RNA-Seq gene expression data (log transformed relative to array median) were 
obtained for 81 ER-negative and 234 Luminal A tumours from TCGA via cBioportal. NR (a) and CoR (b) 
expression was determined in from the TCGA database and in cell lines MDA-MB-468 and MCF7 (c,d). 
Expression of LXR relative to corepressor in the TCGA data is shown in (e). TCGA data are presented as 
log transformed and normalized to array-median with 10–90th centiles (a,c,e). Error bars represent SEM 
of 3–4 independent replicates for cell line analysis (c,d). Statistical analysis was performed using two-tailed 
Mann–Whitney U tests for (a,b), two-tailed student t-test (c,d), or Pearson’s correlation (f,g). ** p < 0.01, *** 
p < 0.001, ns = not significant. 
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Next, we hypothesised that if corepressors were responsible for the dampened 
response to ligand in ER-positive disease, then the ratio of LXR to corepressor should 
predict target gene expression. As expected, we found that the ratio of LXR to all three 
corepressors was significantly higher in ER-negative tumours compared to ER-
positive (Figure 4e; two-way ANOVA: p < 0.0001) supporting the proposal that LXR is 
better able to activate its transcriptional targets in ER-negative disease. Furthermore, 
whilst there was no correlation between LXRA and ABCA1 in the ER-positive cohort 
(Figure 2e), when assessing a correlation between ABCA1 expression and the ratio 
of LXRA/NCOR1 we found a significant positive correlation (Pearson correlation: R = 
0.27, p < 0.0001; Figure 4f). Although the expression of APOE was significantly 
correlated with LXRA alone (Figure 2f), when the corepressors were included in the 
analysis the strength of correlation increased (NCOR1 r = 0.32; NCOR2 r = 0.36; LCOR 
r = 0.44 (Figure 4g)). Surprisingly, the strength of correlation between target gene and 
LXR was not improved by the addition of CoR expression in ER-negative disease ratio 
analysis. As a control we performed the same analyses for LXRB/NR1H2 and found 
no correlation with ABCA1 nor APOE in either subtype with any LXRB/CoR ratio (data 
not shown). These analyses reveal that the ratio of LXR to CoR is strongly correlated 
with target gene expression in all breast cancers analysed. These data are consistent 
with the hypothesis that the relative expression of LXRA to corepressors is the 
determinant of target gene responsiveness to ligand and that differences in this ratio 
between BCa subtypes determines their ability to dynamically respond to changes in 
cholesterol metabolic flux. 
3.4. Removal of Corepressors Equalizes the Response of ER-Negative and ER-
Positive Cell Lines to Ligand 
Since corepressor expression and LXR transcriptional response to ligand appeared 
to be associated, we tested if knock-down of the corepressors in ER-positive cells 
equalized the response to ligand between MCF7 and MDA-MB-468 cells. 
Furthermore, basal expression of target genes should become elevated in knock-
down cells owing to derepression following loss of corepressor activity. To this end we 
impaired NCOR1/NCOR2 or LCOR expression in luciferase reporter MDA-MB-468 
and MCF7 cells using silencing RNA (50%–80% knock-down was observed for all 
corepressors in both cells lines (Figure S8)), followed by treatment with 26-OHC or 
vehicle control. Under control conditions (siCON) LXR activation in response to 26-
OHC was, as expected, significantly higher in MDA-MB-468 than MCF7 cells (two-
tailed student’s t-test: p < 0.0001 (Figure 5a)). Knock-down of NCOR or LCOR 
however, significantly enhanced the transcriptional response to ligand in both cell lines 
(two-way ANOVA: p < 0.05 (Figure 5a)) and led to equivalent transcriptional responses 
to 26-OHC in MCF7 and MDA-MB-468 cells (paired two-tailed t-test: siNCOR p = 0.28; 
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siLCOR p = 0.29 (Figure 5a)) suggesting corepressor expression was an important 
factor in determining the differential response of these two cell types to 26-OHC. This 
observation was recapitulated at the phenotype level, as corepressor knock-down led 
to a significantly enhanced attenuation of cell viability in response to 26-OHC 
treatment (non-linear regression comparison of fits: p < 0.0001 for both cell lines 
(Figure 5b)). When the basal expression of canonical LXR target genes were 
measured, we observed elevated expression of both ABCA1 and APOE with 
corepressor knock-down relative to control treated cells, again in both cell lines (two-
way ANOVA: p < 0.0001 (Figure 5c)). In summary, these knock-down experiments 
support the hypothesis that corepressors are important determinants of the differential 
transcriptional activity of LXR between BCa subtypes. 
 
Figure 5. Corepressors determine differential response of cell lines to 26-OHC. NCOR or LCOR, were 
knocked-down in LXR-luciferase reporter MCF7 and MDA-MB-468 cells and treated with vehicle control 
(VC) or 26-OHC (10 µM) for 16 h (a). Endogenous LXR activity was determined after knockdown for 
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ABCA1 (b) and APOE (c). Response to 26-OHC was assessed following corepressor knockdown by 
MTT (d). One-way ANOVA (a–c) and non-linear regression (d) were used to test for significant 
differences. *** p < 0.001, **** p < 0.0001, amb. = curve fit was ambiguous. 
4. Discussion 
The importance of cholesterol and cholesterol metabolism in breast and other cancers 
is increasingly appreciated. The purpose of this study was to clarify whether the 
activity of LXR was different between ER-positive and ER-negative BCa and identify 
factors that may be responsible for any difference. We established that expression of 
LXR’s regulatory factors were skewed towards a transcriptionally poised state in ER-
negative disease, but towards ligand insensitivity in ER-positive disease. Furthermore, 
LXRA expression positively correlated with that of its target genes in ER-negative 
tumours but not in ER-positive disease. Nuclear corepressor expression was elevated 
in primary ER-positive disease and experimental manipulation in vitro established they 
were critical in suppressing the response to ligand in ER-positive BCa. These data 
indicate that ER-negative tumours are particularly sensitive to elevated cholesterol 
and, given the increasing appreciation of the role of LXR signalling in BCa, potentially 
explain why ER-negative disease is more likely to be altered by cholesterol lowering 
interventions than ER-positive disease [39–41]. 
NR repression is a mechanism to overcome anti-proliferative actions in a range of 
cancer types including prostate [9,10] and bladder [11]. We observed anti-proliferative 
actions of the scOHC-LXR signalling axis, but it was surprising that a permissive anti-
proliferative LXR signalling environment was retained in the more aggressive ER-
negative BCa subtype. In our study we evaluated T47D, MCF7, MDA-MB-468 and 
MDA-MB-231 cells, all of which responded in vitro consistently with in vivo 
observations from primary breast tumours; the ER-positive models had a dampened 
transcriptional response to LXR ligands compared to ER-negative. A previous report 
indicated that ER-positive MCF7 and T47D cells were more sensitive to LXR induced 
G0/G1 arrest than ER-negative MDA-MB-231 cells [32], but at the same time 
indicated, like us, that LXR stimulation led to higher induction of ABCA1 in ER-negative 
cells than in ER-positive ones. This discrepancy in sensitivity between cell cycle and 
direct transcriptional regulation, probably reflects the fact that the synthetic ligands 
used in the cell cycle arrest analysis are not oestrogenic, whereas in our study we 
observe the opposing actions of scOHCs on ER and LXR in ER-positive cells. As we 
demonstrate here, there are differences in NR biology between BCa subtypes beyond 
ER/PR expression, and responsiveness to LXR ligands is influenced by corepressor 
expression and indicates differential cholesterol metabolism between BCa subtypes. 
Retention of LXR signalling in some tumour types suggests a selective advantage that 
compensates for the anti-proliferative actions of the scOHC-LXR axis [32]. The 
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oxysterol signalling axis is emerging as a route through which ER-negative BCa 
metastasis may occur [17]. It would be interesting to determine if the early tumour 
development requires repressed LXR activity so as to impair its anti-proliferative 
actions, and contrast with a return to LXR activation in later stage disease to support 
migration. Consistent with this is the observation that 25-OHC is elevated in the serum 
of breast cancer patients at relapse compared to those with primary disease [18]. 
The differences we observed in LXR activity between subtypes expand on previous 
observations that NR cofactors could usefully serve as therapeutic biomarkers, which 
are targetable through epigenetic drugs (e.g., HDAC inhibitors that impair their 
epigenetic transcription silencing targets and that are recruited by NCOR1 and 
NCOR2) aimed at reinstating pre-cancer gene expression patterns and 
responsiveness. NCOR1 expression, for example, was found to be an independent 
and favourable prognostic marker in a mixed BCa cohort [42]. This may in part be 
explained by Tamoxifen’s dependence on NCOR1 recruitment to and repression of 
ER target genes in ER-positive BCa [43]. In therapy naïve ER-positive tumours our 
data suggest corepressor levels are high, perhaps to prevent LXR (and indeed other 
NRs such as VDR) from driving anti-proliferative transcriptional programs. The impact 
of high corepressor expression on scOHC dependent ER activity may also be 
important. Several scOHCs are oestrogenic and pro-proliferative when liganded with 
ER, indicating that elevated corepressor expression may serve to impede scOHC-ER 
dependent proliferation. 
LCOR is also of therapeutic and prognostic interest as its recruitment to promoters by 
agonists can repress gene expression rather than activate [44]. It is tempting to link 
two of our observations; LCOR levels were significantly higher in ER-positive disease 
(and in MCF7 cells), and agonist treatment led to repression of APOE (Figure 2d) in 
MCF7 cells only. LCOR expression has previously been reported to be associated 
with better survival in BCa patients [37], particularly if nuclear localization is 
considered [45], which presumably reflects its inhibitory actions on oestrogen receptor 
signalling. Further research is required to understand if manipulation of LCOR 
expression can mediate the selective modulation of LXR ligand function, as our 
observations of APOE transcription could suggest. The methodology we employed to 
identify an unbiased panel of LXR target genes, which was then used to test if LXR 
was transcriptionally active or repressed in different tumour types, has potentially 
identified a large set of novel LXR target genes. Our analysis combined ChIP-Seq 
data from multiple cell types with validation of potential targets by assessing 
expression in primary BCa samples and induction analysis in vitro. This approach 
resulted in multiple apparently novel LXR target genes being identified, with three out 
of three validated by qPCR. The first of these LCP2, has been reported as differentially 
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expressed between primary and metastatic colorectal cancer [46] and is a prognostic 
biomarker for colorectal cancer patients [47]. TNFRSF1B expression has been linked to 
increased BCa risk [48,49] and to chemotherapy resistance via enhanced AKT 
signalling and PARP mediated DNA repair [50]. DOK2 has tumour suppression roles 
in several cancer types as it impairs MAPK activation and loss of its expression is 
associated with poor survival in lung adenocarcinoma [51], whilst in BCa greater 
DOK2 expression is associated with significantly longer disease free survival [52]. 
These possible LXR targets, as well as others in ST1 require further evaluation to 
ascertain the extent to which they, through aberrant cholesterol metabolism and LXR 
signalling, may influence tumour biology. 
It is interesting to note that many of lifestyle factors reported by the World Cancer 
Research Fund’s Continuous Update Project [53] that associate with BCa, are body 
composition metrics and nutritional parameters that are directly associated with LDL-
C, a key precursor of scOHCs. LDL-C, Obesity, Waist-Hip-Ratio and Waist 
Circumference are associated with incidence and survival of BCa [54,55] and clinically 
recommended diets/lifestyle changes that lower LDL-C (e.g., high fish-oil and 
carotenoid intake, the Mediterranean Diet, reduced animal calorie intake), protect 
against BCa and relapse, particularly in the hormone receptor negative setting 
[41,53,56,57]. Pharmacological manipulation of LDL-C with lipophilic statins improves 
BCa survivorship [39], specifically reducing early (<4 years) relapse events [40], again, 
a feature typical of ER-negative disease. Our data are consistent with the hypothesis 
that ER-negative tumours are more sensitive to changes in systemic cholesterol flux; 
future work should clarify if dietary or pharmacological suppression of scOHC 
signalling could modify disease prognosis. 
5. Conclusions 
In this current study, scOHC were confirmed as natural LXR agonists in BCa cell lines, 
and we observed that their activity is regulated to a large extent by corepressors. This 
is the first demonstration that transcriptional activation of LXR target genes by 
scOHCs may be dependent on tumour-subtype specific expression of corepressors. 
A combination of mechanistic and clinical trial studies should help confirm the 
relevance of the data described here in people, and would allow further exploration of 
LXR as a potential therapeutic target that links dietary and lifestyle regulation of 
cholesterol metabolism with cancer progression and survival. 
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Abstract: Low fruit and vegetable consumption and high saturated fat consumption 
causes elevated circulating cholesterol and are breast cancer risk factors. During 
cholesterol metabolism, oxysterols form that bind and activate the liver X receptors 
(LXRs). Oxysterols halt breast cancer cell proliferation but enhance metastatic 
colonization, indicating tumour suppressing and promoting roles. Phytosterols and 
phytostanols in plants, like cholesterol in mammals, are essential components of the 
plasma membrane and biochemical precursors, and in human cells can alter LXR 
transcriptional activity. Here, a panel of breast cancer cell lines were treated with four 
dietary plant sterols and a stanol, alone or in combination with oxysterols. LXR 
activation and repression were measured by gene expression and LXR-luciferase 
reporter assays. Oxysterols activated LXR in all cell lines, but surprisingly 
phytosterols failed to modulate LXR activity. However, phytosterols significantly 
inhibited the ability of oxysterols to drive LXR transcription. These data support a role 
for phytosterols in modulating cancer cell behaviour via LXR, and therefore suggest 
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merit in accurate dietary recordings of these molecules in cancer patients during 
treatment and perhaps supplementation to benefit recovery. 
Keywords: phytosterols; liver X receptor; transcription; breast cancer; cholesterol; 
oxysterols 
 
Figure1. Chemical structure of cholesterol, side-chain oxysterols and plant sterols/stanols: (a)cholesterol 
differences from oxysterols 24(S)-OHC, 25-OHC, (25R)26-OHC and 24(S),25-EC are highlighted; (b) 
structures of phytostanol (sitostanol (STAN)) and phytosterols (β-sitosterol (SITO); campesterol 
(CAMP); brassicasterol (BRAS); stigmasterol (STIG) used in this study. Differences in structure with 
cholesterol are shown in red. 
Plant sterols and stanols (PSSs) are analogous to cholesterol in that they are 
synthesized by plants to serve as structural components of plant cell membranes but 
are also functionally analogous to oxysterols as they are precursors in plant hormone 
synthesis. While cholesterol and ergosterol are ubiquitous as the ‘bulk’ sterols in 
mammalian and fungal cells respectively, plant cells contain a wide variety of sterols, 
with over 250 now known to exist [14]. The most abundant phytosterol in the human 
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diet is β-sitosterol (SITO) but several other plant sterol/stanols are commonly 
consumed, either in whole foods or added to common consumer products such as 
margarines and yoghurts, including sitostanol (STAN), campesterol (CAMP), 
brassicasterol (BRAS) and stigmasterol (STIG) [15]. The purpose of why plant cells 
require such an array of PSSs remains unclear, but the range of structural forms 
(Figure 1b), many of which mimic mammalian cholesterol modifications [16], provides 
an exploitable variety of biophysical properties [17] for use in prevention and treatment 
of cholesterol-related diseases in humans. The variety of properties, such as side 
chain branching, length and saturation, and the functions these different biophysical 
properties confer to PSSs in mammalian cell physiology remains far from fully 
understood. 
Given the structural similarities of PSSs relative to mammalian cholesterol and 
oxysterol derivatives (Figure 1), it is not surprising that PSSs can modulate 
mammalian physiology if accumulated in sufficient concentrations. At the cellular 
level, PSSs integrate into the plasma membrane where they alter membrane fluidity, 
lateral pressure on protein complexes, and initiation of signalling cascades [17]. At the 
systemic level, PSSs have important effects on cholesterol metabolism: PSSs inhibit 
activity of key enzymes involved in cholesterol metabolism [18], impair cholesterol 
uptake from the diet [19], abrogate enzymatic conversion of cholesterol into oxysterols 
by competitive inhibition of members of the cytochrome P450 family [20], and are 
ligands of the LXRs [21]. LXRA and LXRB are activated by PSS across the 20–100 
nM range when assessed in cell-free coactivator recruitment assays [22]. In cell-based 
transcription assays, however, PSS treatment has been reported to be ineffective at 
altering transcription [18], or able to induce [21,22], and repress [20,23–25] LXR target 
gene expression. Selective modulation of LXRs by PSSs is therefore dependent on 
cell and tissue, and perhaps disease-specific factors. 
Other than how PSSs can significantly lower circulating cholesterol levels, relatively 
little is known about their biological functions at the molecular level in normal and 
diseased tissues. In vitro and animal research suggests anti-cancer properties for 
PSSs, including inhibition of BCa growth and metastasis [26–28]. These data are 
supported by observational data from free-living individuals (i.e., not part of an 
intervention or trial) consuming diets rich in plant materials [29] and healthy dietary 
patterns associated with high PSSs intake, have lower cancer incidence and improved 
survival [30]. In addition, in clinically controlled intervention trials that have reduced 
saturated fat intake [5,31], lower rates of BCa and/or improved survival was observed 
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in the groups with highest PSS intakes. Improved understanding of the molecular 
pathways that underpin these clinical and epidemiological observations outlined 
above could help in the development and implementation of novel nutritive and 
lifestyle-based cancer prevention and treatment strategies. In this study, we have 
explored whether, at the transcriptional level, PSSs alter transcriptional programs 
exerted by oxysterols through LXR. 
2. Results 
2.1. PSSs Are Poor Transcriptional Activators of LXRA in Breast Cancer Cell 
Cultures 
Given the structural similarities between oxysterols and phytosterols (Figure 1), and 
that previous reports that conflict as to whether PSSs activate or repress LXR, we 
wanted to establish if PSSs regulated the oxysterol-LXR signalling axis in breast 
cancer cells. We selected a range of PSSs with similar structures (with variations in 
branching and saturation) and that are commonly consumed in the diet (STAN, SITO, 
CAMP, BRAS, STIG). Biological activity of PSSs was confirmed by performing cell 
viability assays after 48 h of treatment. Aside from MCF7 cells being completely 
insensitive to BRAS, all PSSs lowered viability in all three cell lines at 100 µM, and to 
varying extents at lower concentrations. MD-MB-468 were the most sensitive line to 
PSSs with viability significantly affected by STAN at 100 nM and above (p < 0.05 
(Figure 2a)), by SITO, CAMP and BRAS at 1 µM and above, and STIG at 10 µM and 
above (Figure 2a). CAMP impaired MDA-MB-231 viability at 100 nM and above, while 
STIG was effective at 1 µM and above, SITO and BRAS at 10 µM and 100 µM, and 
STAN at 100 µM only (Figure 2b). MCF7 viability was impaired at 100 nM and above 
by both SITO and STIG, at 10 µM by STAN and at 100 µM by CAMP. MCF7 were 
insensitive to BRAS over the concentrations tested (Figure 2c). 
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Figure 2. Phytosterols are anti-proliferative in breast cancer cell cultures. The anti-proliferative effects of 
STIG, SITO, CAMP, BRASS and STIG over 48 h was assessed by MTT in (a) MDA-MB-468, (b) MDA-
MB-231, and (c) MCF7 cells. Cell viability relative to vehicle control was measured after treating with 
plant sterols and stanols (PSSs) at indicated concentrations. Data are presented as mean of three 
independent replicates (open circles) with SEM. For assessing changes between individual 
concentrations and vehicle, one-way ANOVA with Holm-Sidak correction for multiple testing and post-
test for linear trend was performed. Significance levels are indicated by € = p < 0.05 and # = p < 0.0001. 
Linear trend was significant for all PSS in all cell lines except for BRAS in MCF7 (ns). 
To determine the capacity of PSSs to drive LXRA specific transcription, a panel of 
stably transduced LXRA-luciferase reporter cell lines representing hormone receptor 
negative (MDA-MB-468, MDA-MB-231) and positive disease (MCF7) were treated 
with individual PSSs over a wide concentration range (from 1 pM to 100 µM) as 
described previously [32]. As a control we first treated cells with either the synthetic 
agonist (GW3965) or antagonist (GSK2033) and found LXR was induced in all cell 
lines by the agonist and repressed by the inhibitor (MDA-MB-468: 20-fold increase, 2-
fold decrease (Figure 3a); MDA-MB-231 20-fold increase, 5-fold decrease (Figure 3b); 
MCF7 4-fold increase, 3-fold decrease (Figure 3c)). In contrast, treatment with PSSs 
led to far more modest responses. With increasing concentration, treatment with some 
PSSs induced linear trends towards repression (MDA-MB-468) or activation (MCF7). 
In MDA-MB-468 cells, increasing concentrations of STAN and SITO resulted in a 
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weak but significant linear trend towards repression (STAN: p = 0.002, R2 = 0.25, Slope 
= −0.03; SITO: p = 0.03, R2 = 0.063, Slope =−0.015 (Figure 3a)), but no single 
concentration led to a significant difference in LXRA activity when compared to vehicle 
control (Figure 3a). In MDA-MB-231 cells, there was a weak linear trend towards 
activation by SITO (p = 0.038, R2 = 0.09, Slope = 0.017 (Figure 3b)). LXRA activity was 
increased by 1.4-fold with 100 nM STAN relative to vehicle control (two-way ANOVA 
with Holm-Sidak multiple correction: p = 0.019 (Figure 3b)), but not at any other 
concentrations nor by any other PSS. In MCF7 cells, increasing concentrations of 
BRAS and STIG were associated with significant linear trends towards weak LXRA 
activation (BRAS: p = 0.0002, R2 = 0.25, Slope = −0.049; STIG: p = 0.0049, R2 = 0.15, 
Slope = −0.023; (Figure 3c)). High concentrations of BRAS (50 µM p < 0.0001 (Figure 
3c)) and multiple concentrations of STIG (p < 0.05 (Figure 3c)) resulted in statistically 
significant, but minor (<1.5) increases in LXRA activity compared to vehicle-treated 
control cells. From these reporter assays we concluded that across the typical 
physiological range, these PSSs had relatively little effect on LXRA activity in any cell 
type studied. tivity in any cell type studied.  
 
Figure 3. Liver X receptors (LXRs) is only weakly modulated by PSSs treatment in breast cancer cell 
lines. A luciferase reporter driven by an LXR alpha (LXRA) responsive promoter was stably transfected 
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into (a) MDA-MB-468, (b) MDA-MB-231, and (c) MCF7. Relative luciferase activity was measured after 
treating with synthetic ligands GW3965 (GW), GSK2033 (GSK), or PSSs at indicated concentrations 
for 16 h and is shown normalised to vehicle control (VC). Data are presented as mean of three 
independent replicates (open circles) with SEM. For assessing changes between individual 
concentrations and vehicle, one-way ANOVA with Holm-Sidak correction for multiple testing and post-
test for linear trend was performed. Significance levels are indicated by € = p < 0.05 and # = p < 0.0001, 
or for linear trend Slope, R2 and p value are indicated. 
2.2. PSSs Impair Side-Chain Oxysterol Mediated Activation of LXRA 
The effects of PSSs across all cell lines tested, combined with previous reports that 
PSSs are bona fide LXR ligands led us to hypothesize that in our cell lines at least, 
the role of PSSs could be to alter the response of LXR to other ligands rather than 
directly influence LXR. To test this, stable LXRA reporter cell lines were treated with 
individual oxysterols (24(S)-OHC, 25-OHC, (25R)26-OHC or 24(S),25-EC)), at low (1 
µM) or high (10 µM) concentrations alone, or paired with PSSs (STAN, SITO, CAMP, 
BRAS and STIG) at 10 µM for 16 h. 
The strong inducers of LXRA transcription being 24(S)-OHC and 24(S),25-EC (Figure 
4) were in agreement with previous reports [9]. At low (1 µM) dose, 24(S),25-EC driven 
activity was impaired equally by all PSSs, but to different magnitudes depending on 
the cell line. A 74–84% reduction in LXRA activity was observed in MDA-MB-468 cells 
(p < 0.0001 for all PSSs (Figure 4a)), 31–34% reduction in MDA-MB-231 cells (p < 
0.001 for all PSSs (Figure 4b)) and 23–30% reduction in MCF7 cells (p < 0.05 for all 
PSSs except STAN where p = 0.07 (Figure 4c)). More variability was observed in the 
high (10 µM) dose treatments. 10 µM 24(S),25-EC elicited a stronger transcriptional 
response from LXRA compared to 1 µM treatments, and differences in the abilities of 
the various PSSs to impair LXRA were now also evident. In MDA-MB-468 and MDA-
MB-231 cell lines, SITO and STAN were more effective inhibitors than CAMP, BRAS 
and STIG (Figure 4a–c; Table S1). Interestingly, in MDA-MB-468 cells CAMP failed to 
repress 24-25-EC induced LXRA transcriptional activity (p > 0.05 (Figure 4a)), as did 
BRAS in MDA-MB-231 cells (Figure 4b). In MCF7 cells, repression of activation was 
similar irrespective of PSSs (Figure 4c). 
At 1µM, 24(S)-OHC induced activity was similarly impaired by all PSSs (Figure4). In 
MDA-MB-468 cells the PSSs suppressed by 62–68% (p < 0.0001 for all PSSs (Figure 
4a)), by 24–48% in MDA-MB-231 cells (p < 0.01 for all PSSs except STAN where p > 
0.05 (Figure 4b)), and by 30–42% in MCF7 cells (p < 0.0001 for all PSSs except SITO 
where p > 0.05 (Figure 4c)). Again, the higher dose, 10 µM, elicited a stronger 
transcriptional response (3–4-fold stronger) LXRA compared to 1 µM treatments. 
Differences in the ability of the PSSs to impair LXRA were again also evident at the 
higher dose 
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(10 µM) experiment series. In both MDA-MB-468 and MDA-MB-231, SITO and STAN 
were more effective inhibitors (61–74%) than CAMP, BRASS or STIG (40–61%) which 
were statistically equivalent (Figure 4a–c; Table S1). 
The weakest activators of LXRA were 25-OHC and (25R)26-OHC, eliciting 
maximum responses of 6- and 5-fold over vehicle control in the ER-negative lines 
respectively, and less than 2.5-fold activation in MCF7 cells. At the lower (1 µM) dose 
25-OHC, PSSs inhibited LXR by 54–83% in MDA-MB-468 (p < 0.0001 for all PSSs 
(Figure 4a), and by 40–48% in MDA-MB-231 (p < 0.01 for all PSSs (Figure 4b; Table 
S1)). 
In MCF7 cells 25-OHC induced LXRA activity was only 1.8-fold above vehicle control, 
and this was almost entirely ablated by each PSS (p < 0.01 for all PSSs (Figure 4c)). 
Figure 4a shows that (25R)26-OHC failed to increase LXRA activity significantly in 
MCF7 cells. Unlike for the other oxysterols, 10 µM 25-OHC did not increase LXRA 
activity relative to 1 µM in MDA-MB-468 cells (Figure 4a) but did enhance LXRA 
activity in MDA-MB-231 (Figure 4b) and MCF7 (Figure 4c) cells. PSSs inhibited high 
dose 25-OHC driven LXR by 30–43% in MDA-MB-468 (p < 0.001 for all PSSs (Figure 
4a; Table S1)). In MDA-MB-231 and MCF7 cells, SITO and STAN were stronger 
inhibitors (41–58%) than the other PSSs (0–36%) (Figure 4b,c; Table S1). (25R)26-
OHC combined with the PSSs showed similar repression patterns as observed for 25-
OHC. At the lower (1 µM) dose in MDA-MB-468, all PSSs inhibited (25R)26-OHC 
induced activity (p < 0.01 for all PSSs (Figure 4a)), but SITO, CAMP BRAS and STIG 
failed to inhibit activation in either MDA-MB-231 or MCF7 cells (Figure 4b,c). SITO 
and STAN were highly effective at inhibiting high (10 µM) dose (25R)26-OHC induced 
LXRA activity in MDA-MB-468 cells (Figure 4a), while in MDA-MB-231 cells inhibition 
was between 54–59% (p < 0.0001 for all PSSs (Figure 4b)) and in MCF7 with 10 µM 
dose only BRAS and STIG failed to inhibit LXRA activity (Figure 4c). 
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Figure 4. Phytosterols inhibit oxysterol driven LXR activation in breast cancer cells. Oxysterol-mediated 
LXR activity was measured in the presence of PSSs or synthetic LXR antagonist GSK2033. (a) MDA-
MB-468 (b), MDA-MB-231 (c) and MCF7 LXR-luciferase reporter cell lines were treated with oxysterols 
alone or in combination with SITO, STAN, CAMP, BRASS, STIG (10 µM) or GSK2033 (GSK; 1 µM). 
Data show mean of four independent replicates (open circles) with SEM, except for GSK where mean 
and SEM of two independent replicates are shown. Significant induction by oxysterols relative to vehicle 
is indicated above the oxysterol columns. Significant repression of activation is indicated above the PSS 
columns. One-way ANOVA with Holm-Sidak correction for multiple testing was performed on for PSS 
co-treatments relative to oxysterol alone, or one-tailed t-test to compare GSK co-treatment with 
oxysterol alone. Significance levels are indicated by € = p < 0.05 and # = p < 0.0001. 
- 265 - 
Interestingly, despite the PSSs having little to no effect alone (Figures 2 and 3), they 
significantly attenuated oxysterol mediated LXR activation. This was systematically 
observed across all three breast cancer cell lines for all the PSSs tested, but 
collectively our data indicated that SITO and STAN are more efficient inhibitors of 
oxysterol driven LXRA activity than the other PSSs assayed (Figure 5, Table S1). To 
formally assess this hypothesis, we established the percentage inhibitory activity (from 
100% indicating the PSSs completely prevented oxysterol induced activity, to 0% 
where there was no significant difference in LXR activity between oxysterol and 
oxysterol plus PSSs treated cells) of each PSSs in combination with each oxysterol in 
each cell line. At low (1 µM) dose oxysterol, there were no differences in the ability of 
the various PSSs to inhibit LXRA activation (p > 0.05 for all PSSs (Figure 5a; Table 
S1)), although, when considered together, PSSs were generally able to repress 
activation in MDA-MB-468 cells better than in MDA-MB-231 and MCF7 (Figure 5a). In 
the high (10 µM) dose experiment series however, differences in the abilities of the 
PSSs to suppress oxysterol induced LXRA activity emerged. STAN and SITO 
emerged as the most potent inhibitors across all cell lines and all oxysterols (Figure 
5b, Supplementary Table S1). 
 
Figure 5. Inhibition of oxysterol induced LXR activity by PSS and cell lines. The percentage efficiency with 
which each PSS impairs activation of LXR by each oxysterol was calculated in each cell line for both low (1 
µM (a)) and high (10 µM (b)) dose PSS treatment. Individual oxysterols are represented by circles with range 
and mean shown in box plots. Statistical differences in the abilities of different PSS to impair oxysterol 
mediated LXR activation are denoted by different letters (shared letters indicate no significant difference 
between PSS). Statistical significance was determined using two-way ANOVA. 
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2.3. STAN and SITO Inhibit Oxysterol Mediated Activation of the LXR Target Genes 
ABCA1 and APOE 
Parental cell lines MDA-MB-468, MDA-MB-231 and MCF7 were treated with the 
endogenous agonists 24(S)-OHC or (25R)-26-OHC (10 µM), or synthetic LXR ligand 
GW3965 (1 µM) alone or in combination with SITO or STAN (10 µM) for 16 h. As 
expected, ABCA1 was activated by both oxysterols and GW3965 in all three cell lines 
(p < 0.0001 in each cell line (Figure 6a–c)). In combination experiments, the induction 
of ABCA1 mRNA expression by both synthetic and the oxysterol ligands was impaired 
by SITO and STAN in MDA-MB-468, MDA-MB-231 and MCF7 cells (p < 0.0001 for all 
agonist:PSS pairings (Figure 6a–c)), with the exception of GW3965 in MCF7 (p > 0.05 
(Figure 6c)). 
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Figure 6. STAN and SITO suppress oxysterol mediated LXR expression of target genes. Hormone 
receptor negative (MDA-MB-468 (a) and MDA-MB-231 (b)) and positive (MCF7 (c)) cells were treated 
with LXR ligands (synthetic 1 µM, oxysterol 10 µM) for 16 h alone or in combination with SITO or STAN 
and expression of ABCA1 and APOE were assessed by Taqman assays (∆∆Ct using HPRT and 
normalised to vehicle). Data shown are mean of three independent replicates (circles) with SEM. One-
way ANOVA with Holm-Sidak correction for multiple testing was performed, significance is indicated by 
€ = p < 0.05 and # = p < 0.0001. 
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For APOE expression, results were similar to those observed for ABCA1 in MDA-MB-
468 and MDA-MB-231, except the repression was more dramatic. For example, 
activation by any ligand in MDA-MB-468 cells was completely abrogated by either PSS 
(Figure 6a). In MDA-MB-231 cells this repression pattern was similar but not absolute 
(Figure 6b). In MCF7 cells, agonist-dependent inhibition of APOE expression was 
observed (as previously reported) and this was unaltered by co-treatment 
with either PSS (Figure 6c). 
STAN and SITO alone did not elicit change in expression of either ABCA1or APOE in 
MDA-MB-468 cells (p > 0.05 for all (Supplementary Figure S1a)). In MDA-MB-231 
cells, however, both SITO and STAN induced ABCA1 and APOE (p < 0.0001 for all 
(Supplementary Figure S1b)). In MCF7 cells, ABCA1 was repressed by SITO (p = 
0.032) but not by STAN, and APOE was significantly repressed by both PSSs (p < 
0.0001 for both (Supplementary Figure S1c)). Collectively, these data suggest that 
small changes in LXR target genes are induced by PSS, but that there are cell line 
differences in responses. MDA-MB-468 are relatively resistant to PSSs mediated 
target gene changes, PSSs induce target gene expression in MDA-MB-231 and 
repress in MCF7. 
3. Discussion 
When humans consume PSSs, 0.04–5% is absorbed [19,33–35], but this depends on 
the chemistry of the specific PSS [19,35], the genetics of the individual, and any 
pathologies [19,34]. Although absorption efficiency is considered low when compared 
to dietary cholesterol, this belies the fact that PSSs circulate in concentrations far 
higher than many biologically active derivatives of cholesterol. Indeed, circulating 
concentrations of total PSSs may exceed 100 µM in some high intake individuals, and 
even in the general population, the mean concentration is likely to exceed 20 µM [36]. 
While this is some 50–200 times lower than cholesterol (4–5 mM), it is 5000–20,000 
greater than typical 17b-estrodiol (1 nM), 20–100 times greater than Vitamin D (50 
nM), and up to 1000-fold higher than most oxysterols. At physiological concentrations 
typical for high intake individuals and far below, we found PSSs have modest effects 
on LXR activity in BCa cell lines in culture. Although we did not measure levels of 
oxysterols or conversion of cholesterol to oxysterols in our cell culture systems, we 
note that there was little capacity for repression of basal LXR activity by PSS. In these 
breast cancer cell types however, LXR activity was strongly driven by oxysterols 
indicating a significant capacity for induction. It was only in this strongly ligand-
activated state that PSSs could inhibit LXR mediated transcription. From our data, we 
concluded that classifying PSSs as LXR agonists or antagonists would be overly 
simplistic, and cell type and the presence of other ligands must be considered. 
- 269 - 
Instead, our data indicate phytosterols are, in regard to the BCa cell lines we evaluated 
and in the context of potent LXR agonists, competitive inhibitors. These data have 
implications for the development of novel LXR targeting drugs, as interaction with (a 
PSS rich) diet may alter the efficacy of LXR targeting. Controlling dietary intake and 
dietary recording during trials could help differentiate apparent responders and non-
responders to LXR targeting compounds. 
The extent to which PSSs inhibited oxysterol dependent LXR activity was dependent 
on the cell line and on the oxysterol with which they were co-incubated. The most 
efficient activators of LXR were 24(S),25-EC and 24(S)-OHC (in agreement with 
previous reports [9]), and SITO and STAN were the most efficient inhibitors of 
oxysterol-mediated LXR activation. SITO and STAN differ in molecular structure by 
just a single unsaturated bond in the B-ring (Figure 1b). As we observed such similar 
behaviour between SITO and STAN in terms of interfering with LXR transcription 
across all our assays and cell lines, saturation in the B-ring probably doesn’t influence 
inhibition of LXR, and previous reports indicate that there is no difference between 
phytosterols and phytostanols in lowering circulating cholesterol [37]. Furthermore, 
STIG is identical to SITO except for an unsaturated bond between the 22nd and 23rd 
carbon in the side chain, and this difference appears sufficient to partially attenuate 
the ability of STIG to compete with oxysterols for LXR binding. An unsaturated bond 
such as this makes the side chain less flexible and allows for decreased rotational 
freedom but may also be more prone to oxidative or enzymatic attack. A series of 
synthetic STIG derivatives with modifications to either the 22nd or 23rd carbon led to 
several compounds able to selectively modulate LXR target genes; ABCA1 expression 
was strongly enhanced while other canonical targets such as FASN were unaltered 
[38]. In subsequent work addition of a hydroxyl group at C24 to stigmastane led to 
robust activation of ABCA1 and FASN [39]. Understanding selective modulation of 
LXR is a critical research gap as there are both disease-promoting and disease 
prevention components to the oxysterol-LXR signalling cascade. 
PSSs are structurally and functionally related to oxysterols thus supporting at a 
biochemical and modelling level, the hypothesis they are selective LXR modulators 
rather than simple agonists or antagonists. Notably, Kaneko et al., demonstrated in a 
different cell type to those we assayed, HEK293 cells, that SITO, BRASS, CAMP and 
STIG at 10 µM could activate LXR driven luciferase activity [21]. In contrast, SITO was 
unable to activate an LXR-luciferase reporter in CHO-7 cells [18]. The canonical LXR 
target gene ABCA1 was also shown to be increased by SITO, STAN and CAMP in 
Caco2 cell cultures [22], but Brauner et al., demonstrated in the same cell line that 
CAMP or SITO co-treatment attenuated cholesterol induced ABCA1 expression [20], 
supporting our conclusion that a biologically meaningful role for PSSs is most apparent 
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in fine-tuning or moderating LXR’s response to ligand. Down-regulation of LXR target 
genes (NPC1L1, HMGCR, SR-BI and LDLR) occurs in HepG2 [23], and ABCG5/8 is 
reduced in Caco2 cells with 7-ketostigmasterol at 60 µM [24]. In vivo, hamsters fed 
phytosterol diets show reduced expression of LXR targets ABCG5, microsomal 
triglyceride protein (MTP) and the esterification enzyme ACAT [25]. Mice fed high 
doses of STIG, which reached 7 mM in the lumen, had unaltered LXR transcription 
[40]. 
In silico docking of polyphenols to LXR has recently been reported [41], and the 
interactions described here would benefit from similar computational modelling, 
especially by assessing additional PSSs with more diverse biophysical properties 
(e.g., side chain branching, saturation and length) to yield information about the 
structural requirements of PSSs that allow them to inhibit LXR. At the physiological 
level, dietary PSS intervention in BCa patients with a time-resolved sampling of normal 
and tumour breast tissue would allow assessment of the molecular and cell biology 
changes initiated by PSSs. Longer term follow-ups of patients would help indicate if 
antagonism of LXR altered risk of disease relapse or whether ER-dependent tumour 
growth could be inhibited by chronic low-dose dietary changes or acute 
pharmacological intake of PSS. 
The data on PSSs we report here indicate that dietary sterols may have differential 
effects on breast cancer pathophysiology. The stringent activation of LXR by 
oxysterols is inhibited by PSS, but whether this translates into a possible dietary 
suppression of human LXR-oxysterol signalling in tumour prone tissues such as the 
breast, or metastatic sites such as the bone, remains to be determined. This is a 
clinically important question as ER-negative disease remains more challenging to 
successfully treat than ER-positive disease and a role for oxysterol signalling in breast 
cancer progression is now apparent, despite no clear difference in oxysterol 
concentrations between subtypes [42]. Our data provide a potential molecular 
explanation as to why diets, lifestyles, and chronic pharmacological treatments, which 
are associated with cholesterol suppression, are also associated with improved 
outcomes. In our model, PSSs could limit the ability of oxysterols to drive LXR 
signalling, which is an important observation given (25R)26-OHC promotes ER-
negative breast cancer metastasis in mouse models [11]. Further work that directly 
addresses how dietary PSSs accumulate in tumour prone tissues and metastatic sites, 
and their ability to enter and regulate immune cells is warranted following our 
observations. 
4. Materials and Methods 
4.1. Cell Culture and Cell Lines 
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MDA-MB-468, MDA-MB-231 (models of triple negative breast cancer), and MCF7 
(model of luminal A breast cancer) cell lines were originally obtained from ATCC. All 
cells were routinely maintained at 37 ◦C with 5% CO2 in a humidified incubator and 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher, Altrincham, 
UK, Cat: 31966047) supplemented with 10% fetal calf serum (FCS) (Thermo Fisher, 
Cat: 11560636). Routine passaging of cells was completed every 3–4 days and 
seeded at 1 × 106 live cells per T75 tissue culture treated flask (Nunc, Thermo Fisher, 
Cat: 
10364131) to maintain confluence between 20% and 80%. 
4.2. Drugs and Reagents 
Drugs stocks were stored at −20 ◦C as follows: GSK2033 was provided by C. Cummins 
(University of Toronto, Canada) and then later purchase from ToCris (Bristol, UK, Cat: 
5694) and stored at 20 mM diluted in ETOH, T0901317 (Cayman, Ann Arbor, USA, 
Cat: 71810) at 100 mM diluted in DMSO. Oxysterols were sourced from Avanti Polar 
Lipids: 24(S)-OHC (Cat: 700071), 25-OHC (Cat: 700019), (25R)26-OHC (Cat: 700021) 
and 24(S),25-EC (Cat: 700037). Stocks of 10 mM were prepared in nitrogen flushed 
ethanol to prevent auto-oxidation. The following phytosterols were provided by E. 
Trautwein (Unilever, Vlaardingen, The Netherlands) or later purchased from Avanti 
and stored in NFE at 5 or 20 mM stocks at −20 ◦C: β-sitosterol (Cat: 700095) (SITO), 
β-sitostanol (Cat: 700121) (STAN), campesterol (Cat: 700126) (CAMP), brassicasterol 
(Cat: 700122) (BRAS) or stigmasterol (Cat: 700062) 
(STIG). Puromycin Hydrochloride (Santa Cruz, Cat: sc-108071) stocks diluted in water 
and stored as 25 mg/mL aliquots. 
4.3. MTT Assays 
Cells were seeded in 96 well plates at 2.5 × 104 cells/well and incubated for 16 h. 
Vehicle (ethanol) or PSSs with the range of concentration between 1 pM to 100 µM 
was added for 48 h, media was removed, and cells were washed with PBS. Phenol 
red free DMEM with 10% FBS was added to each well along with MTT reagent (final 
concentration 0.5 mg/mL). After 4 h incubation at 37 ◦C, media was 
removed and replaced with 100 µL of DMSO/well. Absorbance at 540 nm was read 
using a CLARIOstar. 
4.4. Reporter Cell Lines and Luciferase Assays 
This method has been published previously [32]. Briefly, 3 × 104 cells were plated in 
each well of a 
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24-well plate and incubated overnight. Cignal Lentiviral particles (LXRα) were 
purchased from Qiagen (Manchester, UK, Cat: CLS-7041L) and transduced into the 
cells using 8 µg/mL SureEntry transduction reagent at MOI at manufacturers 
recommendations. After 18h the particles were removed and fresh DMEM 
supplemented with 0.1 mM Non-Essential Amino Acids (Thermo Fisher, Cat: 
12084947) and 
100 U/mL penicillin and 100 µg/mL streptomycin (Thermo Fisher, Cat: 10378016) 
were added to the cells. Cells were passaged and puromycin used to select 
successfully transduced cells. Reporter cell line insertion and response were validated 
previously [32]. For luciferase quantitation, 30,000 transfected cells/well were seeded 
into 24-well plates and allowed to attach under normal culture conditions for 8 h. 
Cultures were treated with ligands, inhibitors or vehicle control as indicated in figure 
legends for 16 h. Luciferase assays were carried out by transferring cell lysates to 
white-walled 96-well plates and luminescence was assessed using the Tecan Spark 
using autoinjectors. 
4.5. mRNA Isolation, Reverse Transcription and qPCR 
Cells were plated in 6 well plates (2.5 × 105 cells/well) and incubated overnight before 
treatment with vehicle (ethanol) or LXR ligands. mRNA analysis was performed as 
described previously [43,44]. Briefly, Promega ReliaprepTM RNA Cell Miniprep System 
was used for the RNA extraction (Promega, Southampton, UK, Cat: #Z6012), and 
product guidelines were followed using approximately 5 × 105 cells (allowing for 
doubling time). On column DNase 1 digestion was performed and RNA was eluted in 
30 µL water. Purified RNA was stored at −80 ◦C. The GoScriptTM Reverse Transcription 
kit (Promega, Cat: A5003) was used for the cDNA synthesis, and product guidelines 
followed using 500 ng total RNA/reaction and x random primers. The resulting cDNA 
was then diluted 1 in 5 in water and stored at −20 ◦C. Taqman Fast Advanced 
Mastermix (Thermo Fisher, Paisley, UK, Cat: 4444557) was used with Taqman assays 
(Thermo Fisher, Paisley, UK, Cat: 4331182) on a QuantStudio Flex 7 (Applied 
Biosystems Life Tech, Thermo Scientific) for gene expression experiments. Taqman 
assays (Hs02800695_m1–HPRT1, Hs01059137_m1–ABCA1, Hs00171168_m1–
APOE) and Mastermix were stored at −20 ◦C. Gene expression was analysed using 
the ∆∆Ct method and normalised to the housekeeping gene HPRT1. 
4.6. Statistical Analysis 
All statistics and graph preparation were performed in Graph pad Prism version 6. 
One-way ANOVA with Holm-Sidak correction for multiple testing was used to 
determine differences between vehicle and individual concentrations of PSS in MTT 
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cell viability and LXR-Luciferase activation assays. A post-test was applied to test for 
a linear trend with increasing PSS concentration and Slope, R2 and p value reported. 
For analysis of PSS repression of oxysterol induced LXR activity one-way ANOVA 
with Holm-Sidak correction for multiple testing was used and to compare effects of 
PSS across all cells and oxysterols two-way ANOVA was applied. For gene 
expression analysis one-way ANOVA 
was applied. 
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